<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001499" GROUP_ID="DEMENTIA" ID="259900042420172574" MERGED_FROM="" MODIFIED="2008-06-02 15:23:59 +0200" MODIFIED_BY="Helen Collins" REVIEW_NO="44" REVMAN_SUB_VERSION="5.0.11" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="9.0">
<COVER_SHEET MODIFIED="2008-06-02 15:23:59 +0200" MODIFIED_BY="Helen Collins">
<TITLE>Physostigmine for dementia due to Alzheimer's disease</TITLE>
<CONTACT MODIFIED="2008-06-02 15:23:59 +0200" MODIFIED_BY="Helen Collins"><PERSON ID="13013" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>João M</FIRST_NAME><MIDDLE_INITIALS>JMC</MIDDLE_INITIALS><LAST_NAME>Coelho Filho</LAST_NAME><EMAIL_1>jmacedocoelho@yahoo.com.br</EMAIL_1><ADDRESS><DEPARTMENT>Departamento de Medicina Clinica</DEPARTMENT><ORGANISATION>Universidade Federal do Ceara</ORGANISATION><ADDRESS_1>Rua Eduardo Garcia 650, Apto. 1400</ADDRESS_1><CITY>Fortaleza</CITY><ZIP>60.150.100</ZIP><REGION>Ceara</REGION><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+ 55 85-4866157</PHONE_1><FAX_1>+ 55 85-4866157</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-06-02 15:23:59 +0200" MODIFIED_BY="Helen Collins"><PERSON ID="13013" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>João M</FIRST_NAME><MIDDLE_INITIALS>JMC</MIDDLE_INITIALS><LAST_NAME>Coelho Filho</LAST_NAME><EMAIL_1>jmacedocoelho@yahoo.com.br</EMAIL_1><ADDRESS><DEPARTMENT>Departamento de Medicina Clinica</DEPARTMENT><ORGANISATION>Universidade Federal do Ceara</ORGANISATION><ADDRESS_1>Rua Eduardo Garcia 650, Apto. 1400</ADDRESS_1><CITY>Fortaleza</CITY><ZIP>60.150.100</ZIP><REGION>Ceara</REGION><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+ 55 85-4866157</PHONE_1><FAX_1>+ 55 85-4866157</FAX_1></ADDRESS></PERSON><PERSON ID="7198" ROLE="AUTHOR"><PREFIX>Mrs</PREFIX><FIRST_NAME>Jacqueline</FIRST_NAME><LAST_NAME>Birks</LAST_NAME><SUFFIX>MA (Cantab) MSc (Oxon) C Stat</SUFFIX><POSITION>NIHR Senior Medical Statistician</POSITION><EMAIL_1>jacqueline.birks@csm.ox.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Centre for Statistics in Medicine</DEPARTMENT><ORGANISATION>University of Oxford</ORGANISATION><ADDRESS_1>Wolfson College</ADDRESS_1><ADDRESS_2>Linton Road</ADDRESS_2><CITY>Oxford</CITY><ZIP>OX2 6UD</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+ 44 (0)1865 284403</PHONE_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-06-02 14:08:07 +0100" MODIFIED_BY="Helen Collins">
<UP_TO_DATE>
<DATE DAY="2" MONTH="6" YEAR="2008"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="10" MONTH="1" YEAR="2008"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="6" YEAR="2010"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="1999"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2001"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2001"/>
</DATES>
<WHATS_NEW MODIFIED="2008-06-02 13:46:31 +0100" MODIFIED_BY="Helen Collins">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-06-02 13:46:31 +0100" MODIFIED_BY="Helen Collins">
<DATE DAY="2" MONTH="6" YEAR="2008"/>
<DESCRIPTION>
<P>January 2008: an update search was run; two references were retrieved, both of which were excluded</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="2" MONTH="6" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-06-02 13:45:06 +0100" MODIFIED_BY="Helen Collins">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-06-02 13:45:06 +0100" MODIFIED_BY="Helen Collins">
<DATE DAY="5" MONTH="8" YEAR="2005"/>
<DESCRIPTION>
<P>August 2005: an update search was carried out; no new references were found</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="26" MONTH="2" YEAR="2001"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>University of Oxford</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Universidade Federal do Ceara, Brazil</NAME>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>CAPES Foundation, Brazil (Joao M Coelho Filho)</NAME>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-06-02 13:53:25 +0100" MODIFIED_BY="Helen Collins">
<SUMMARY MODIFIED="2008-06-02 13:47:36 +0100" MODIFIED_BY="Helen Collins">
<TITLE MODIFIED="2008-06-02 13:47:24 +0100" MODIFIED_BY="Helen Collins">Limited evidence of effectiveness of physostigmine for the symptomatic treatment of Alzheimer's disease</TITLE>
<SUMMARY_BODY MODIFIED="2008-06-02 13:47:36 +0100" MODIFIED_BY="Helen Collins">
<P>Physostigmine is an acetylcholinesterase inhibitor; it works by obstructing the enzyme responsible for ACh destruction in the synaptic cleft. Studies conducted more than 20 years ago suggested that physostigmine could improve memory in people with or without dementia. Investigation of this property has been limited by the very short half-life of physostigmine. Various forms of administering the drug have been tried to overcome this problem, most recently a controlled-release (CR) oral formulation, and a skin patch. An additional limiting factor has been a high incidence of adverse effects, including nausea, vomiting and diarrhoea. Physostigmine appears to have no advantage over some newer anticholinesterase drugs. The short half-life remains a serious disadvantage and requires complex forms of administration. There is no reason to recommend further research into this drug.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-06-02 13:47:02 +0100" MODIFIED_BY="Helen Collins">
<ABS_BACKGROUND>
<P>The main pharmacological approach for the treatment of Alzheimer's disease (AD) has been based on the use of agents potentiating cholinergic transmission, particularly by inhibiting acetylcholinesterase (AChE), the enzyme that destroys acetylcholine after it has been secreted into the synaptic clefts. Physostigmine is an AChE inhibitor originally extracted from calabar beans. It is licensed in many countries as an agent for reversing the effect of drugs and poisons causing the anticholinergic syndrome. Studies conducted more than 20 years ago suggested that physostigmine could improve memory in people with or without dementia. Investigation of this property has been limited by the very short half-life of physostigmine. Various forms of administering the drug have been tried to overcome this problem, most recently a controlled-release (CR) oral formulation, and a skin patch. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To determine the clinical efficacy and safety of physostigmine in Alzheimer's disease. </P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>The Specialized Register of the Cochrane Dementia and Cognitive Improvement Group (CDCIG), <I>The Cochrane Library</I>, MEDLINE, EMBASE, PsycINFO, CINAHL and LILACS were searched on 10 January 2008 using the terms: physostigmine OR syrapton OR antilirium. The CDCIG Specialized Register contains records from all major health care databases (CENTRAL, MEDLINE, EMBASE, PsycINFO, CINAHL, LILACS) as well as from many trials databases and grey literature sources.</P>
<P>We asked Forest Laboratories and Pharmax, owners of the rights to market physostigmine for Alzheimer's disease, for additional data and reports of clinical trials but we did not receive any information. </P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>All relevant unconfounded, double-blind, randomized, placebo-controlled trials in which physostigmine was administered for more than one day to patients with dementia of Alzheimer type. </P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2008-06-02 13:47:02 +0100" MODIFIED_BY="Helen Collins">
<P>Data were extracted independently by two reviewers (JMC and JB), pooled where appropriate and possible, and the weighted or standardized mean differences or Peto odds ratios (95% CI) were estimated. Where possible, intention-to-treat analysis was used.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Fifteen studies were included using four different methods of administration of physostigmine. Four studies, 29 people, used intravenous infusion; seven, 131 people, used a conventional oral form; four, 1456 people, used a controlled-release oral form, and one study of 181 people used a verum skin patch. </P>
<P>
<B>Intravenous infusion</B>
<BR/>There are no usable results from the intravenous infusion trials, </P>
<P>
<B>Oral form</B>
<BR/>The few results from the trials of the conventional oral form showed no benefit of physostigmine compared with placebo. <BR/>
<B>
<BR/>Controlled release</B>
<BR/>The results from two of the four studies of the controlled-release physostigmine apply only to a group of patients identified as responders in a pre-randomization titration period. The best dose physostigmine was associated with improvement on the ADAS-Cog score compared with placebo at 6, 12 weeks. There were statistically significantly higher numbers of patients from the physostigmine group withdrawing from the trial (22/183 vs 2/183)(OR 5.92, 95% confidence limits 2.59 to 13.54, p&lt;0.0001) and suffering at least one event of nausea, vomiting, diarrhoea, anorexia, dizziness, stomach pain, flatulence or sweating compared with placebo at 6 weeks. There were statistically significantly higher numbers of patients from the physostigmine group withdrawing from the trial due to adverse events (13/83 vs 5/93)(OR 3.05, 95% CI 1.15 to 8.07, p=0.02) and suffering at least one event of nausea, vomiting, diarrhoea, anorexia, dizziness, stomach pain, tremor, asthenia or sweating compared with placebo at 12 weeks. When no attempt was made to identify responders and all relevant patients with Alzheimer's disease were randomized, fixed dose physostigmine (mean 33 mg/day) was associated with a statistically significantly higher number withdrawing (234/358 vs 31/117)(OR 4.82, 95% CI 3.17 to 7.33, p&lt;0.00001), withdrawing due to adverse events (196/358 vs 10/117) (OR 6.54, 95%CI 4.29 to 9.95, p&lt;0.00001) and suffering at least one event of nausea, vomiting, diarrhoea, anorexia, dizziness, stomach pain, dyspepsia, sweating, asthenia, dyspnoea or abnormal dreaming, but with no benefit on cognition compared with placebo at 24 weeks. </P>
<P>
<B>Verum patch</B>
<BR/>The double dose (delivering mean dose 12 mg/day) was associated with statistically significantly higher numbers suffering at least one adverse event of vomiting, nausea, or abdominal cramps, and the lower dose (delivering mean dose 5.7mg/day) was associated with statistically significantly higher numbers suffering gastrointestinal complaints compared with placebo at 24 weeks. There was no difference between physostigmine (higher and lower dose) and placebo for numbers improved (CGIC) at 24 weeks.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>The evidence of effectiveness of physostigmine for the symptomatic treatment of Alzheimer's disease is limited. Even in a controlled release formulation designed to overcome the short half-life, physostigmine showed no convincing benefit and adverse effects remained common leading to a high rate of withdrawal.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-06-02 13:53:25 +0100" MODIFIED_BY="Helen Collins">
<BACKGROUND>
<P>Alzheimer's disease is a progressive disorder characterized by irreversible decline in intellectual abilities and by changes in behaviour and personality. It is the commonest cause of dementia in older people, and it imposes considerable burden on patients and carers. As the aged population grows, the number of individuals world wide with Alzheimer's disease is expected to rise to 34 million in the next three decades, a dramatic increase from 7.3 million today. This is an alarming prospect, particularly in the absence of effective preventive and therapeutic interventions.</P>
<P>Although many of the mechanisms of Alzheimer's disease remain only partially understood, impairment of the cholinergic system has been well documented (<LINK REF="REF-Davies-1976" TYPE="REFERENCE">Davies 1976</LINK>, <LINK REF="REF-Perry-1977" TYPE="REFERENCE">Perry 1977</LINK>, <LINK REF="REF-Sims-1980" TYPE="REFERENCE">Sims 1980</LINK>, <LINK REF="REF-Coyle-1983" TYPE="REFERENCE">Coyle 1983</LINK>). Brains of individuals with Alzheimer's disease show a decrease in acetylcholine (ACh) neurotransmitter levels, as well as a loss of cholinergic innervation in neural areas implicated in learning and memory (<LINK REF="REF-Whitehouse-1982" TYPE="REFERENCE">Whitehouse 1982</LINK>; <LINK REF="REF-Doucette-1986" TYPE="REFERENCE">Doucette 1986</LINK>). Thus, the main pharmacological approach for the treatment of Alzheimer's disease has been based on the use of agents for potentiating cholinergic transmission, particularly by inhibiting acetylcholinesterase (AChE), the enzyme responsible for ACh destruction in the synaptic cleft. </P>
<P>Physostigmine is an AChE inhibitor originally isolated from the extract of calabar bean. It has been used widely for different purposes, ranging from an historical role in rituals and primitive medicine, to its present-day use for the treatment of poisoning and diseases such as myasthenia gravis. Physostigmine is approved by regulatory agencies in Europe and by US Food and Drug Administration (FDA) as an agent to reverse the anticholinergic effects of clinical or toxic dosages of drugs.</P>
<P>Studies conducted in the 1970s suggest that physostigmine could improve memory in normal subjects (<LINK REF="REF-Davis-1978" TYPE="REFERENCE">Davis 1978</LINK>), as well as in patients with dementia (<LINK REF="STD-Davis-1979" TYPE="STUDY">Davis 1979</LINK>). Several subsequent clinical trials with small numbers of patients have shown that physostigmine can improve memory, but the results have not been consistent across all the studies. Moreover, a limiting factor has been a high incidence of adverse effects, including nausea, vomiting and diarrhoea. </P>
<P>The development of physostigmine has been hindered by its extensive first-pass metabolism and short plasma half-life (approximately 30 minutes). The variability in the results of the physostigmine studies may reflect the different administration regimens that have been used. Both oral and intravenous routes have been explored, but both were unsatisfactory, owing to the pharmacological properties of the drug in the case of oral administration, and to its unsuitability for long-term therapy in the case of parenteral administration. Clinical trials using continuous intravenous infusion, transdermal and, more recently, oral controlled-release (CR) physostigmine and verum patch formulations, have been conducted in an attempt to yield more prolonged AChE inhibition. Adverse effects have remained common, but such trials have also claimed some beneficial effect of physostigmine on cognitive function. The application for approval of the CR formulation (physostigmine salicylate formulation named Synapton)of physostigmine is currently with regulatory agencies.</P>
</BACKGROUND>
<OBJECTIVES>
<UL>
<LI>To determine whether there is evidence of any beneficial effect from physostigmine in Alzheimer's disease. </LI>
<LI>To assess the incidence and severity of adverse effects.</LI>
</UL>
</OBJECTIVES>
<METHODS MODIFIED="2008-06-02 13:51:26 +0100" MODIFIED_BY="Helen Collins">
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>All relevant unconfounded, double-blind, randomized, placebo-controlled trials of longer than one day were selected. Trials in which the allocation to the treatment was not randomized, or in which the allocation to the treatment was not concealed were excluded.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>People with Alzheimer's disease as diagnosed by operational criteria such as DSM (<LINK REF="REF-APA-1994" TYPE="REFERENCE">APA 1994</LINK>) and NINCDS-ADRDA (National Institute of Neurological and Communication Disorders and Stroke-Alzheimer's Disease and Related Disorders Association) (<LINK REF="REF-McKhann-1984" TYPE="REFERENCE">McKhann 1984</LINK>).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Physostigmine given at any dose for more than one day, by any means of administration and with placebo control.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<UL>
<LI>Cognitive function (as measured by psychometric tests)</LI>
<LI>Global impression (such as CIBIC)</LI>
<LI>Functional performance</LI>
<LI>Behavioural disturbance</LI>
<LI>Mood</LI>
<LI>Safety as measured by the incidence of adverse effects (including side-effects) leading to withdrawal</LI>
<LI>Dependency </LI>
<LI>Acceptability of treatment (as measured by withdrawal from trial)</LI>
<LI>Quality of life</LI>
<LI>Effect on carer</LI>
<LI>Death</LI>
<LI>Use of services including institutionalization</LI>
</UL>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-06-02 13:50:12 +0100" MODIFIED_BY="Helen Collins">
<P>The Specialized Register of the Cochrane Dementia and Cognitive Improvement Group (CDCIG) was searched on 10 January 2008 for all years up to 2005. This register contains records from the following major healthcare databases <I>The Cochrane Library</I>, MEDLINE, EMBASE, PsycINFO, CINAHL and LILACS, and many ongoing trial databases and other grey literature sources. The following search terms were used: physostigmine OR synapton OR antilirium.</P>
<P>
<I>The Cochrane Library,</I> MEDLINE, EMBASE, PsycINFO and CINAHL were searched separately on 10 January 2008 for records added to these databases after December 2005 to January 2008. The search terms used to identify relevant controlled trials on dementia, Alzheimer's disease and mild cognitive impairment for the Group's Specialized Register can be found in the Group's module on <I>The Cochrane Library</I>. These search terms were combined with the following search terms and adapted for each database, where appropriate: physostigmine OR synapton OR antilirium</P>
<P>On 10 January 2008, the Specialized Register consisted of records from the following databases:</P>
<SUBSECTION>
<HEADING LEVEL="3">Healthcare databases</HEADING>
<UL>
<LI>CENTRAL: (The Cochrane Library 2006, Issue 1);</LI>
<LI>MEDLINE (1966 to 2006/07, week 5);</LI>
<LI>EMBASE (1980 to 2006/07);</LI>
<LI>PsycINFO (1887 to 2006/08, week 1);</LI>
<LI>CINAHL (1982 to 2006/06);</LI>
<LI>SIGLE (Grey Literature in Europe) (1980 to 2005/03);</LI>
<LI>LILACS: Latin American and Caribbean Health Science Literature (http://bases.bireme.br/cgi-bin/wxislind.exe/iah/online/?IsisScript=iah/iah.xis&amp;base=LILACS&amp;lang=i&amp;form=F) (last searched 29 August 2006).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Conference proceedings</HEADING>
<UL>
<LI>ISTP (http://portal.isiknowledge.com/portal.cgi) (Index to Scientific and Technical Proceedings) (to 29 August 2006);</LI>
<LI>INSIDE (BL database of Conference Proceedings and Journals) (to June 2000);.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Theses</HEADING>
<UL>
<LI>Index to Theses (formerly ASLIB) (http://www.theses.com/) (UK and Ireland theses) (1716 to 11 August 2006);</LI>
<LI>Australian Digital Theses Program (http://adt.caul.edu.au/): (last update 24 March 2006);</LI>
<LI>Canadian Theses and Dissertations (http://www.collectionscanada.ca/thesescanada/index-e.html): 1989 to 28 August 2006);</LI>
<LI>DATAD - Database of African Theses and Dissertations (http://www.aau.org/datad/backgrd.htm);</LI>
<LI>Dissertation Abstract Online (USA) (http://wwwlib.umi.com/dissertations/gateway) (1861 to 28 August 2006).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Ongoing trials</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">UK</HEADING>
<UL>
<LI>National Research Register (http://www.update-software.com/projects/nrr/) (last searched issue 3/2006);</LI>
<LI>ReFeR (http://www.refer.nhs.uk/ViewWebPage.asp?Page=Home) (last searched 30 August 2006);</LI>
<LI>Current Controlled trials: Meta Register of Controlled trials (mRCT) (http://www.controlled-trials.com/) (last searched 30 August 2006) :</LI>
<LI>ISRCTN Register - trials registered with a unique identifier</LI>
<LI>Action medical research</LI>
<LI>Kings College London</LI>
<LI>Laxdale Ltd</LI>
<LI>Medical Research Council (UK)</LI>
<LI>NHS Trusts Clinical Trials Register</LI>
<LI>National Health Service Research and Development Health Technology Assessment Programme (HTA)</LI>
<LI>National Health Service Research and Development Programme 'Time-Limited' National Programmes</LI>
<LI>National Health Service Research and Development Regional Programmes</LI>
<LI>The Wellcome Trust</LI>
<LI>Stroke Trials Registry (http://www.strokecenter.org/trials/index.aspx) (last searched 31 August 2006);</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Netherlands</HEADING>
<UL>
<LI>Nederlands Trial Register (http://www.trialregister.nl/trialreg/index.asp) (last searched 31 August 2006);</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">USA/International</HEADING>
<UL>
<LI>ClinicalTrials.gov (http://www.ClinicalTrials.gov) (last searched 31 August 2006) (contains all records from http://clinicalstudies.info.nih.gov/);</LI>
<LI>IPFMA Clinical trials Register: www.ifpma.org/clinicaltrials.html. The Ongoing Trials database within this Register searches http://www.controlled-trials.com/isrctn, http://www.ClinicalTrials.gov and http://www.centerwatch.com/. The ISRCTN register and Clinicaltrials.gov are searched separately. Centerwatch is very difficult to search for our purposes and no update searches have been done since 2003.</LI>
<LI>The IFPMA Trial Results databases searches a wide variety of sources among which are:</LI>
<LI>http://www.astrazenecaclinicaltrials.com (seroquel, statins)</LI>
<LI>http://www.centerwatch.com</LI>
<LI>http://www.clinicalstudyresults.org</LI>
<LI>http://clinicaltrials.gov</LI>
<LI>http://www.controlled-trials.com</LI>
<LI>http://ctr.gsk.co.uk</LI>
<LI>http://www.lillytrials.com (zyprexa)</LI>
<LI>http://www.roche-trials.com (anti-abeta antibody)</LI>
<LI>http://www.organon.com</LI>
<LI>http://www.novartisclinicaltrials.com (rivastigmine)</LI>
<LI>http://www.bayerhealthcare.com</LI>
<LI>http://trials.boehringer-ingelheim.com</LI>
<LI>http://www.cmrinteract.com</LI>
<LI>http://www.esteve.es</LI>
<LI>http://www.clinicaltrials.jp</LI>
</UL>
<P>
<I>This part of the IPFMA database is searched and was last updated on 4 September 2006;</I>
</P>
<UL>
<LI>Lundbeck Clinical Trial Registry (http://www.lundbecktrials.com) (last searched 15 August 2006);</LI>
<LI>Forest Clinical trial Registry (http://www.forestclinicaltrials.com/) (last searched 15 August 2006).</LI>
</UL>
<P>The search strategies used to identify relevant records in MEDLINE, EMBASE, PsycINFO, CINAHL and LILACS can be found in the Group's module on <I>The Cochrane Library.</I>
</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Pharmaceutical company records</HEADING>
<P>Forest Laboratories and Pharmax, owners of the rights to market physostigmine for Alzheimer's disease, were requested to provide data and reports of clinical trials but we did not receive any information. The Protocol for this Review was sent to them for comments as well.</P>
</SUBSECTION>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-06-02 13:51:26 +0100" MODIFIED_BY="Helen Collins">
<SUBSECTION>
<HEADING LEVEL="3">Selection of studies</HEADING>
<P>A single reviewer (JMC) discarded citations deemed irrelevant on the basis of the title of the publication and its abstract. In the presence of any suggestion that the article could possibly be relevant, it was retrieved for further assessment. Two reviewers (JMC &amp; JB) independently selected the trials for inclusion in the review from the culled citation list. Disagreements were resolved by discussion.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Quality assessment</HEADING>
<P>The same two reviewers (JMC and JB) assessed the methodological quality of each trial with particular emphasis on the allocation concealment. The trials were ranked using the Cochrane approach:</P>
<P>Category A (adequate) where the report described allocation of treatment by: (i) some form of centralised randomized scheme, such as having to provide details of an enrolled participant to an office by phone to receive the treatment group allocation; (ii) some form of randomization scheme controlled by a pharmacy; (iii) numbered or coded containers, such as in a pharmaceutical trial in which capsules from identical-looking numbered bottles are administrated sequentially to enrolled participants; (iv) an on-site or coded computer system, given that the allocations were in a locked, unreadable file that could be accessed only after inputting the characteristics of an enrolled participant; or (v) if assignment envelopes were used, the report should at least specify that they were sequentially numbered, sealed, opaque envelopes; (vi) other combinations of described elements of the process that provided assurance of adequate concealment.</P>
<P>Category B (intermediate) where the report described allocation of treatment by: (i) use of a 'list' of 'table' to allocate assignments; (ii) use of 'envelopes' or 'sealed envelopes'; (iii) stating the study as 'randomized' without further detail.</P>
<P>Category C (inadequate) where the report described allocation of treatment by: (i) alternation; (ii) reference to case record numbers, dates of birth, day of week, or any other such approach; (iii) any allocation procedure that is entirely transparent before assignment, such as an open list of random numbers or assignments.</P>
<P>Empirical research has demonstrated that lack of adequate allocation concealment is associated with bias. Trials which have taken inadequate measures to conceal allocation have been shown to yield more pronounced estimates of treatment effect than trials which have taken adequate measures. Trials with unclear allocation concealment produce estimates less pronounced than inadequately concealed trials, but more pronounced than adequately concealed trials (<LINK REF="REF-Chalmers-1983" TYPE="REFERENCE">Chalmers 1983</LINK>; <LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Inclusion criteria</HEADING>
<P>Trials were included if they conformed to categories A or B, while those falling into category C were excluded.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data extraction</HEADING>
<P>Data were independently extracted by two reviewers (JMC and JB) and cross-checked. Any discrepancies were resolved by discussion.</P>
<P>For each outcome measure summary statistics were sought which included assessments from all patients. These statistics included means, standard deviations, and numbers in each treatment group for continuous variables and total numbers in each treatment group and totals experiencing the outcome for binary variables. To allow an intention-to-treat analysis, summary statistics on all patients were sought irrespective of compliance, whether or not the patient was subsequently deemed ineligible, or otherwise excluded from treatment or follow-up. If any of the above statistics were not available in the publications, an "on-treatment" analysis was conducted using summary statistics which included patients who completed treatment according to the protocol.</P>
<P>For continuous variables, or ordinal variables which can be approximated to continuous variables, the main outcomes of interest are the final assessment and the change from baseline at final assessment. For some ordinal and binary outcomes, the endpoint category relative to baseline category is the outcome of interest. For others, such as the global impression of change, the endpoint itself is of clinical relevance as all patients are by definition at the same baseline score. The baseline assessment is defined as the latest available assessment prior to randomization, but no longer than two months before.</P>
<P>In studies where a cross-over design was used, only data from the first treatment period were included. Data from titration period prior to the randomized phase of the study, were not used to assess safety and efficacy. Data from open, follow-on phases after the randomized phase were not used to assess safety or efficacy because patients were usually not randomized, nor were treatments concealed.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data analysis</HEADING>
<P>A vast number of rating scales and tests have been devised to assess outcomes in clinical trials testing treatments for dementia. There is much duplication, as each scale purports to assess one of the five or six main characteristics of dementia but with varying procedures. For continuous or ordinal variables, such as psychometric test scores, clinical global impression scales, functional and quality of life scales, the main outcomes of interest were the final assessment scores and the changes in score from baseline. If the analyses reported by the investigators suggest that parametric methods and a normal approximation were appropriate, then the outcome measures were treated as continuous variables. The method of weighted mean difference was used for the meta-analyses when the same outcome measure was used in all included trials, otherwise the method of standardized mean difference was used.</P>
<P>For binary outcomes such as institutionalization, global impression and death, the endpoint itself was of interest and the Peto method of the 'typical odds ratio' was used.</P>
<P>A test for heterogeneity of treatment effect between the trials was made. If no heterogeneity was indicated then a fixed effect parametric approach was taken.</P>
<P>The null hypotheses to be tested were that, for any of the above outcomes, physostigmine has no effect compared with placebo.</P>
</SUBSECTION>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-06-02 13:53:25 +0100" MODIFIED_BY="Helen Collins">
<STUDY_DESCRIPTION MODIFIED="2008-06-02 13:52:12 +0100" MODIFIED_BY="Helen Collins">
<P>The fifteen trials fell into four groups, according to the drug formulation used: physostigmine intravenous infusion (PI) (3 trials); conventional oral physostigmine (COP) (7 trials); controlled release physostigmine (CR) trials (4 trials) and verum skin patch (1 trial). The trial groups differed in design, formulation and administration schemes, aims, outcomes and clinical applicability. In this review, particular attention is drawn to the CR trials, as CR is the physostigmine formulation for which approval from regulatory agencies is currently being sought.</P>
<P>In only five of the studies were more than 30 patients enrolled; these were the CR trials and the verum patch trial. Regarding the diagnostic criteria for Alzheimer's disease, 11/15 studies adopted NINCDS-ADRDA criteria, alone or in combination with other criteria; 3/15 adopted DSM III. Three studies, carried out before 1988, established diagnoses according to different sets of clinical, laboratory and radiological characteristics. The severity of the disease was mentioned in all studies, and was mild to moderate in all cases. The criteria used to establish the severity of the disease were: MMSE score; Memory and Information Test (MIT); Dementia Rating Scale; duration of illness; and performance of activities of daily living (ADL). Baseline characteristics are summarised in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="3">Trials of physostigmine infusion</HEADING>
<P>There are only three studies, with 29 patients in total. They all employed a crossover design, and were of short duration, between one and five days for each phase with a wash-out phase between the two treatment phases. The difficulties encountered in the administration of treatment and the short half-life of physostigmine had severely limited the design. Two studies used a dose titration phase before the randomized treatment in order to identify an optimal dose for each patient. The average dose was approximately 0.5 mg of physostigmine per hour.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Trials of oral physostigmine</HEADING>
<P>There are seven included studies with 131 patients in total. Six used a cross-over design, and one a parallel group design. Six trials started with a dose titration period in order to find the optimal or highest tolerated dose for each patient. Each phase of the cross-over trials was less than one week except for <LINK REF="STD-Sano-1993" TYPE="STUDY">Sano 1993</LINK>, which used two periods of six weeks each. The drug was administered at two-hourly intervals, with a total daily dose ranging from 3.5 to 16 mg divided into four to eight doses. Four trials used wash-out periods between the titration and randomized periods and between the phases of the randomized period, but these could be as short as one day.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Trials of controlled release physostigmine </HEADING>
<P>The four studies using CR formulation were the most recent studies (<LINK REF="STD-Thal-1996a" TYPE="STUDY">Thal 1996a</LINK>; <LINK REF="STD-Thal-1996b" TYPE="STUDY">Thal 1996b</LINK>, <LINK REF="STD-Thal-1999" TYPE="STUDY">Thal 1999</LINK> and <LINK REF="STD-van-Dyck-2000" TYPE="STUDY">van Dyck 2000</LINK>), the first three being carried out by the same group of researchers. In total 1456 patients were randomized.</P>
<P>
<LINK REF="STD-Thal-1996a" TYPE="STUDY">Thal 1996a</LINK> and <LINK REF="STD-Thal-1996b" TYPE="STUDY">Thal 1996b</LINK> enrolled 1111 patients in an initial 4-week dose titration stage during which their cognition was assessed repeatedly using the ADAS-Cog. After completion of this stage 366 were described as responders because they had improved by 3 points on the ADAS-Cog scale at some point. The dose taken whilst displaying this improvement was defined as the patient's best dose. Those without a 3 point improvement on the ADAS-Cog (449) were described as non-responders. Two hundred and ninety six patients withdrew before the end of the initial stage on account of adverse events. Responders and non-responders were randomized to separate trials of 6 week's duration. If randomized to treatment, the responders were given their best dose, the mean dose being 24.7 mg /day divided into 2 doses, the non-responders their highest tolerated dose, the mean dose being 24.3 mg /day divided into 2 doses.</P>
<P>
<LINK REF="STD-Thal-1999" TYPE="STUDY">Thal 1999</LINK>
<BR/>The design differed from the other trials, and potentially should provide superior evidence on the efficacy of CR physostigmine for older people with AD. There was no prior division into responders and non-responders, and participants suffering adverse events were not eliminated before randomization. 475 patients were randomized. Excessive space has been devoted to the reporting of the ITT analyses which have used the LOCF methodology. Over 24 weeks, when patients suffer a progressive condition and there are differential withdrawal rates bias is likely and LOCF is not an appropriate method of dealing with missing data. The tables do not report the means of the placebo groups, only the differences between the treatment and placebo groups. A conclusive presentation of results would demand means, standard errors of means and numbers in each group for each outcome.</P>
<P>
<LINK REF="STD-van-Dyck-2000" TYPE="STUDY">van Dyck 2000</LINK>
<BR/>An initial 3-week dose-enrichment phase was used to select potential responders to physostigmine who then entered the 12-week randomized phase after a 4-week placebo washout. During the dose-enrichment phase subjects received, in random order, placebo or 24 or 30 mg/day of physostigmine and were identified as responders if they showed at least 3 points improvement on the ADAS-Cog on physostigmine treatment compared with placebo. This also identified a best dose which was used in the randomized phase. Eight hundred and fifty patients entered the dose-enrichment phase, 546 completed it, and 196 were identified as responders, but only 176 entered the randomized, double-blind phase. The mean physostigmine dose during the randomized phase was 26.8 mg/day divided into 2 doses, 54% taking 24mg and 46% taking 30mg/day.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Verum patch trial</HEADING>
<P>The transdermal system of delivery aimed to release physostigmine continuously over 24 hours. Each patch contained 30 mg of physostigmine, and released about 5.7 mg over 24 hours. One trial of this system has been reported <LINK REF="STD-M_x00f6_ller-1999" TYPE="STUDY">Möller 1999</LINK>. 181 patients in total with mild to moderate Alzheimer's disease were randomized to placebo, one patch per day or two patches per day for 24 weeks of treatment. At 24 weeks this was the longest trial.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Outcomes</HEADING>
<P>The outcomes measured and respective scales (an acronym is given if it is well known) used in the studies are listed below. Further details about these scales, where available, are presented in <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK> .</P>
<P>
<B>1. Cognitive function </B>
<BR/>
</P>
<UL>
<LI>Buschke Selective Reminding Test (BSRT)</LI>
<LI>Modified Buschke Selective Reminding Test - memory (mod BSRT)</LI>
<LI>Verbal Paired Associate Learning - memory (VPAL)</LI>
<LI>Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog)</LI>
<LI>Neuropsychological Test Battery (NTB)</LI>
<LI>Digit span test</LI>
<LI>Boston Naming Test (BNT)</LI>
<LI>Mini-Mental State Examination (MMSE)</LI>
<LI>Modified Mini-Mental State Examination (mod-MMSE)</LI>
<LI>Wechsler Adult Intelligence Scale (WAIS)</LI>
<LI>Wechsler Adult Intelligence Scale-revised (WAIS-R)</LI>
<LI>Controlled Word Association (COWAT)</LI>
<LI>Category naming</LI>
<LI>Rosen Drawing Test (RDT)</LI>
<LI>Figure copy</LI>
<LI>Word or picture recognition</LI>
<LI>Famous faces Test (retrieval from remote memory)</LI>
<LI>The Squire's Memory Questionnaire (SMQ)</LI>
</UL>
<P>
<B>2. Global impression </B>
<BR/>
</P>
<UL>
<LI>Clinical Global Impression of Change (CGIC)</LI>
<LI>Clinician Interview-Based Impression of Change Plus (CIBIC-Plus)</LI>
<LI>Geriatric Evaluation by Relatives Rating Instrument (GERRI)</LI>
<LI>Sandoz Clinical Assessment - Geriatric(SCAG)</LI>
</UL>
<P>
<B>3. Functional performance</B>
<BR/>
</P>
<UL>
<LI>Activities of Daily Living (ADL)</LI>
<LI>Instrumental Activities of Daily Living (IADL)</LI>
<LI>Nurses Observational Scale for Inpatient Evaluation (NOSIE)</LI>
<LI>Performance Test of Activities of Daily Living (PADL)</LI>
</UL>
<P>
<B>4. Mood</B>
<BR/>
</P>
<UL>
<LI>Brief Psychiatric Rating Scale (BPRS)</LI>
<LI>Geriatric Depression Scale (GDS)</LI>
</UL>
<P>
<B>5. Safety as measured by the incidence of adverse effects (including side-effects) leading to withdrawal<BR/>6. Dependency<BR/>7. Acceptability of treatment (as measured by withdrawal from trial)<BR/>8. Quality of life<BR/>9. Effect on carer<BR/>10. Death<BR/>11. Use of services including institutionalization</B>
</P>
<P>Side effects were formally assessed in 5 (5/15) trials.</P>
</SUBSECTION>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-06-02 13:52:50 +0100" MODIFIED_BY="Helen Collins">
<P>Pharmax / Forest Laboratories were contacted and asked to provide information on unpublished or ongoing trials, but they decided not to release any date prior to regulatory approval. After full assessment, 15 studies were eventually classified as included and 31 as excluded. The commonest reasons for exclusion were non-randomization, and absence of double-blinding. Seven of the 15 included studies were published in more than one medical journal.</P>
<P>All the included studies were described as double-blind and randomized but only <LINK REF="STD-van-Dyck-2000" TYPE="STUDY">van Dyck 2000</LINK> gave further details on the methods.</P>
<P>The method of administration of physostigmine restricted the design on the trials using i.v. infusion and the first oral form (COP). Patients had to be assessed during the i.v.infusion and thus the trials were difficult to manage, and of necessity tested only a small number of patients and were of only a few days' duration. The oral form required many doses per day and these trials were also short and small.</P>
<P>The CR oral physostigmine trials attempted to identify responders before randomization. Responders were identified by a certain improvement measured on a cognitive test. Therefore results only apply to a selected sub group of the people with Alzheimer's disease of moderate severity. In <LINK REF="STD-Thal-1996a" TYPE="STUDY">Thal 1996a</LINK> and <LINK REF="STD-Thal-1996b" TYPE="STUDY">Thal 1996b</LINK> 296 (26.6%) patients discontinued before randomization, most of them (62.5%) due to adverse effects during the titration phase.</P>
<P>Most of the studies failed to comment on dropouts, leading to uncertainty as to which patients entered the analyses. When information was available, the reasons for dropouts were either decline of the patient's condition or adverse effects from treatment. The CR trials reported dropouts and intention-to-treat analyses were performed using the last observation carried forward (LOCF) methodology. In the <LINK REF="STD-Thal-1999" TYPE="STUDY">Thal 1999</LINK> CR study, a comparatively well designed physostigmine trial, high rates of dropouts were reported: 26% among placebo patients; 61% among those receiving 30 mg of physostigmine; and 68% among those receiving 36 mg of physostigmine.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-06-02 13:53:25 +0100" MODIFIED_BY="Helen Collins">
<SUBSECTION>
<HEADING LEVEL="3">Physostigmine infusion</HEADING>
<P>It was not possible to extract any quantitative results from any of the three included studies. <LINK REF="STD-Asthana-1995" TYPE="STUDY">Asthana 1995</LINK> reported difficulties in testing patients due to the frequent occurrence of adverse events. <LINK REF="STD-Davis-1982" TYPE="STUDY">Davis 1982</LINK> used different scales for outcome depending on the initial severity of the patient's dementia. <LINK REF="STD-Gustafson-1987" TYPE="STUDY">Gustafson 1987</LINK> only provided a narrative description of the results. Only one trial, <LINK REF="STD-Asthana-1995" TYPE="STUDY">Asthana 1995</LINK>, mentioned adverse effects. Five patients experienced nausea, vomiting, dizziness, headache, nightmares or fatigue during the dose-finding phase and 5/9 patients could not tolerate their previously identified optimal dose during the randomized phase.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Oral physostigmine</HEADING>
<P>In the COP trials of crossover design it was not possible to extract data relating to the first phase alone. The results derived from all phases were not considered reliable owing to problems of possible carry-over of the effects of previous treatment. The parallel group study, <LINK REF="STD-Thal-1989" TYPE="STUDY">Thal 1989</LINK> provided results which showed no statistically significant effects.</P>
<P>No trials provided data on adverse effects. Two trials made no mention at all of safety monitoring. Five trials provided a description of adverse effects which were usually gastrointestinal and occurred during the dose-finding phase. They were often resolved by lowering the dose.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Controlled release oral physostigmine</HEADING>
<P>The design of the combined trial of <LINK REF="STD-Thal-1996a" TYPE="STUDY">Thal 1996a</LINK> and <LINK REF="STD-Thal-1996b" TYPE="STUDY">Thal 1996b</LINK> has limited the usefulness of the information. The patients initially enter a titration phase of 4 weeks from which they were eliminated if they suffered adverse events. Those retained were classified as responders if at some point they showed improvement of 3 points on the ADAS-Cog, or otherwise as non-responders before entering separate randomized trials. The report of these trials concentrates on the responders' trial. There are tables of treatment and placebo effects for each outcomes for the ITT and completers' analyses. The precise size of each group and the standard errors are not reported. The ITT analyses are based on last observation carried forward (LOCF ) for the primary outcomes (ADAS-Cog and CGIC) for which assessments were made at baseline, 2, 4 and 6 weeks from baseline. It is stated that LOCF was not used for the secondary outcomes (MMSE, IADL, and PSMS) because assessments were only carried out at baseline and 6 weeks. It is unclear what the ITT analyses of the secondary outcomes represent. The ITT and completers' analyses should involve identical numbers for the secondary outcomes but do not. There is only one table of results from the non-responders trial. The sizes of the groups are missing and it is not stated whether ITT or completers' analyses are being reported. There is no information on withdrawals, or adverse events for the non-responders.</P>
<P>All quantitative results refer to the responders; there are no results from the non-responders' analyses. The results of the analysis of treatment effect show that there are no significant differences between physostigmine and placebo for MMSE, PSMS and IADL , but there is a significant difference in favour of physostigmine for ADAS-Cog ( ITT, MD -1.75, 95% CI -2.90, -0.60) and CGIC (ITT, MD 0.26, 95% CI 0.06, 0.46) at 6 weeks. There is a statistically significant effect in favour of placebo for withdrawals by the 6-week endpoint (24/183 vs 9/183) (OR 2.71, 95% CI 1.33, 5.53).There is a statistically significant effect in favour of placebo for withdrawals due to adverse events by the 6-week endpoint (22/183 vs 2/183) (OR 5.92, 95% CI 2.59, 13.54). There are significant differences, in favour of placebo, for the number of patients suffering at least one event of nausea, vomiting, diarrhoea, anorexia, dizziness, stomach pain, flatulence, or sweating, by 6 weeks.</P>
<P>Although it is reported by <LINK REF="STD-Thal-1999" TYPE="STUDY">Thal 1999</LINK> that there is benefit due to 30mg and 36 mg per day compared with placebo on cognition and global measures and no benefit on activities of daily living and the GERRI, it is impossible to confirm the results because too little quantitative evidence is reported. The main investigator has not replied to a request for this essential information and therefore it is impossible to interpret the results. There is information on withdrawals and adverse events.</P>
<P>The 30 and 36 mg/day groups have been added together for these analyses. There is a statistically significant effect in favour of placebo compared with physostigmine for withdrawals by the 24-week endpoint (234/358 vs 31/117) (OR 4.82, 95% CI 3.17, 7.33). There is a statistically significant effect in favour of placebo for withdrawals due to adverse events by the 24-week endpoint (196/358 vs 10/117) (OR 6.54, 95% CI 4.29, 9.95). There are significant differences in favour of placebo, for the number of patients suffering at least one event of nausea, vomiting, diarrhoea, anorexia, dizziness, stomach pain, dyspepsia, sweating, asthenia, dyspnoea or abnormal dreaming by 24 weeks.</P>
<P>The results from <LINK REF="STD-van-Dyck-2000" TYPE="STUDY">van Dyck 2000</LINK> are for responders and show that there are no significant differences between physostigmine and placebo for CGIC, MMSE, and IADL , but there is a significant difference in favour of physostigmine for ADAS-Cog (ITT, MD -2.02, 95% CI -3.59, -0.45) at 12 weeks. There are no significant differences between physostigmine and placebo for the number of withdrawals before the end of treatment. There is a statistically significant effect in favour of placebo for withdrawals due to adverse events by the 12-week endpoint (13/83 vs 5/93) (OR 3.05, 95% CI 1.15, 8.07). There are significant differences, in favour of placebo, for the number of patients suffering at least one event of nausea, vomiting, diarrhoea, anorexia, dizziness, stomach pain, tremor, asthenia or sweating, by 12 weeks.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Physostigmine verum patch </HEADING>
<P>The results from <LINK REF="STD-M_x00f6_ller-1999" TYPE="STUDY">Möller 1999</LINK> show no significant difference between physostigmine and placebo for CGIC, single and double dose at 24 weeks.There are no significant differences between physostigmine and placebo for the number of withdrawals before the end of treatment and the number of serious adverse events, single- and double-dose at 24 weeks. There are significant differences in favour of placebo compared with double dose physostigmine for the number of patients suffering at least one adverse event of vomiting, nausea and abdominal cramps, and for placebo compared with single dose physostigmine for gastrointestinal complaints at 24 weeks. The total number of adverse events was very low.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>The studies of i.v. physostigmine and the original oral physostigmine are of historical interest only and provide little useful information. Physostigmine will never be used in these forms for Alzheimer's disease. Most studies were conducted in the 1980s and they reflect the initial phase of clinical trials of treatment of dementia with anticholinesterase drugs. The studies were designed to test the efficacy and safety of physostigmine, but the problems with the designs of the studies, constrained by the short half-life of the drug, resulted in the objectives being difficult to meet.</P>
<P>The recent controlled-release oral physostigmine trials should have taken advantage of new standards in clinical trials for Alzheimer's disease. Unfortunatley, they are marred by serious methodological limitations, and inadequate and unsatisfactory reporting of results. The true rate of adverse events will be under-estimated, when patients are withdrawn before randomization if they suffer an adverse event in the dose-titration phase. Furthermore, the identification of responders prior to entering the randomized phase hinders interpretation of the results and leaves us with a very unclear concept of the population to which the results apply.</P>
<P>
<LINK REF="STD-M_x00f6_ller-1999" TYPE="STUDY">Möller 1999</LINK> is a well-designed trial, and the patch method of administration appears to have advantages over other methods. Unfortunately the doses delivered by the single- and double-doses of patches used were too low to test efficacy. The very low level of adverse events would support this interpretation.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>The net evidence of effectiveness of physostigmine for the symptomatic treatment of Alzheimer's disease is limited. Even in CR formulation, physostigmine showed no convincing effect and adverse effects remained common leading to a high rate of withdrawal.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Physostigmine appears to have no advantage over some newer anticholinesterase drugs. The short half-life remains a serious disadvantage and requires complex forms of administration. There is no reason to recommend further research into this drug.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>This original review was carried out during the attachment of Dr J M Coelho Filho as a Visiting Fellow at the Department of Clinical Geratology, University of Oxford, Oxford, UK. </P>
<P>Dr Coelho Filho was supported by CAPES Foundation, Education Ministry, Brazil; his attachment to the Department of Clinical Geratology in Oxford was part of his Doctoral Programme at the Departamento de Fisiologia e Farmacologia, Universidade Federal do Ceará, Fortaleza, Brazil.</P>
<P>We are grateful to Corinne Cavender for her work as consumer editor on this review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known. </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>-JCF and JB extracted data, assessed methodological quality of studies and developed inclusion/exclusion criteria.<BR/>-JB did the meta-analysis<BR/>-JCF wrote the body of the text, which was edited by JB<BR/>-JCF: updates</P>
<P>-Consumer Editor: Corinne Cavender</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-06-02 14:07:19 +0100" MODIFIED_BY="Helen Collins">
<STUDIES MODIFIED="2008-06-02 14:05:12 +0100" MODIFIED_BY="Helen Collins">
<INCLUDED_STUDIES MODIFIED="2008-06-02 14:03:44 +0100" MODIFIED_BY="Helen Collins">
<STUDY DATA_SOURCE="PUB" ID="STD-Asthana-1995" MODIFIED="2008-06-02 13:59:39 +0100" MODIFIED_BY="Helen Collins" NAME="Asthana 1995" YEAR="1995">
<REFERENCE MODIFIED="2008-06-02 13:58:54 +0100" MODIFIED_BY="Helen Collins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Asthana S, Greig NH, Hegedus L, Holloway HH, Raffaele KC, Schapiro MB, Soncrant TT</AU>
<TI>Clinical pharmacokinetics of physostigmine in patients with Alzheimer's disease</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>1995</YR>
<VL>58</VL>
<PG>299-309</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Asthana S, Greig NH, Raffaele KC, Berardi A, Schapiro MB, Soncrant TT</AU>
<TI>Pharmacokinetic and pharmacodynamic properties of physostigmine following steady-state intravenous infusion in subjects with Alzheimer's disease</TI>
<SO>Proceedings of the Annual Scientific Meeting of the American Geriatrics Society and the American Federation for Aging Research, May 19-22</SO>
<YR>1994</YR>
<CY>Los Angeles CA</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-06-02 13:59:27 +0100" MODIFIED_BY="Helen Collins" NOTES="&lt;p&gt;Asthana S, Raffaele KC, Berardi A, Greig NH, Haxby JV, Schapiro MB, Soncrant TT. Treatment of Alzheimer disease by continuous intravenous infusion of physostigmine. Alzheimer Dis Assoc Disord 1995; 9 (4): 223-32.&lt;/p&gt;" NOTES_MODIFIED="2008-06-02 13:59:27 +0100" NOTES_MODIFIED_BY="Helen Collins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Asthana S, Raffaele KC, Berardi A, Greig NH, Haxby JV, Schapiro MB, Soncrant TT</AU>
<TI>Treatment of Alzheimer disease by continuous intravenous infusion of physostigmine</TI>
<SO>Alzheimer Disease and Associated Disorders</SO>
<YR>1995</YR>
<VL>9</VL>
<NO>4</NO>
<PG>223-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-06-02 13:59:39 +0100" MODIFIED_BY="Helen Collins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Asthana S, Raffaele KC, Grieg NH, Schapiro MB, Blackman MR, Soncrant TT</AU>
<TI>Neuroendocrine responses to intravenous infusion of physostigmine in patients with Alzheimer disease</TI>
<SO>Alzheimer Disease and Associated Disorders</SO>
<YR>1999</YR>
<VL>13</VL>
<NO>2</NO>
<PG>102-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Beller-1985" MODIFIED="2008-06-02 13:59:59 +0100" MODIFIED_BY="Helen Collins" NAME="Beller 1985" YEAR="1985">
<REFERENCE MODIFIED="2008-06-02 13:59:59 +0100" MODIFIED_BY="Helen Collins" NOTES="&lt;p&gt;Beller SA, Overall JE, Swann AC. Efficacy of oral physostigmine in primary degenerative dementia: a double blind study of response to different dose level. Psychopharmacology 1985; 87: 147-151.&lt;/p&gt;" NOTES_MODIFIED="2008-06-02 13:59:59 +0100" NOTES_MODIFIED_BY="Helen Collins" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Beller SA, Overall JE, Swann AC</AU>
<TI>Efficacy of oral physostigmine in primary degenerative dementia: a double blind study of response to different dose level</TI>
<SO>Psychopharmacology</SO>
<YR>1985</YR>
<VL>87</VL>
<PG>147-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Davis-1982" MODIFIED="2008-06-02 14:00:21 +0100" MODIFIED_BY="Helen Collins" NAME="Davis 1982" YEAR="1982">
<REFERENCE MODIFIED="2008-06-02 14:00:14 +0100" MODIFIED_BY="Helen Collins" NOTES="&lt;p&gt;Davis KL, Mohs RC. Enhancement of memory processes in Alzheimer's disease with multiple-dose intravenous physostigmine. Am J Psychiatry 1982; 139: 1421-1424 .&lt;/p&gt;" NOTES_MODIFIED="2008-06-02 14:00:14 +0100" NOTES_MODIFIED_BY="Helen Collins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davis KL, Mohs RC</AU>
<TI>Enhancement of memory processes in Alzheimer's disease with multiple-dose intravenous physostigmine</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1982</YR>
<VL>139</VL>
<PG>1421-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-06-02 14:00:21 +0100" MODIFIED_BY="Helen Collins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mohs RC, Davis KL</AU>
<TI>A signal detectability analysis of the effect of physostigmine on memory in patients with Alzheimer's disease</TI>
<SO>Neurobiology of Aging</SO>
<YR>1982</YR>
<VL>3</VL>
<PG>105-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gustafson-1987" MODIFIED="2008-06-02 14:00:31 +0100" MODIFIED_BY="Helen Collins" NAME="Gustafson 1987" YEAR="1987">
<REFERENCE MODIFIED="2008-06-02 14:00:31 +0100" MODIFIED_BY="Helen Collins" NOTES="&lt;p&gt;Gustafson L, Edvinsson L, Dahlgren N, Hagberg B, Risberg J, Rosen I, Ferno H. Intravenous physostigmine treatment of Alzheimer's disease evaluated by psychometric testing, regional cerebral blood flow (rCBF) measurement, and EEG. &lt;br&gt;Psychopharmacology Berl 1987; 93: 31-5 .&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-06-02 14:00:31 +0100" NOTES_MODIFIED_BY="Helen Collins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gustafson L, Edvinsson L, Dahlgren N, Hagberg B, Risberg J, Rosen I, Ferno H</AU>
<TI>Intravenous physostigmine treatment of Alzheimer's disease evaluated by psychometric testing, regional cerebral blood flow (rCBF) measurement, and EEG</TI>
<SO>Psychopharmacology Berlin</SO>
<YR>1987</YR>
<VL>93</VL>
<PG>31-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harrell-1990" MODIFIED="2008-06-02 14:00:56 +0100" MODIFIED_BY="Helen Collins" NAME="Harrell 1990" YEAR="1990">
<REFERENCE MODIFIED="2008-06-02 14:00:38 +0100" MODIFIED_BY="Helen Collins" NOTES="&lt;p&gt;Harrell LE, Callaway R, Morere D, Falgout J. The effect of long-term physostigmine administration in Alzheimer's disease. Neurology 1990; 40: 1350-1354.&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;Harrell LE, Callaway R, Morere D, Falgout J. The effect of long-term physostigmine administration in Alzheimer's disease. Neurology 1990; 40: 1350-1354.&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;br&gt;Harrell LE, Callaway R, Morere D, Falgout J. The effect of long-term physostigmine administration in Alzheimer's disease. Neurology 1990; 40: 1350-1354.&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-06-02 14:00:38 +0100" NOTES_MODIFIED_BY="Helen Collins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harrell LE, Callaway R, Morere D, Falgout J</AU>
<TI>The effect of long-term physostigmine administration in Alzheimer's disease</TI>
<SO>Neurology</SO>
<YR>1990</YR>
<VL>40</VL>
<PG>1350-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-06-02 14:00:56 +0100" MODIFIED_BY="Helen Collins" NOTES="&lt;p&gt;Harrell LE, Jope RS, Falgout J, Callaway R, Avery C, Spiers M, Leli D, Morere D, Halsey JH Jr. Biological and neuropsychological characterization of physostigmine responders and nonresponders in Alzheimer's disease. &lt;br&gt;J Am Geriatr Soc 1990; 38(2): 113-22 .&lt;/p&gt;" NOTES_MODIFIED="2008-06-02 14:00:56 +0100" NOTES_MODIFIED_BY="Helen Collins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harrell LE, Jope RS, Falgout J, Callaway R, Avery C, Spiers M, Leli D, Morere D, Halsey JH Jr</AU>
<TI>Biological and neuropsychological characterization of physostigmine responders and nonresponders in Alzheimer's disease</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>1990</YR>
<VL>38</VL>
<NO>2</NO>
<PG>113-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jenike-1990" MODIFIED="2008-06-02 14:01:39 +0100" MODIFIED_BY="Helen Collins" NAME="Jenike 1990" YEAR="1990">
<REFERENCE MODIFIED="2008-06-02 14:01:29 +0100" MODIFIED_BY="Helen Collins" NOTES="&lt;p&gt;Jenike MA, Albert M, Baer L, Gunther J. Oral physostigmine as treatment for primary degenerative dementia: a double-blind placebo-controlled inpatient trial. &lt;br&gt;J Geriatr Psychiatry Neurol 1990; 3: 13-17.&lt;/p&gt;" NOTES_MODIFIED="2008-06-02 14:01:29 +0100" NOTES_MODIFIED_BY="Helen Collins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jenike MA, Albert M, Baer L, Gunther J</AU>
<TI>Oral physostigmine as treatment for primary degenerative dementia: a double-blind placebo-controlled inpatient trial</TI>
<SO>Journal of Geriatric Psychiatry and Neurology</SO>
<YR>1990</YR>
<VL>3</VL>
<PG>13-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-06-02 14:01:39 +0100" MODIFIED_BY="Helen Collins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jenike MA, Albert MS, Heller H, Gunther J, Goff D</AU>
<TI>Oral physostigmine treatment for patients with presenile and senile dementia of the Alzheimer's type: a double-blind placebo-controlled trial</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1990</YR>
<VL>51</VL>
<PG>3-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mohs-1985" MODIFIED="2008-06-02 14:02:06 +0100" MODIFIED_BY="Helen Collins" NAME="Mohs 1985" YEAR="1985">
<REFERENCE MODIFIED="2008-06-02 14:01:58 +0100" MODIFIED_BY="Helen Collins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davis KL, Mohs RC</AU>
<TI>Memory enhancement with oral physostigmine in AD (letter)</TI>
<SO>New England Journal of Medicine</SO>
<YR>1983</YR>
<VL>308</VL>
<PG>721</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-06-02 14:02:06 +0100" MODIFIED_BY="Helen Collins" NOTES="&lt;p&gt;Mohs RC, Davis BM, Johns CA, Mathe AA, Greenwald BS, Horvath TB, Davis KL. Oral physostigmine treatment of patients with Alzheimer's disease. Am J Psychiatry 1985; 142: 28-33 .&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-06-02 14:02:06 +0100" NOTES_MODIFIED_BY="Helen Collins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mohs RC, Davis BM, Johns CA, Mathe AA, Greenwald BS, Horvath TB, Davis KL</AU>
<TI>Oral physostigmine treatment of patients with Alzheimer's disease</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1985</YR>
<VL>142</VL>
<PG>28-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-M_x00f6_ller-1999" NAME="Möller 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Möller HJ, Hampel H, Hegerl U, Schmitt W, Walter K</AU>
<TI>Double-blind, randomized, placebo-controlled clinical trial on the efficacy and tolerability of a physostigmine patch in patients with senile dementia of the Alzheimer's type</TI>
<SO>Pharmacopsychiatry</SO>
<YR>1999</YR>
<VL>32</VL>
<NO>3</NO>
<PG>99-106</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sano-1993" MODIFIED="2008-06-02 14:02:29 +0100" MODIFIED_BY="Helen Collins" NAME="Sano 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bell K, Sano M, Stricks L, Marder K, Stern Y, Mayeux R</AU>
<TI>Physostigmine in Alzheimer's Disease: risk / benefit consideration</TI>
<SO>Neurology</SO>
<YR>1990</YR>
<VL>40</VL>
<NO>Suppl 1</NO>
<PG>229</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-06-02 14:02:29 +0100" MODIFIED_BY="Helen Collins" NOTES="&lt;p&gt;Sano M, Bell K, Marder K, Stricks L, Stern Y, Mayeux R. Safety and efficacy of oral physostigmine in the treatment of Alzheimer disease. Clin Neuropharmacol 1993; 16: 61-9 .&lt;/p&gt;" NOTES_MODIFIED="2008-06-02 14:02:29 +0100" NOTES_MODIFIED_BY="Helen Collins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sano M, Bell K, Marder K, Stricks L, Stern Y, Mayeux R</AU>
<TI>Safety and efficacy of oral physostigmine in the treatment of Alzheimer disease</TI>
<SO>Clinical Neuropharmacology</SO>
<YR>1993</YR>
<VL>16</VL>
<PG>61-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stern-1987" MODIFIED="2008-06-02 14:02:55 +0100" MODIFIED_BY="Helen Collins" NAME="Stern 1987" YEAR="1987">
<REFERENCE MODIFIED="2008-06-02 14:02:55 +0100" MODIFIED_BY="Helen Collins" NOTES="&lt;p&gt;Stern Y, Sano M, Mayeux R. Effects of oral physostigmine in Alzheimer's disease. Ann Neurol 1987; 22: 306-10.&lt;/p&gt;" NOTES_MODIFIED="2008-06-02 14:02:55 +0100" NOTES_MODIFIED_BY="Helen Collins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stern Y, Sano M, Mayeux R</AU>
<TI>Effects of oral physostigmine in Alzheimer's disease</TI>
<SO>Annals of Neurology</SO>
<YR>1987</YR>
<VL>22</VL>
<PG>306-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stern Y, Sano M, Mayeux R</AU>
<TI>Long term administration of oral physostigmine in Alzheimer's disease</TI>
<SO>Neurology</SO>
<YR>1988</YR>
<VL>38</VL>
<PG>1837-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thal-1989" MODIFIED="2008-06-02 14:03:21 +0100" MODIFIED_BY="Helen Collins" NAME="Thal 1989" YEAR="1989">
<REFERENCE MODIFIED="2008-06-02 14:03:21 +0100" MODIFIED_BY="Helen Collins" NOTES="&lt;p&gt;Thal LJ, Masur DM, Blau AD, Fuld PA, Klauber MR. Chronic oral physostigmine without lecithin improves memory in Alzheimer's disease. J Am Geriatr Soc 1989; 37: 42-8 .&lt;/p&gt;" NOTES_MODIFIED="2008-06-02 14:03:21 +0100" NOTES_MODIFIED_BY="Helen Collins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thal LJ, Masur DM, Blau AD, Fuld PA, Klauber MR</AU>
<TI>Chronic oral physostigmine without lecithin improves memory in Alzheimer's disease</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>1989</YR>
<VL>37</VL>
<PG>42-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thal-1996a" NAME="Thal 1996a" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Thal LJ, Schwartz G, Sano M, Weiner M, Knopman D, Harrell L, Bodenheimer S, Rossor M, Philpot M, Schor J, Goldberg A. A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease. Neurology 1996; 47: 1389-1395 .&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thal LJ, Schwartz G, Sano M, Weiner M, Knopman D, Harrell L, Bodenheimer S, Rossor M, Philpot M, Schor J, Goldberg A</AU>
<TI>A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease</TI>
<SO>Neurology</SO>
<YR>1996</YR>
<VL>47</VL>
<PG>1389-1395</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thal-1996b" NAME="Thal 1996b" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Thal LJ, Schwartz G, Sano M, Weiner M, Knopman D, Harrell L, Bodenheimer S, Rossor M, Philpot M, Schor J, Goldberg A. A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease. Neurology 1996; 47:1389-1395.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thal LJ, Schwartz G, Sano M, Weiner M, Knopman D, Harrell L, Bodenheimer S, Rossor M, Philpot M, Schor J, Goldberg A</AU>
<TI>A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease</TI>
<SO>Neurology</SO>
<YR>1996</YR>
<VL>47</VL>
<PG>1389-1395</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thal-1999" NAME="Thal 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Thal LJ, Ferguson JM, Mintzer J, Raskin A, Targum SD. A 24-week randomized trial of controlled-release physostigmine in patients with Alzheimer's disease. Neurology 1999; 52: 1146-1152.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thal LJ, Ferguson JM, Mintzer J, Raskin A, Targum SD</AU>
<TI>A 24-week randomized trial of controlled-release physostigmine in patients with Alzheimer's disease</TI>
<SO>Neurology</SO>
<YR>1999</YR>
<VL>52</VL>
<PG>1146-1152</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Dyck-2000" MODIFIED="2008-06-02 14:03:44 +0100" MODIFIED_BY="Helen Collins" NAME="van Dyck 2000" YEAR="2000">
<REFERENCE MODIFIED="2008-06-02 14:03:44 +0100" MODIFIED_BY="Helen Collins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Dyck CH, Newhouse P, Falk WE, Mattes JA, for the Physostigmine Study Group</AU>
<TI>Extended-release physostigmine in Alzheimer's disease</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2000</YR>
<VL>57</VL>
<PG>157-164</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-06-02 14:05:12 +0100" MODIFIED_BY="Helen Collins">
<STUDY DATA_SOURCE="PUB" ID="STD-Agnoli-1983" MODIFIED="2008-06-02 14:03:58 +0100" MODIFIED_BY="Helen Collins" NAME="Agnoli 1983" YEAR="1983">
<REFERENCE MODIFIED="2008-06-02 14:03:58 +0100" MODIFIED_BY="Helen Collins" NOTES="&lt;p&gt;Agnoli A, Martucci N, Manna V, Conti L, Fioravanti M. Effect of cholinergic and anticholinergic drugs on short-term memory in Alzheimer's dementia: a neuropsychological and computerized electroencephalographic study. &lt;br&gt;Clin Neuropharmacol 1983; 6: 311-23.&lt;/p&gt;" NOTES_MODIFIED="2008-06-02 14:03:58 +0100" NOTES_MODIFIED_BY="Helen Collins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Agnoli A, Martucci N, Manna V, Conti L, Fioravanti M</AU>
<TI>Effect of cholinergic and anticholinergic drugs on short-term memory in Alzheimer's dementia: a neuropsychological and computerized electroencephalographic study</TI>
<SO>Clinical Neuropharmacology</SO>
<YR>1983</YR>
<VL>6</VL>
<PG>311-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ashford-1981" NAME="Ashford 1981" YEAR="1981">
<REFERENCE NOTES="&lt;p&gt;Ashford J, Soldinger S, Schaeffer J, Cochran L, Jarvik LF Physostigmine and its effect on six patients with dementia. American Journal of Psychiatry 1981; 138: 829-30.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ashford J, Soldinger S, Schaeffer J, Cochran L, Jarvik LF</AU>
<TI>Physostigmine and its effect on six patients with dementia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1981</YR>
<VL>138</VL>
<PG>829-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Becker-1988" NAME="Becker 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Becker R, Giacobini E, Elble R, McIlhany M, Sherman K</AU>
<TI>Potential pharmacotherapy of Alzheimer disease. A comparison of various forms of physostigmine administration</TI>
<TO>Potential pharmacotherapy of Alzheimer disease. A comparison of various forms of physostigmine administration</TO>
<SO>Acta Neurologica Scandinavica</SO>
<YR>1988</YR>
<VL>77</VL>
<NO>Suppl 116</NO>
<PG>19-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bentley-2007" NAME="Bentley 2007" YEAR="2007">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bentley P, Driver J, Dolan RJ</AU>
<TI>Cholinesterase inhibition modulates visual and attentional brain responses in Alzheimer's disease and health</TI>
<SO>Brain</SO>
<YR>2007</YR>
<VL>12</VL>
<PG>1460-2156</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bierer-1993" NAME="Bierer 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bierer LM, Aisen PS, Davidson M, Ryan TM</AU>
<TI>A pilot study of oral physostigmine plus yohimbine in patients with Alzheimer's disease</TI>
<SO>Alzheimer Disease and Associated Disorders</SO>
<YR>1993</YR>
<VL>7</VL>
<NO>2</NO>
<PG>98-104</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bierer-1994" NAME="Bierer 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bierer LM, Aisen PS, Davidson M, Ryan TM, Schmeidler J, Davis KL</AU>
<TI>A pilot study of clonidine plus physostigmine in Alzheimer's disease</TI>
<SO>Dementia</SO>
<YR>1994</YR>
<VL>5</VL>
<PG>243-246</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blin-1998" NAME="Blin 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blin J, Ivanoiu A, De Volder A, Michel C, Bol A, Verellen C, Seron X, Duprez T, Laterre EC</AU>
<TI>Physostigmine results in an increased decrement in brain glucose consumption in Alzheimer's disease</TI>
<SO>Psychopharmacology Berl</SO>
<YR>1998</YR>
<VL>136</VL>
<PG>256-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Caltagirone-1982" MODIFIED="2008-06-02 14:04:44 +0100" MODIFIED_BY="Helen Collins" NAME="Caltagirone 1982" YEAR="1982">
<REFERENCE MODIFIED="2008-06-02 14:04:44 +0100" MODIFIED_BY="Helen Collins" NOTES="&lt;p&gt;Caltagirone C, Gainotti G, Masullo C. Oral administration of chronic physostigmine does not improve cognitive or mnesic performances in Alzheimer's presenile dementia. Intern J Neuroscience 1982; 16: 247-249.&lt;/p&gt;" NOTES_MODIFIED="2008-06-02 14:04:44 +0100" NOTES_MODIFIED_BY="Helen Collins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Caltagirone C, Gainotti G, Masullo C</AU>
<TI>Oral administration of chronic physostigmine does not improve cognitive or mnesic performances in Alzheimer's presenile dementia</TI>
<SO>International Journal of Neuroscience</SO>
<YR>1982</YR>
<VL>16</VL>
<PG>247-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Caltagirone-1983" MODIFIED="2008-06-02 14:04:53 +0100" MODIFIED_BY="Helen Collins" NAME="Caltagirone 1983" YEAR="1983">
<REFERENCE MODIFIED="2008-06-02 14:04:53 +0100" MODIFIED_BY="Helen Collins" NOTES="&lt;p&gt;Caltagirone C, Albanese A, Gainotti G, Masullo C. Acute administration of individual optimal dose of physostigmine fails to improve mnesic performances in Alzheimers presenile dementia. Intern J Neuroscience 1983; 18: 143-48.&lt;/p&gt;" NOTES_MODIFIED="2008-06-02 14:04:53 +0100" NOTES_MODIFIED_BY="Helen Collins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Caltagirone C, Albanese A, Gainotti G, Masullo C</AU>
<TI>Acute administration of individual optimal dose of physostigmine fails to improve mnesic performances in Alzheimers presenile dementia</TI>
<SO>International Journal of Neuroscience</SO>
<YR>1983</YR>
<VL>18</VL>
<PG>143-48</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Christie-1981" NAME="Christie 1981" YEAR="1981">
<REFERENCE NOTES="&lt;p&gt;Christie JE, Shering A, Ferguson J, Glen IM. Physostigmine and arecoline: effects of intravenous infusions in Alzheimer presenile dementia. Brit J Psychiat 1981; 138: 46-50.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Christie JE, Shering A, Ferguson J, Glen IM</AU>
<TI>Physostigmine and arecoline: effects of intravenous infusions in Alzheimer presenile dementia</TI>
<SO>Brit J Psychiat</SO>
<YR>1981</YR>
<VL>138</VL>
<PG>46-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cummings-1993" NAME="Cummings 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cummings JL, Gorman DG, Shapira J</AU>
<TI>Physostigmine ameliorates the delusions of Alzheimer's disease</TI>
<SO>Biol Psychiatry</SO>
<YR>1993</YR>
<VL>33</VL>
<NO>7</NO>
<PG>536-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gorman DG, Read S, Cummings JL</AU>
<TI>Cholinergic therapy of behavioral disturbances in Alzheimer's disease</TI>
<SO>Neuropsychiatry, Neuropsychology and Behavioral Neurology</SO>
<YR>1993</YR>
<VL>6</VL>
<NO>6</NO>
<PG>229-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Davis-1979" NAME="Davis 1979" YEAR="1979">
<REFERENCE NOTES="&lt;p&gt;This is a letter reporting the preliminary results of the effect of physostigmine on 6 patients (3 nondemented elderly women, 2 with Alzheimer's disease and 1 with Huntington's disease)&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davis KL, Mohs RC</AU>
<TI>Enhancement of memory by physostigmine</TI>
<TO>Enhancement of memory by physostigmine</TO>
<SO>N Engl J Med</SO>
<YR>1979</YR>
<VL>301</VL>
<PG>946-947</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Giuffra-1990" NAME="Giuffra 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Giuffra M, Mouradian MM, Bammert J, Claus JJ, Mohr E, Ownby J, Chase TN</AU>
<TI>Prolonged intravenous infusion of physostigmine in Alzheimer's disease</TI>
<SO>Neurology</SO>
<YR>1990</YR>
<VL>40</VL>
<NO>Suppl 1</NO>
<PG>229</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Imbimbo-2001" MODIFIED="2008-06-02 14:05:12 +0100" MODIFIED_BY="Helen Collins" NAME="Imbimbo 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-06-02 14:05:12 +0100" MODIFIED_BY="Helen Collins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Imbimbo BP</AU>
<TI>Pharmacodynamic tolerability relationships of cholinesterase inhibitors for Alzheimer's disease</TI>
<SO>CNS Drugs</SO>
<YR>2001</YR>
<VL>15</VL>
<PG>375-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jenike-1990b" NAME="Jenike 1990b" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jenike MA, Albert MS, Baer L</AU>
<TI>Oral physostigmine as treatment for dementia of the Alzheimer type: a long-term outpatient trial</TI>
<SO>Alzheimer Disease and Associated Disorders</SO>
<YR>1990</YR>
<VL>4</VL>
<NO>4</NO>
<PG>226-231</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jotkowitz-1983" NAME="Jotkowitz 1983" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;Jotkowitz S. Lack of clinical efficacy of chronic oral physostigmine in Alzheimer's disease. Ann Neurol 1983; 14: 690-1. &lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jotkowitz S</AU>
<TI>Lack of clinical efficacy of chronic oral physostigmine in Alzheimer's disease</TI>
<SO>Ann Neurol</SO>
<YR>1983</YR>
<VL>14</VL>
<PG>690-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levy-1992" NAME="Levy 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levy A, Brandeis R, Treves TA, Meshulam T, Feiler D, Mewassi F, Wengier A, Glikfeld P, Grunwald J, Dachir S, Rabey JM, Levy D, Korczyn AD</AU>
<TI>Transdermal physostigmine in Alzheimer's disease (AD)</TI>
<SO>Neurobiology of Aging</SO>
<YR>1992</YR>
<VL>13</VL>
<NO>Suppl 1</NO>
<PG>S125</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levy-1994" NAME="Levy 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levy A, Brandeis R, Treves TA, Meshulam Y, Mawassi F, Feiler D, Wengier A, Glikfeld P, Grunwald J, Dachir S, et al</AU>
<TI>Transdermal physostigmine in the treatment of Alzheimer's disease</TI>
<SO>Alzheimer Dis Assoc Disord</SO>
<YR>1994</YR>
<VL>8</VL>
<PG>15-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marin-1995" NAME="Marin 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Marin DB, Bierer LM, Lawlor BA, Ryan TM, Jacobson R, Schmeidler J, Mohs RC, Davis KL. L-deprenyl and physostigmine for the treatment of Alzheimer's disease. &lt;br&gt;Psychiatry Res 1995; 58: 181-189.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marin DB, Bierer LM, Lawlor BA, Ryan TM, Jacobson R, Schmeidler J, Mohs RC, Davis KL</AU>
<TI>L-deprenyl and physostigmine for the treatment of Alzheimer's disease</TI>
<SO>Psychiatry Res</SO>
<YR>1995</YR>
<VL>58</VL>
<PG>181-189</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mitchell-1986" NAME="Mitchell 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mitchell A, Drachman DA, O'Donnell B, Glosser G</AU>
<TI>Oral physostigmine in Alzheimer's disease</TI>
<SO>Neurology</SO>
<YR>1986</YR>
<VL>36</VL>
<NO>Suppl 1</NO>
<PG>295</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Muramoto-1979" NAME="Muramoto 1979" YEAR="1979">
<REFERENCE NOTES="&lt;p&gt;Muramoto O, Sugishita M, Sugita H, Toyokura Y. Effect of physostigmine on constructional and memory tasks in Alzheimer's disease. Arch-Neurol 1979; 36 :501-3.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Muramoto O, Sugishita M, Sugita H, Toyokura Y</AU>
<TI>Effect of physostigmine on constructional and memory tasks in Alzheimer's disease</TI>
<SO>Arch-Neurol</SO>
<YR>1979</YR>
<VL>36</VL>
<PG>501-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Muramoto-1984" NAME="Muramoto 1984" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;Muramoto O, Sugishita M, Ando K. Cholinergic system and constructional praxis: A further study of physostigmine in Alzheimer's disease. J Neurol Neurosurg Psychiatry 1984; 47: 485-491.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Muramoto O, Sugishita M, Ando K</AU>
<TI>Cholinergic system and constructional praxis: A further study of physostigmine in Alzheimer's disease</TI>
<SO>J Neurol Neurosurg Psychiatry</SO>
<YR>1984</YR>
<VL>47</VL>
<PG>485-491</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peters-1979" NAME="Peters 1979" YEAR="1979">
<REFERENCE NOTES="&lt;p&gt;Peters BH, Levin HS. Effects of physostigmine and lecithin on memory in Alzheimer disease. Ann Neurol 1979; 6: 219-21.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peters BH, Levin HS</AU>
<TI>Effects of physostigmine and lecithin on memory in Alzheimer disease</TI>
<SO>Ann Neurol</SO>
<YR>1979</YR>
<VL>6</VL>
<PG>219-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schemechel-1984" NAME="Schemechel 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schmechel DE, Schmitt F, Horner J, Wilkinson WE</AU>
<TI>Lack of effect of oral physostigmine and lecithin in patients with probable Alzheimer's disease</TI>
<SO>Neurology</SO>
<YR>1984</YR>
<VL>34</VL>
<NO>Suppl 1</NO>
<PG>280</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schneider-1993" NAME="Schneider 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Schneider LS, Olin JT, Pawluczyk S. A double-blind crossover pilot study of l-deprenyl (selegiline) combined with cholinesterase inhibitor in Alzheimer's disease. &lt;br&gt;Am J Psychiatry 1993; 150: 321-3.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schneider LS, Olin JT, Pawluczyk S</AU>
<TI>A double-blind crossover pilot study of l-deprenyl (selegiline) combined with cholinesterase inhibitor in Alzheimer's disease</TI>
<SO>Am J Psychiatry</SO>
<YR>1993</YR>
<VL>150</VL>
<PG>321-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schwartz-1986" NAME="Schwartz 1986" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;Schwartz AS, Kohlstaedt EV. Physostigmine effects in Alzheimer's disease: relationship to dementia severity. &lt;br&gt;Life Sci 1986; 38: 1021-8.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schwartz AS, Kohlstaedt EV</AU>
<TI>Physostigmine effects in Alzheimer's disease: relationship to dementia severity</TI>
<SO>Life Sci</SO>
<YR>1986</YR>
<VL>38</VL>
<PG>1021-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sevush-1991" NAME="Sevush 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;Sevush S, Guterman A, Villalon AV. Improved verbal learning after outpatient oral physostigmine therapy in patients with dementia of the Alzheimer type. J Clin Psychiatry 1991; 52: 300-3.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sevush S, Guterman A, Villalon AV</AU>
<TI>Improved verbal learning after outpatient oral physostigmine therapy in patients with dementia of the Alzheimer type</TI>
<SO>J Clin Psychiatry</SO>
<YR>1991</YR>
<VL>52</VL>
<PG>300-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-1979" NAME="Smith 1979" YEAR="1979">
<REFERENCE NOTES="&lt;p&gt;Smith CM, Swash M. Physostigmine in Alzheimer's disease [letter] . Lancet 1979; 1: 42.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith CM, Swash M</AU>
<TI>Physostigmine in Alzheimer's disease [letter]</TI>
<SO>Lancet</SO>
<YR>1979</YR>
<VL>1</VL>
<PG>42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Storey-1992" NAME="Storey 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Storey P, Harrell L, Duke L, Callaway R, Marson D</AU>
<TI>Does chronic oral physostigmine alter the course of Alzheimer's disease?</TI>
<SO>Neurobiology of Aging</SO>
<YR>1992</YR>
<VL>13</VL>
<NO>Suppl 1</NO>
<PG>S126</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sunderland-1992" NAME="Sunderland 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Sunderland T, Molchan S, Lawlor B, Martinez R, Mellow A, Martinson H, Putnam K, Lalonde F. A strategy of &amp;quot;combination chemotherapy&amp;quot; in Alzheimer's disease: rationale and preliminary results with physostigmine plus deprenyl. &lt;br&gt;Int Psychogeriatr 1992; 4 (Suppl 2): 291-309.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sunderland T, Molchan S, Lawlor B, Martinez R, Mellow A, Martinson H, Putnam K, Lalonde F</AU>
<TI>A strategy of "combination chemotherapy" in Alzheimer's disease: rationale and preliminary results with physostigmine plus deprenyl</TI>
<SO>Int Psychogeriatr</SO>
<YR>1992</YR>
<VL>4</VL>
<NO>Suppl 2</NO>
<PG>291-309</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thal-1983" NAME="Thal 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thal LJ, Fuld PA, Masur DM, Sharpless NS</AU>
<TI>Oral physostigmine and lecithin improve memory in Alzheimer's disease</TI>
<SO>Ann Neurol</SO>
<YR>1983</YR>
<VL>13</VL>
<PG>491-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thal LJ, Fuld PA</AU>
<TI>Memory enhancement with oral physostigmine in Alzheimer's disease</TI>
<SO>N Eng J Med</SO>
<YR>1983</YR>
<VL>24</VL>
<PG>720</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tune-1991" NAME="Tune 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tune L, Brandt J, Frost JJ, Harris G, Mayberg H, Steele C, Burns A, Sapp J, Folstein MF, Wagner HN, Pearlson GD</AU>
<TI>Physostigmine in Alzheimer's disease: effects on cognitive functioning, cerebral glucose metabolism analyzed by positron emission tomography and cerebral blood flow analyzed by single photon emission tomography</TI>
<SO>Acta Psychiatr Scand</SO>
<YR>1991</YR>
<VL>Suppl 366</VL>
<PG>61-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wettstein-1982" NAME="Wettstein 1982" YEAR="1982">
<REFERENCE NOTES="&lt;p&gt;Wettstein A. Double-blind, placebo-controlled trial of lecithin and physostigmine in Alzheimer's disease. Schweiz Arch Neurol Neurochir Psychiatr 1982; 131: 223-224 .&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wettstein A</AU>
<TI>Double-blind, placebo-controlled trial of lecithin and physostigmine in Alzheimer's disease</TI>
<SO>Schweiz Arch Neurol Neurochir Psychiatr</SO>
<YR>1982</YR>
<VL>131</VL>
<PG>223-224</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wettstein A</AU>
<TI>No effect from double-blind trial of physostigmine and lecithin in Alzheimer's disease</TI>
<SO>Ann Neurol</SO>
<YR>1983</YR>
<VL>13</VL>
<PG>201-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-06-02 14:07:19 +0100" MODIFIED_BY="Helen Collins">
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-APA-1994" NAME="APA 1994" TYPE="BOOK">
<AU>American Psychiatric Association</AU>
<SO>Diagnostic and Statistical Manual of Mental Disorders,4th edition(DSM-IV)</SO>
<YR>1994</YR>
<PB>American Psychiatric Press</PB>
<CY>Washington DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chalmers-1983" NAME="Chalmers 1983" NOTES="&lt;p&gt;Chalmers TC, Celano P, Sacks HS, Smith H, Jr. Bias in treatment assignment in controlled clinical trials. N Engl J Med 1983; 309(22): 1358-61.&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Chalmers TC, Celano P, Sacks HS, Smith H, Jr</AU>
<TI>Bias in treatment assignment in controlled clinical trials</TI>
<SO>N Engl J Med</SO>
<YR>1983</YR>
<VL>309</VL>
<NO>22</NO>
<PG>1358-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Coyle-1983" NAME="Coyle 1983" NOTES="&lt;p&gt;Coyle JT, Price DL, DeLong MR. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 1983; 219: 1184-90.&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Coyle JT, Price DL, DeLong MR</AU>
<TI>Alzheimer's disease: a disorder of cortical cholinergic innervation</TI>
<SO>Science</SO>
<YR>1983</YR>
<VL>219</VL>
<PG>1184-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Davies-1976" NAME="Davies 1976" NOTES="&lt;p&gt;Davies P, Maloney AJF. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976; 2: 1403. &lt;/p&gt;&lt;p&gt;&lt;br&gt;&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Davies P, Maloney AJF</AU>
<TI>Selective loss of central cholinergic neurons in Alzheimer's disease</TI>
<SO>Lancet</SO>
<YR>1976</YR>
<VL>2</VL>
<PG>1403</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Davis-1978" NAME="Davis 1978" NOTES="&lt;p&gt;Davis KL, Mohs RC, Tinklenberg JR, Pfefferbaum A, Hollister LE, Koppel BS. Physostigmine improvement of long term memory processes in normal humans. Science 1978; 201: 272-274.&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Davis KL, Mohs RC, Tinklenberg JR, Pfefferbaum A, Hollister LE, Koppel BS</AU>
<TI>Physostigmine improvement of long term memory processes in normal humans</TI>
<SO>Science</SO>
<YR>1978</YR>
<VL>201</VL>
<PG>272-274</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Davis-1979" NAME="Davis 1979" NOTES="&lt;p&gt;Davis KL, Mohs RC, Tinklenberg JR. Enhancement of memory by physostigmine. &lt;br&gt;N Engl J Med 1979; 301: 946.&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Davis KL, Mohs RC, Tinklenberg JR</AU>
<TI>Enhancement of memory by physostigmine</TI>
<SO>N Engl J Med</SO>
<YR>1979</YR>
<VL>301</VL>
<PG>946</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Doucette-1986" NAME="Doucette 1986" NOTES="&lt;p&gt;Doucette R, Fisman M, Hachinski VC, Mersky H. Cell loss from the nucleous basalis of Meynert in Alzheimer's disease. Can J Neurol Sci, 1986; 13: 435-40.&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Doucette R, Fisman M, Hachinski VC, Mersky H</AU>
<TI>Cell loss from the nucleous basalis of Meynert in Alzheimer's disease</TI>
<SO>Can J Neurol Sci,</SO>
<YR>1986</YR>
<VL>13</VL>
<PG>435-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McKhann-1984" NAME="McKhann 1984" TYPE="JOURNAL_ARTICLE">
<AU>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM</AU>
<TI>Clinical diagnosis of Alzheimer's disease</TI>
<SO>Neurology</SO>
<YR>1984</YR>
<VL>34</VL>
<PG>939-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Perry-1977" NAME="Perry 1977" NOTES="&lt;p&gt;Perry EK, Perry RH, Blessed G, Tomlinson BE. Necropsy evidence of central cholinergic deficits in senile dementia. Lancet 1977; 1 (8004): 189.&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Perry EK, Perry RH, Blessed G, Tomlinson BE</AU>
<TI>Necropsy evidence of central cholinergic deficits in senile dementia</TI>
<SO>Lancet</SO>
<YR>1977</YR>
<VL>1</VL>
<NO>8004</NO>
<PG>189</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" NAME="Schulz 1995" NOTES="&lt;p&gt;Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273(5):408-12&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<NO>5</NO>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sims-1980" NAME="Sims 1980" NOTES="&lt;p&gt;Sims NR, Smith CC, Davison AN. Glucose metabolism and acetylcholine synthesis in relation to neuronal activity in Alzheimer's disease . Lancet 1980; 1: 333-5.&lt;br&gt;&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Sims NR, Smith CC, Davison AN</AU>
<TI>Glucose metabolism and acetylcholine synthesis in relation to neuronal activity in Alzheimer's disease</TI>
<SO>Lancet</SO>
<YR>1980</YR>
<VL>1</VL>
<PG>333-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Whitehouse-1982" NAME="Whitehouse 1982" NOTES="&lt;p&gt;Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, DeLong MR. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 1982; 215: 1237.&lt;br&gt;&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, DeLong MR</AU>
<TI>Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain</TI>
<SO>Science</SO>
<YR>1982</YR>
<VL>215</VL>
<PG>1237</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2008-06-02 14:07:19 +0100" MODIFIED_BY="Helen Collins">
<REFERENCE ID="REF-Coelho-Filho-2001" MODIFIED="2008-06-02 14:07:19 +0100" MODIFIED_BY="Helen Collins" NAME="Coelho Filho 2001" TYPE="COCHRANE_REVIEW">
<AU>Coelho Filho JM, Birks J</AU>
<TI>Physostigmine for dementia due to Alzheimer's disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>2 10.1002/14651858.CD001499 10.1002/14651858.CD001499</NO>
<IDENTIFIERS MODIFIED="2008-06-02 14:07:19 +0100" MODIFIED_BY="Helen Collins">
<IDENTIFIER MODIFIED="2008-06-02 14:07:19 +0100" MODIFIED_BY="Helen Collins" TYPE="DOI" VALUE="10.1002/14651858.CD001499"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-06-02 13:57:30 +0100" MODIFIED_BY="Helen Collins">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-06-02 13:55:21 +0100" MODIFIED_BY="Helen Collins" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2008-06-02 13:54:17 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Asthana-1995">
<CHAR_METHODS>
<P>Design:<BR/>Double-blind<BR/>randomized<BR/>placebo-controlled <BR/>crossover </P>
<P>Washout period (minimum 1 week) between the two study phases<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: USA<BR/>Number: 9 patients <BR/>Sex: 4 males, 5 females<BR/>Age (mean): 68.7 years (+/- 12.1)<BR/>Diagnosis Criteria: NINCDS-ADRDA <BR/> Hachinski score &lt; 4.<BR/>Battery of laboratory tests to exclude other illnesses.<BR/>CAT scan or MRI: normal or only cortical atrophy.<BR/>Other medication stopped 3 weeks before trial entry<BR/>Severity of AD: mild to moderate<BR/>Duration of symptoms (mean): 4.1 years (+/- 1.6).<BR/>MMSE score (mean): 22.2 (+/- 3.4).<BR/>Blessed dementia score (mean): 7.7 (+/-6.7).<BR/>Blessed Memory Information Concentration Test score (mean): 25.1 (+/- 5.5).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-06-02 13:54:17 +0100" MODIFIED_BY="Helen Collins">
<P>1. placebo<BR/>2. physostigmine: continuous i.v. infusion, (0.02 to 1.041 mg/h) optimal dose</P>
<P>During drug or placebo infusions, all patients received methscopolamine bromide (2.5mg orally every 8 h).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>BSRT<BR/>PALW<BR/>GRS<BR/>Stroop Color Word Interference Test<BR/>digit symbol<BR/>figure copying<BR/>COWAT<BR/>category fluency<BR/>TT<BR/>calculations<BR/>Adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Best dose of physostigmine identified in a previous dose-finding phase<BR/>Psychometric performance was analyzed for all participants, but Geriatric Rating Scale (functional assessment) was for 8 subjects.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Beller-1985">
<CHAR_METHODS>
<P>Design:<BR/>Double-blind<BR/>randomized<BR/>placebo controlled<BR/>multiple phase crossover design (2 days x 4) </P>
<P>Order of dose conditions randomized separately for each patient<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: USA<BR/>Number: 8 inpatients in a geropsychiatric unit.<BR/>Sex: 4 males and 4 females<BR/>Age: 58-83 years<BR/>Diagnosis Criteria: DSM III for PDD<BR/>Severity of AD: moderate to moderately severe Reisberg scores 3-5<BR/>MIT scores 6-13</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. placebo<BR/>2. oral physostigmine 0.5 mg every 2 hours 7 doses per day (3.5 mg per day)<BR/>3. oral physostigmine 1.0 mg every 2 hours 7 doses per day (7.0 mg/day)<BR/>4. oral physostigmine 2.0 mg every 2 hours 7 doses per day (14.0 mg/day)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>BSRT<BR/>SCAG<BR/>BPRS<BR/>NOSIE</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Outcomes assessed on the second day of treatment.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Davis-1982">
<CHAR_METHODS>
<P>Design:<BR/>Double-blind<BR/>randomized<BR/>placebo controlled<BR/>crossover study</P>
<P>Two to 4 days generally separated each infusion (occurred at the same time of day)<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: USA<BR/>Number: 10 patients <BR/>Sex: 8 males; 2 females<BR/>Age: 50-68 years<BR/>Severity of AD: moderate <BR/>Patients with at least 1-year history of progressive memory loss<BR/>Diagnosis criteria: Clinical history, physical examination, CAT scan, brain skull films, CSF analysis and serum analysis (for excluding other conditions). Not clear if all patients had such radiologic and laboratory examinations.<BR/>MIT &lt; =10 <BR/>DRS &gt; =4 </P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. placebo<BR/>2. physostigmine i.v.optimal dose ( 0.125, 0.25 or 0.5mg dissolved in 100cc of normal saline at a constant rate over 30 min.)+2.5mg Probanthine, a cholinergic antagonist that does not cross the blood-brain barrier, i.v. 5 min before every infusion to minimize physostigmine's peripheral effects.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Famous faces test (retrieval from remote memory)<BR/>Digit span test<BR/>Word or picture recognition test (recognition memory test)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Optimal dose found in a prior dose finding phase. All patients were free of psychoactive medications for at least two weeks prior to physostigmine.<BR/>Results were subjected to a technique (signal detectability analysis) which suggested that new items were more discriminable following physostigmine, and that patient's criteria for saying that they recognized an item also changed with physostigmine infusion.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Gustafson-1987">
<CHAR_METHODS>
<P>Design:<BR/>Double-blind <BR/>randomized<BR/>placebo controlled<BR/>crossover study</P>
<P>
<BR/>One-day washout period between drug and placebo.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Sweden<BR/>Number: 10 patients <BR/>Sex: 5 males and 5 females<BR/>Age: 49-71 years.<BR/>Diagnosis criteria: Clinical evaluation (focused upon differential diagnosis between AD, dementia of the Pick type, and cerebrovascular dementia).<BR/>The Hachinski ischemic score and rating scales for identification of AD and of Pick's disease were used.<BR/>CT scan performed in seven patients (normal in three cases and slight atrophy in four).<BR/>Severity of AD: Mean duration of the disease: 3.8 years (1.5-5.4 years).<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. placebo<BR/>2. physostigmine i.v. (bolus injection of 0.5mg followed by infusion for 2 hours; mean total amount given: 1.9 mg)+30mg propantheline bromide was given to reduce the autonomic side effects of physostigmine.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Neurophsychological test battery<BR/>Reaction time (RT)<BR/>Examination for aphasia<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Outcomes assessed before infusion (RT and aphsia items), during infusion (RT, the neuropsychological battery, the aphsaia examination, and memory), and about three hours after the drug infusion (RT only).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Harrell-1990">
<CHAR_METHODS>
<P>Design:<BR/>Double-blind <BR/>randomozed<BR/>placebo controlled<BR/>crossover <BR/>(2 weeks X 2)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: USA<BR/>Number: 20 patients <BR/>Sex: 9 males, 11 females<BR/>Age: 51-77 years (mean age, 63+/-3.1 years)<BR/>Diagnosis criteria: NINCDS-ADRDA<BR/>Clinical and laboratory examination, particularly to rule out other causes of dementia. CAT scan: normal or diffuse atrophy.<BR/>Hachinski Score &lt; 4<BR/>Severity of AD: All patients had at least a one-year history of progressive cognitive impairment.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. placebo<BR/>2. oral physostigmine: optimal dose (1, 1.5, 2.0 or 2.5mg /dose)(six doses per day every 2 h) </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>BSRT<BR/>Category generation<BR/>Picture recognition<BR/>Finger tapping<BR/>Side effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>The best dose of physostigmine was identified in a previous dose-finding phase (two weeks). Then all patients were treated at home with physostigmine ( 2 weeks) up to randomization. Neuropsychological testing performed at the end of each two-week interval.<BR/>One patient was excluded due to deterioration in language function prior to crossover.<BR/>One patient presented cardiac toxicity (fibrillation-flutter) with physostigmine.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-06-02 13:54:52 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Jenike-1990">
<CHAR_METHODS>
<P>Design:<BR/>Double-blind <BR/>randomized<BR/>placebo controlled<BR/>crossover study <BR/>(1 week X 2)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-06-02 13:54:52 +0100" MODIFIED_BY="Helen Collins">
<P>Country: USA<BR/>Number: 23 patients<BR/>Sex: 12 males, 11 females<BR/>Age: 53-89 years (mean of 66 years)<BR/>Diagnosis criteria: NINCDS-ADRDA<BR/>Other possible causes of dementia were ruled out by laboratory tests<BR/>CT scans and EEGs were normal<BR/>Severity of AD: Mild to moderate cognitive impairment.<BR/>Patients scores on the Mattis Dementia Rating Scale (maximum possible score, 144): 81-140 (mean of 115).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. placebo<BR/>2. oral physostigmine optimal dose <BR/>Doses: Not specified</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Delayed Recognition Span Test (DRST)<BR/>BSRT<BR/>ADAS<BR/>BNT<BR/>Digit span<BR/>Figure copy</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Details on administration scheme, including doses, are not available in this paper.<BR/>One patient was excluded from the analysis (missing data due to inability to carry out some of the tests)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Mohs-1985">
<CHAR_METHODS>
<P>Design:<BR/>Double-blind<BR/>randomized<BR/>placebo controlled crossover study <BR/>3-5 days X 2</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: USA<BR/>Number: 12 patients <BR/>Sex: 8 males; 4 females.<BR/>Age: 52-76 years (mean age: 62.3 years).<BR/>Diagnosis criteria: Clinical history, CAT scans and laboratory examinations mainly to rule out other possible causes of dementia.<BR/>Severity of AD: All patients had at least a 1-year history of cognitive impairment<BR/>MIT scores 1-17 (mean, 9.8) <BR/>DRS 0 -5.5 (mean, 2.9)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. placebo<BR/>2. oral physostigmine optimal dose (0.5, 1.0, 1.5 or 2.0 mg every 2 hours 8 doses/day) <BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>ADAS</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Preliminary dose finding phase<BR/>Two patients did not complete the study: one had no improvement on any dose of physostigmine in the dose-finding phase and the other was dropped out, due to delusions and hallucinations while receiving physostigmine, and excluded from analysis.</P>
<P>Oucomes assessed on the last day of each treatment condition.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-M_x00f6_ller-1999">
<CHAR_METHODS>
<P>Design:<BR/>Double-blind<BR/>randomized<BR/>placebo-controlled<BR/>parallel group<BR/>24 weeks<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Germany<BR/>27 centres<BR/>Number: 181 patients <BR/>Sex:52 % female<BR/>Age: 69.3 +/- 8.2 years.<BR/>Diagnosis Criteria: NINCDS-ADRDA <BR/>DSM-III-R<BR/>Severity of AD: MMSE 10-24<BR/>Mod Hachinski =&lt; 4<BR/>Hamilton DS =&lt; 16<BR/>Exclusion: other forms of dementia<BR/>major disease<BR/>history of alcohol or drug abuse<BR/>vitamin deficiency</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. placebo<BR/>2. verum patch applied once a day containing 30 mg physostigmine, releasing about 5.7mg over 24 hours<BR/>3. 2 verum patches applied once a day containing 30x2 mg physostigmine, releasing about 5.7x2 mg over 24 hours</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>ADAS-Cog<BR/>CGIC<BR/>NOSGER<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>There was a 4 week placebo phase before randomization</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-06-02 13:55:21 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Sano-1993">
<CHAR_METHODS>
<P>Design:<BR/>Double-blind<BR/>randomized<BR/>placebo-controlled<BR/>crossover <BR/>6 weeks X 2</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: USA<BR/>Number: 29 patients <BR/>Sex: No information<BR/>Age: 69.1 +/- 9.1 years.<BR/>Diagnosis Criteria: NINCDS-ADRDA <BR/>Severity of AD: Average duration of illness: 4.2 +/- 0.3 years<BR/>Mean mMMSE: 35.65 +/- 7.22 (equivalent to 18 on the MMSE)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-06-02 13:55:21 +0100" MODIFIED_BY="Helen Collins">
<P>1. placebo<BR/>2. oral physostigmine highest tolerated dose (2-4 mg every 2 hours, 4 doses/day)</P>
<P>Placebo - 6 weeks<BR/>Route: Oral</P>
<P>Doses:<BR/>2-4 mg every 2 hours (4 daily doses) for 6 weeks.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>BSRT<BR/>SIP<BR/>SMQ</P>
<P>Side effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Optimal dose determined during a 2 day dose titration phase. After receiving two first doses, patients were discharged to take medication under supervision at home (compliance assessment method not mentioned) for 6 weeks.</P>
<P>BSRT was administered before the first phase (dose-titration), six times during dose-titration phase. In the second phase (crossover) memory testing were performed twice at the end of the 6 week interval. ECG and other outcome measures were also completed at this time.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Stern-1987">
<CHAR_METHODS>
<P>Design:<BR/>Double-blind <BR/>randomized<BR/>placebo controlled<BR/>crossover <BR/>(6 phases of 4-6 weeks each, placebo administered in 1 randomly selected phase)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: USA<BR/>Number: 22 patients.<BR/>Sex: No information<BR/>Age: 58.7 - 75.5 years (average 67.1 years).<BR/>Diagnosis criteria: NINCDS-ADRDA , DSM III<BR/>Severity of AD: Average score on the modified Mini-Mental State Examination (mMMS): 41 (32.7-49.3)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. placebo<BR/>2. oral physostigmine highest tolerated or best individual doses 12.5-16.0mg/day taken every 2 h in 4 -6 doses) </P>
<P>13 patients had not the best dose and the dose used was the highest tolerated which was not reported in the paper.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>BSRT<BR/>MMSE Modified (mMMSE)<BR/>WAIS-R<BR/>Digit Symbol<BR/>WMS<BR/>COWAT<BR/>Category naming<BR/>RDT<BR/>Cancelations (letters, shapes)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Best dose, or highest tolerated dose determined in a 5-day phase prior to randomization. BSRT was administered twice daily and other tests on the third day of each crossover period.<BR/>12 patients were excluded before randomisation due to inability to perform the tests.<BR/>This is an extended double-blind crossover trial with 14 out of 22 patients included in the previous study by Stern 1987. Information on the remaining 8 patients was not available. </P>
<P>The participants were: 8 out of 9 defined as responders in the previous study by the same authors; 4 out of 9 nonresponders and 2 out of 4 patients who performed worse on physostigmine than on placebo.</P>
<P>The underlying hypothesis in this study was that extended exposure to oral physostigmine might be required for the drug to be effective.</P>
<P>SRT and neurologic evaluation were performed at the completion of each interval.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Thal-1989">
<CHAR_METHODS>
<P>Design:<BR/>double-blind<BR/>randomized<BR/>placebo controlled<BR/>parallel group</P>
<P>Second phase: the best dose of physostigmine or placebo from the first phase was mantained for 6 weeks</P>
<P>Finally all individuals were crossed over to placebo for 2 additional weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: USA<BR/>Number: 16 outpatients <BR/>Sex: No information<BR/>Age: 56-80 years (mean 64 years).<BR/>Diagnosis criteria: Research diagnostic criteria for AD (Eisdorfer and Cohen, 1980) and NINCDS-ADRDA <BR/>Patients showed atrophy or no change on CT scan, and normal and diffusely slow EEG.<BR/>Severity of AD: Early to moderate AD<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. placebo<BR/>2. oral physostigmine best dose (10, 15 or 20 mg/day in 5 divided doses) <BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>BSRT<BR/>Rosen Construction Task<BR/>NOSIE<BR/>ADL<BR/>IADL<BR/>PADL<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Patients titrated to highest tolerated dose in first 3 weeks after randomization. In addition to assessing memory, this trial attempted to assess the effect of physostigmine on other areas of cognition. It was the first trial on physostigmine assessing functional performance.<BR/>All patients were begun on placebo for 1 week, and then baseline testing was carried out. The patients wre tested with 3 dise and placebo over the next 4 weeks to find the best tolerated dose. This was followed by the 6 week randomized phase using the best tolerated dose or placebo, and both groups completed with 2 weeks on placebo.</P>
<P>Psychometric testing was performed before the first phase (baseline), at the end of each week in the first phase, every 2 weeks in the second phase, and at the end of the last study period (placebo).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Thal-1996a">
<CHAR_METHODS>
<P>Design: <BR/>Randomized<BR/>double-blind<BR/>placebo-controlled<BR/>6 week<BR/>parallel group <BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: USA and UK<BR/>40 centres<BR/>Number: 366 patients <BR/>Sex: 184 males, 182 females<BR/>Diagnosis criteria: NINCDS-ADRDA<BR/>Severity of AD: MMSE between 10 and 26, mean 17.7 <BR/>Hachinski &lt;= 4<BR/>3 or more points improvement on ADAS-Cog during the dose titration phase (responders)<BR/>No medication that affects CNS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. placebo<BR/>2. controlled release physostigmine best dose (18-30 mg per day divided into 2 doses)</P>
<P>Route: Oral</P>
<P>Doses:<BR/>9 mg (105 patients); 12 mg (137 patients) or 15 mg (124 patients) twice daily for 6 weeks.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>ADAS-Cog<BR/>CGIC<BR/>MMSE<BR/>ADL<BR/>PSMS</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>The original paper deals with two randomized parallel trials: one with physostigmine responders, and other with physostigmine non-responders identified in a previous dose-titration phase. For this review, these two trials were considered separetely (Thal (a) 1996; Thal (b) 1996). </P>
<P>A number of 1,111 patients were initially enrolled in the study: 366 were defined as physostigmine responders, 449 as physostigmine non-responders. </P>
<P>263 individuals withdrew from the study prior to randomisation: 185 due to adverse events in the dose-titration phase, and 78 due to multiple reasons in the placebo washout. </P>
<P>Among the 366 responders randomized, 33 withdrew from the study due to adverse effects (24 (13.1%) with physostigmine, and 9 (4.9%) with placebo). In the completers analysis, however, <BR/>the numbers showed in the table do not agree (3 more patients withdrew in each arm).</P>
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Thal-1996b">
<CHAR_METHODS>
<P>Design: <BR/>Randomized<BR/>double-blind<BR/>placebo-controlled<BR/>parallel group <BR/>6 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: USA and UK<BR/>40 centres<BR/>Number: 439 patients <BR/>Sex: <BR/>Diagnosis criteria: NINCDS-ADRDA<BR/>Severity of AD: MMSE between 10 and 26, mean 18.7 <BR/>Hachinski &lt;= 4<BR/>less than 3 points improvement on ADAS-Cog during the dose titration phase (nonresponders)<BR/>No medication that affects CNS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. placebo<BR/>2. controlled release physostigmine best tolerated dose (18-30 mg per day divided into 2 doses)</P>
<P>Route: Oral</P>
<P>Doses:<BR/>9 mg (105 patients); 12 mg (137 patients) or 15 mg (124 patients) twice daily for 6 weeks.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>ADAS-Cog<BR/>CGIC<BR/>MMSE<BR/>ADL<BR/>PSMS</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>ADAS-Cog was administered three times before and every 2 weeks during the double-blind phase. MMSE, IADL, and PSMS were administered once before and -at the final study visit.</P>
<P>A number of 848 patients completed the placebo washout phase, and as 439 of them were included in the non-responders trial and 366 in the responders trial, there are more 43 patients of both groups excluded before randomisation. Information about them is not avaliable in the paper.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Thal-1999">
<CHAR_METHODS>
<P>Design: <BR/>Randomized<BR/>double-blind<BR/>placebo-controlled<BR/>parallel group <BR/>12 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number: 699 patients screened and 475 enrolled in the trial.<BR/>Sex: 60% females<BR/>Age: 73.4 +/-6.9 years<BR/>Diagnosis Criteria:<BR/>NINCDS-ADRDA.<BR/>Complete medical evaluation carried out to rule out another disorder that could result in cognitive impairment.<BR/>Severity of AD: <BR/>Mild to moderate dementia.<BR/>MMSE (range): 12-26<BR/>Hamilton Scale score (range): 0-15<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. placebo<BR/>2.controlled release physostigmine 30 mg /day in 2 divided doses<BR/>3.controlled release physostigmine 36mg/day in 3 divided doses<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>ADAS-Cog<BR/>CIBIC-Plus<BR/>IADL<BR/>CGIC<BR/>GERRI</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-van-Dyck-2000">
<CHAR_METHODS>
<P>Design:<BR/>Double-blind<BR/>randomized<BR/>placebo-controlled<BR/>parallel group<BR/>12 weeks<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: USA<BR/>36 centres<BR/>number: 176<BR/>54.7% female<BR/>Age: 72.8 +/- 8.1 years.<BR/>Diagnosis Criteria: NINCDS-ADRDA <BR/>Severity of AD: MMSE 10-26<BR/>Mod Hachinski =&lt; 4<BR/>Response of at least 3 points improvement on the ADAS-Cog during dose enrichment phase. Nonreponders were discontinued</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. placebo<BR/>2. controlled release physostigmine best dose 24 or 30 mg/d divided into 2 doses<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>ADAS-Cog<BR/>CIBIC-plus<BR/>CGIC<BR/>MMSE<BR/>IADL</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>3-week dose enrichment phase, each patients receiving placebo, 24 and 30 mg/d for 1 week each. Responders were identified (at least 3 points improvement on the ADAS-Cog) when taking physostigmine compared with placebo and allowed to continue to randomized phase.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2008-06-02 13:57:30 +0100" MODIFIED_BY="Helen Collins" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Agnoli-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>It is a non randomized study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ashford-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>Patients were given physostigmine and placebo with order of treatment counterbalanced across the patient group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Becker-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>This is a trial using physostigmine plus lecithin with placebo plus lecithin control. There is no information on sex and age of the participants.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-06-02 13:56:12 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Bentley-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-06-02 13:56:12 +0100" MODIFIED_BY="Helen Collins">
<P>This is a nonrandomized trial where 16 mild Alzheimer patients and 17 age-matched healthy controls were studied. Within-subject placebo-controlled comparisons of effects of physostigmine were performed.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bierer-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomized</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bierer-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>This is a single-blind study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Blin-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>No diagnosis criteria for Alzheimer's disease specified.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Caltagirone-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>This is a non randomized one-arm study where neuropsychological assessment was carried out before and after treatment.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Caltagirone-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>There was no control (placebo) group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Christie-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>The design is unclear.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cummings-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Physostigimine compared with haloperidol, only 2 patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Davis-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>This is a letter reporting the preliminary results of the effect of physostigmine on 6 patients (3 nondemented elderly women, 2 with Alzheimer's disease and 1 with Huntington's disease). Data are not available.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Giuffra-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>This is an abstract with very limited information. We wrote to the authors seeking more details but have not received a reply.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-06-02 13:56:38 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Imbimbo-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-06-02 13:56:38 +0100" MODIFIED_BY="Helen Collins">
<P>This is a review on efficacy and tolerability of seven cholinesterase inhibitors (tacrine, donepezil, rivastigmine, metrifonate, eptastigmine, physostigmine and galantamine) according to the results from six-month placebo-controlled trials.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-06-02 13:56:44 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Jenike-1990b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-06-02 13:56:44 +0100" MODIFIED_BY="Helen Collins">
<P>This is a nonrandomized study. Six patients treated with physostigmine in a previous study were matched with controls and followed for between 9 and 27 months.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-06-02 13:56:49 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Jotkowitz-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-06-02 13:56:49 +0100" MODIFIED_BY="Helen Collins">
<P>This is a nonrandomized study with non blind assessment of outcome.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-06-02 13:56:59 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Levy-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-06-02 13:56:59 +0100" MODIFIED_BY="Helen Collins">
<P>This is an abstract from the 3rd International Conference on Alzheimer's Disease and Related Disorders. It relates to the trial published by Levy et al. (1994) which was excluded as it is a single-blind nonrandomized study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-06-02 13:57:00 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Levy-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-06-02 13:57:00 +0100" MODIFIED_BY="Helen Collins">
<P>This is a single-blind nonrandomized study. No placebo group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Marin-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>All patients received physostigmine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mitchell-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>This an abstract with very limited information.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Muramoto-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>It is a report of the effect of physostigmine on performance of constructional and memory tasks in a patient with Alzheimer's disease.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Muramoto-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>This is a crossover study where half of the patients were given drug or placebo in a non-randomized order, as well as in a single blind fashion.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-06-02 13:57:08 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Peters-1979">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-06-02 13:57:08 +0100" MODIFIED_BY="Helen Collins">
<P>Nonrandomized study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schemechel-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study is reported in abstract format. Data are not available. We sent a letter to the authors seeking more details but they did not reply.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schneider-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>It is a confounded study, as patients who were already receiving tacrine or physostigmine were assigned to receive either L-deprenyl or placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schwartz-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>The description of the study design is unclear. It is a possibly randomized trial, but physostigmine appears to be confounded by lecithin.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-06-02 13:57:13 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Sevush-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-06-02 13:57:13 +0100" MODIFIED_BY="Helen Collins">
<P>This is a crossover study with order of treatment counterbalanced across patients (nonrandomized).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Smith-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>This is a letter reporting the effect of physostigmine in a patient with Alzheimer's disease.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-06-02 13:57:19 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Storey-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-06-02 13:57:19 +0100" MODIFIED_BY="Helen Collins">
<P>This is an abstract from the 3rd International Conference on Alzheimer's Disease and Related Disorders. It is about a nonrandomized trial, where control patients were matched to the treated group on age, sex, and baseline neuropsychological performance.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sunderland-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study designed to evaluate the effect of a combination of physostigmine and lecithin versus either agent alone.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Thal-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>There is no mention of randomization.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-06-02 13:57:30 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Tune-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-06-02 13:57:30 +0100" MODIFIED_BY="Helen Collins">
<P>Nonrandomized study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wettstein-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>There is no mention of randomization.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2008-06-02 13:56:02 +0100" MODIFIED_BY="Helen Collins">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2008-06-02 13:56:02 +0100" MODIFIED_BY="Helen Collins" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-02 13:54:23 +0100" MODIFIED_BY="Helen Collins" RESULT="UNKNOWN" STUDY_ID="STD-Asthana-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-02 13:54:29 +0100" MODIFIED_BY="Helen Collins" RESULT="UNKNOWN" STUDY_ID="STD-Beller-1985">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Davis-1982">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Gustafson-1987">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-02 13:54:47 +0100" MODIFIED_BY="Helen Collins" RESULT="UNKNOWN" STUDY_ID="STD-Harrell-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Jenike-1990">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-02 13:55:02 +0100" MODIFIED_BY="Helen Collins" RESULT="UNKNOWN" STUDY_ID="STD-Mohs-1985">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-02 13:55:11 +0100" MODIFIED_BY="Helen Collins" RESULT="UNKNOWN" STUDY_ID="STD-M_x00f6_ller-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-02 13:55:27 +0100" MODIFIED_BY="Helen Collins" RESULT="UNKNOWN" STUDY_ID="STD-Sano-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-02 13:55:34 +0100" MODIFIED_BY="Helen Collins" RESULT="UNKNOWN" STUDY_ID="STD-Stern-1987">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-02 13:55:39 +0100" MODIFIED_BY="Helen Collins" RESULT="UNKNOWN" STUDY_ID="STD-Thal-1989">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-02 13:55:46 +0100" MODIFIED_BY="Helen Collins" RESULT="UNKNOWN" STUDY_ID="STD-Thal-1996a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-02 13:55:51 +0100" MODIFIED_BY="Helen Collins" RESULT="UNKNOWN" STUDY_ID="STD-Thal-1996b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-02 13:55:57 +0100" MODIFIED_BY="Helen Collins" RESULT="UNKNOWN" STUDY_ID="STD-Thal-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-02 13:56:02 +0100" MODIFIED_BY="Helen Collins" RESULT="YES" STUDY_ID="STD-van-Dyck-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES>
<ADDITIONAL_TABLE ID="TBL-01" NO="1">
<TITLE>Description of included studies at baseline</TITLE>
<TABLE COLS="10" ROWS="22">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Design</P>
</TH>
<TH>
<P>Duration (weeks)</P>
</TH>
<TH>
<P>Number randomized</P>
</TH>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Doses</P>
</TH>
<TH>
<P>Mean age (s.e.)</P>
</TH>
<TH>
<P>%female</P>
</TH>
<TH>
<P>Mean MMSE (s.e.)</P>
</TH>
<TH>
<P>Country</P>
</TH>
</TR>
<TR>
<TD>
<P>Asthana 1995a</P>
</TD>
<TD>
<P>crossover</P>
</TD>
<TD>
<P>5 days X 2</P>
</TD>
<TD>
<P>9</P>
</TD>
<TD>
<P>i.v.infusion</P>
</TD>
<TD>
<P>optimal dose (0.02 - 1.04 mg/hour)</P>
</TD>
<TD>
<P>68.7 (12.1)</P>
</TD>
<TD>
<P>56</P>
</TD>
<TD>
<P>22.2 (3.4)</P>
</TD>
<TD>
<P>USA</P>
</TD>
</TR>
<TR>
<TD>
<P>Beller 1985</P>
</TD>
<TD>
<P>crossover</P>
</TD>
<TD>
<P>2 days X 4 (no washout between phases)</P>
</TD>
<TD>
<P>8</P>
</TD>
<TD>
<P>oral</P>
</TD>
<TD>
<P>placebo, 3.5, 7.0, and 14 mg/day divided into 7 doses at 2 hourly intervals</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>50</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>USA</P>
</TD>
</TR>
<TR>
<TD>
<P>Davis 1982</P>
</TD>
<TD>
<P>crossover</P>
</TD>
<TD>
<P>1 day X 2</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>i.v. infusion</P>
</TD>
<TD>
<P>0.125, 0.25, or 0.5 mg over 30 minutes</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>USA</P>
</TD>
</TR>
<TR>
<TD>
<P>Gustafson 1987</P>
</TD>
<TD>
<P>crossover</P>
</TD>
<TD>
<P>1 day X 2</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>i.v.infusion</P>
</TD>
<TD>
<P>1.9 mg over 2 hours</P>
</TD>
<TD>
<P>61(6)</P>
</TD>
<TD>
<P>50</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Sweden</P>
</TD>
</TR>
<TR>
<TD>
<P>Harrell 1990a</P>
</TD>
<TD>
<P>crossover</P>
</TD>
<TD>
<P>2 weeks X 2 (no washout between phases)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>oral</P>
</TD>
<TD>
<P>highest tolerated dose (6, 9, 12, or 15 mg/day in 6 doses every 2 hours)</P>
</TD>
<TD>
<P>63 (3.1)</P>
</TD>
<TD>
<P>55</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>USA</P>
</TD>
</TR>
<TR>
<TD>
<P>Jenike 1990a</P>
</TD>
<TD>
<P>crossover</P>
</TD>
<TD>
<P>1 week X 2 (no deatils of any washout)</P>
</TD>
<TD>
<P>23</P>
</TD>
<TD>
<P>oral</P>
</TD>
<TD>
<P>optimal dose no details of quantity</P>
</TD>
<TD>
<P>66 (9)</P>
</TD>
<TD>
<P>48</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>USA</P>
</TD>
</TR>
<TR>
<TD>
<P>Mohs 1985</P>
</TD>
<TD>
<P>crossover</P>
</TD>
<TD>
<P>3-5 days X 2 (no details of any washout phase)</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>oral</P>
</TD>
<TD>
<P>highest tolerated dose (4, 8, 12, 16 mg/day divided in 8 doses every 2 hours)</P>
</TD>
<TD>
<P>62.3</P>
</TD>
<TD>
<P>33</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>USA</P>
</TD>
</TR>
<TR>
<TD>
<P>Möller 1999</P>
</TD>
<TD>
<P>parallel group</P>
</TD>
<TD>
<P>24 weeks</P>
</TD>
<TD>
<P>181</P>
</TD>
<TD>
<P>verum patch</P>
</TD>
<TD>
<P>5.7 or 11.4 mg /day delivered over 24 hours</P>
</TD>
<TD>
<P>69.3 (8.2)</P>
</TD>
<TD>
<P>52</P>
</TD>
<TD>
<P>18.1 (4.1)</P>
</TD>
<TD>
<P>Germany</P>
</TD>
</TR>
<TR>
<TD>
<P>Sano 1993</P>
</TD>
<TD>
<P>crossover</P>
</TD>
<TD>
<P>6 weeks X 2 (no washout between phases)</P>
</TD>
<TD>
<P>29</P>
</TD>
<TD>
<P>oral</P>
</TD>
<TD>
<P>highest tolerated dose (8-16 mg/day, divided into 4 doses every 2 hours)</P>
</TD>
<TD>
<P>69.1 (9.1)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>USA</P>
</TD>
</TR>
<TR>
<TD>
<P>Stern 1987</P>
</TD>
<TD>
<P>crossover</P>
</TD>
<TD>
<P>3 days X 2 (1 day washout between phases)</P>
</TD>
<TD>
<P>22</P>
</TD>
<TD>
<P>oral</P>
</TD>
<TD>
<P>optimal or highest tolerated dose (12.5 - 16 mg/day taken every 2 hours, divided into 4-6 doses)</P>
</TD>
<TD>
<P>67.1 (8.4)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>USA</P>
</TD>
</TR>
<TR>
<TD>
<P>Thal 1989</P>
</TD>
<TD>
<P>parallel group</P>
</TD>
<TD>
<P>10 weeks</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>oral</P>
</TD>
<TD>
<P>dose titration to 10, 15 or 20 mg per day divided into 5 doses</P>
</TD>
<TD>
<P>64</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>USA</P>
</TD>
</TR>
<TR>
<TD>
<P>Thal 1996a</P>
</TD>
<TD>
<P>parallel group</P>
</TD>
<TD>
<P>6 weeks</P>
</TD>
<TD>
<P>366</P>
</TD>
<TD>
<P>oral CR</P>
</TD>
<TD>
<P>18, 24 or 30 mg/day divided into 2 doses</P>
</TD>
<TD>
<P>68.6</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>17.7</P>
</TD>
<TD>
<P>USA, UK</P>
</TD>
</TR>
<TR>
<TD>
<P>Thal 1996b</P>
</TD>
<TD>
<P>parallel group</P>
</TD>
<TD>
<P>6 weeks</P>
</TD>
<TD>
<P>439</P>
</TD>
<TD>
<P>oral CR</P>
</TD>
<TD>
<P>18, 24 or 30 mg/day divided into 2 doses</P>
</TD>
<TD>
<P>68.7</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>18.7</P>
</TD>
<TD>
<P>USA , UK</P>
</TD>
</TR>
<TR>
<TD>
<P>Thal 1999</P>
</TD>
<TD>
<P>parallel group</P>
</TD>
<TD>
<P>24 weeks</P>
</TD>
<TD>
<P>475</P>
</TD>
<TD>
<P>oral CR</P>
</TD>
<TD>
<P>30mg/day in 2 divided doses or 36mg/day in 3 divided doses</P>
</TD>
<TD>
<P>73.4 (7.7)</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>19.5 (3.6)</P>
</TD>
<TD>
<P>USA</P>
</TD>
</TR>
<TR>
<TD>
<P>van Dyck 2000</P>
</TD>
<TD>
<P>parallel group</P>
</TD>
<TD>
<P>12 weeks</P>
</TD>
<TD>
<P>176</P>
</TD>
<TD>
<P>oral CR</P>
</TD>
<TD>
<P>24 or 30 mg/day divided into 2 doses</P>
</TD>
<TD>
<P>72.8 (8.1)</P>
</TD>
<TD>
<P>54.7</P>
</TD>
<TD>
<P>18.5 (4.7)</P>
</TD>
<TD>
<P>USA</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" NO="2">
<TITLE>Abbreviations, description and references for rating scales and tests</TITLE>
<TABLE COLS="4" ROWS="44">
<TR>
<TH>
<P>Scale</P>
</TH>
<TH>
<P>Abbreviation</P>
</TH>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Reference</P>
</TH>
</TR>
<TR>
<TD>
<P>Alzheimer's Disease Assessment Scale</P>
</TD>
<TD>
<P>ADAS</P>
</TD>
<TD>
<P>The cognitive test consists of 11 subsets, language, comprehension, recall of test instructions, word finding difficulty, following commands, naming, construction, ideational praxis, orientation, word recall, and word recognition. The maximum score of 70 indicates severe impairment.</P>
</TD>
<TD>
<P>Rosen 1984</P>
</TD>
</TR>
<TR>
<TD>
<P>Activities of Daily Living</P>
</TD>
<TD>
<P>ADL</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Lawton 1969</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Blessed Dementia Rating Scale</P>
</TD>
<TD>
<P>BDRS</P>
</TD>
<TD>
<P>The first three sections measure changes in performance of everyday activities, habits, and personality, interests and drive as answered by the patient's close relative or carer. Each section is scored 0 (normal) -28 (severe impairment). The second three sections form the cognitive test. Information, memory, and concentration are each assessed on a score of 0(complete failure) - 37(normal).</P>
</TD>
<TD>
<P>Blessed 1968</P>
</TD>
</TR>
<TR>
<TD>
<P>Boston Naming Test</P>
</TD>
<TD>
<P>BNT</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Kaplan 1976</P>
</TD>
</TR>
<TR>
<TD>
<P>Brief Psychiatric Rating Scale</P>
</TD>
<TD>
<P>BPRS</P>
</TD>
<TD>
<P>18 items, covering mood and behaviour, are each scored on a 1-7 scale, (not present to very severe)</P>
</TD>
<TD>
<P>Overall, 1962</P>
</TD>
</TR>
<TR>
<TD>
<P>Buschke Selective Reminding Test</P>
</TD>
<TD>
<P>BSRT</P>
</TD>
<TD>
<P>the presentation of a series of words to be remembered, followed by immediate recall of as many as possible. The subject is then reminded only of words that have not been recalled in the previous trial, and is asked again to recall as many words as possible. After six trials storage, retrieval, consistency of retrieval, intrusions and immediate memory are measured.</P>
</TD>
<TD>
<P>Buschke 1973<BR/>Buschke 1974</P>
</TD>
</TR>
<TR>
<TD>
<P>Cancelation Task</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Detection of a specific shape within an array of shapes</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Category Fluency</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Similar to COWAT, with categories fruits, animals and vegetables</P>
</TD>
<TD>
<P>Benton 1974<BR/>Batters 1987</P>
</TD>
</TR>
<TR>
<TD>
<P>Clinical Global Impression of Change</P>
</TD>
<TD>
<P>CGIC</P>
</TD>
<TD>
<P>A rating of global change based on a structured interview of the subject and carer by a clinician unbiased by other outcomes assessments.The patient is assessed using a 7-point Likert scale (higher score indicates improvement) where baseline is rated as 4 and the patient is assessed on a continuum from' very much worse' to 'very much better'.</P>
</TD>
<TD>
<P>Guy 1976</P>
</TD>
</TR>
<TR>
<TD>
<P>Clinician Interview Based Impression of Change with caregiver input</P>
</TD>
<TD>
<P>CIBIC-Plus</P>
</TD>
<TD>
<P>A rating of global change based on a structured interview of the subject and carer by a clinician unbiased by other outcomes assessments.The patient is assessed using a 7-point Likert scale (higher score indicates improvement) where baseline is rated as 4 and the patient is assessed on a continuum from very much worse to very much better.</P>
</TD>
<TD>
<P>Knopman 1994</P>
</TD>
</TR>
<TR>
<TD>
<P>Controlled Oral Word Association Test</P>
</TD>
<TD>
<P>COWAT</P>
</TD>
<TD>
<P>measures verbal fluency for generating words beginning with a given letter or belonging to a category within 60 seconds</P>
</TD>
<TD>
<P>Benton 1974<BR/>Batters 1987</P>
</TD>
</TR>
<TR>
<TD>
<P>Digit Symbol</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Using a key which links the digits 1 to 9 with a symbol, the subject is timed whilst linking a list of the symbols to the correct digit.</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Digit Span</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>A single trial consists of two parts. The subject is given a list of digits, orally and asked to repeat them, and in the second part is asked to repeat them backwards. Each trial increases by one the number of digits in the list. The test stops after failure on both parts of a trial</P>
</TD>
<TD>
<P>Wechsler 1981</P>
</TD>
</TR>
<TR>
<TD>
<P>Dementia Rating Scale</P>
</TD>
<TD>
<P>DRS</P>
</TD>
<TD>
<P>Functional impairment is rated from 0 (no impairment) - 17(serious impairment) .</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Famous Faces</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Designed to assess retrieval from remote memory</P>
</TD>
<TD>
<P>Albert 1981</P>
</TD>
</TR>
<TR>
<TD>
<P>Figure copy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>drawings are copied and assessed for a number of features</P>
</TD>
<TD>
<P>Marlsen-Wilson 1975</P>
</TD>
</TR>
<TR>
<TD>
<P>Finger tapping</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Subjects tap, using a standard finger-tapping apparatus, in a sequential manner first with the right, then the left hand.</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Geriatric evaluation by relative's rating instrument</P>
</TD>
<TD>
<P>GERRI</P>
</TD>
<TD>
<P>consists of 49 questions, each rated on a 5-point frequency scale, designed to assess the frequency of typical behavioural disturbances and complaints in cognitive functioning, social functioning and mood. The higher score indicates greater impairment. The questions are answered by a carer.</P>
</TD>
<TD>
<P>Schwartz 1988</P>
</TD>
</TR>
<TR>
<TD>
<P>Geriatric Depression Scale</P>
</TD>
<TD>
<P>GDS</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Instrumental Activities of Daily Living</P>
</TD>
<TD>
<P>IADL</P>
</TD>
<TD>
<P>the score ranges from 4-32, the lower score indicating better functioning</P>
</TD>
<TD>
<P>Lawton 1969</P>
</TD>
</TR>
<TR>
<TD>
<P>Mattis Dementia Rating Scale</P>
</TD>
<TD>
<P>MDRS</P>
</TD>
<TD>
<P>maximum total of 144</P>
</TD>
<TD>
<P>Bellock 1976</P>
</TD>
</TR>
<TR>
<TD>
<P>Memory and Information Test</P>
</TD>
<TD>
<P>MIT</P>
</TD>
<TD>
<P>A brief mental status test with a score from 0 (serious impairment) -20 (no impairment).</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Mini Mental State Examination</P>
</TD>
<TD>
<P>MMSE</P>
</TD>
<TD>
<P>the MMSE was developed as a short test suitable for the elderly with dementia. It concentrates on the cognitive aspects of mental function, the five sections cover orientation, immediate recall, attention and calculation, delayed recall and language. A maximum score of 30 indicates no impairment.</P>
</TD>
<TD>
<P>Folstein 1975</P>
</TD>
</TR>
<TR>
<TD>
<P>Modified Mini Mental State Examination</P>
</TD>
<TD>
<P>Mod MMSE</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Mayeux 1981</P>
</TD>
</TR>
<TR>
<TD>
<P>Neuropsychological Test Battery</P>
</TD>
<TD>
<P>NTB</P>
</TD>
<TD>
<P>assessing vocabulary, inductive reasoning,verbal memory, spatial memory, reaction time and aphasia</P>
</TD>
<TD>
<P>Hagberg 1976</P>
</TD>
</TR>
<TR>
<TD>
<P>Nurses' Observation scale for Geriatric Patients</P>
</TD>
<TD>
<P>NOSGER</P>
</TD>
<TD>
<P>Information from the carer</P>
</TD>
<TD>
<P>Brunner 1990</P>
</TD>
</TR>
<TR>
<TD>
<P>Nurses' Observation Scale for Inpatient Evaluation</P>
</TD>
<TD>
<P>NOSIE</P>
</TD>
<TD>
<P>NOSIE was developed to measure therapeutic change in the older schizophrenic patient. It is based on observation of an inpatient for three days and each of 80 items is rated on a scale of 0 (never) to 4 (always). The items are categorised into 7 groups, social competence, social interest, personal neatness, cooperation, irritability, manifest psychosis, psychotic depression.</P>
</TD>
<TD>
<P>Honigfeld 1965</P>
</TD>
</TR>
<TR>
<TD>
<P>Performance test of Activities of Daily Living</P>
</TD>
<TD>
<P>PADL</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Kurcansky 1976</P>
</TD>
</TR>
<TR>
<TD>
<P>Verbal and Visual Paired Associate Learning</P>
</TD>
<TD>
<P>PALW</P>
</TD>
<TD>
<P>Memory test of pairs of words or faces</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Picture copy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Pictures are copied and assessed</P>
</TD>
<TD>
<P>Haxby 1985</P>
</TD>
</TR>
<TR>
<TD>
<P>Picture recognition</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Pictures of 7 common items shown to subject, then another 15 picturs of common items. Subjects has to identify those already seen in the first group</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Physical Self Maintenance Scale</P>
</TD>
<TD>
<P>PSMS</P>
</TD>
<TD>
<P>Range 6-30<BR/>Measures functional abilities in elderly subjects</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Recognition memory test</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Measures patient's ability to learn new information</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Revised Wechsler Adult Intelligence Scale</P>
</TD>
<TD>
<P>WAIS-R</P>
</TD>
<TD>
<P>a series of brief subtests, some taken from the WMS, each measuring a different facet of memory, which are summarised into 5 composite scores and finally 2 major scores using weights prescribed by Wechsler. Some subtests of the Revised Wechsler Adult Intelligence Scale (WAIS-R) are identical to those of the WMS-R although the primary purposes of the tests are different.</P>
</TD>
<TD>
<P>Wechsler 1987</P>
</TD>
</TR>
<TR>
<TD>
<P>Rosen Construction Task</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Rosen 1984</P>
</TD>
</TR>
<TR>
<TD>
<P>Sandoz Clinical Assessment Geriatric</P>
</TD>
<TD>
<P>SCAG</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Hamot 1980</P>
</TD>
</TR>
<TR>
<TD>
<P>Sickness Impact Profile</P>
</TD>
<TD>
<P>SIP</P>
</TD>
<TD>
<P>Measures impact of illness on functional abilities in sleep and rest, home management, recreation and pastimes, physical activities, psychosocial activities</P>
</TD>
<TD>
<P>Bergner 1981</P>
</TD>
</TR>
<TR>
<TD>
<P>Squire Memory Questionnaire</P>
</TD>
<TD>
<P>SMQ</P>
</TD>
<TD>
<P>Memory in daily activities</P>
</TD>
<TD>
<P>Squire 1979</P>
</TD>
</TR>
<TR>
<TD>
<P>Stroop Color Word Interference Test</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Naming of colour in which words are printed</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Token Test</P>
</TD>
<TD>
<P>TT</P>
</TD>
<TD>
<P>20 tokens, 5 each of coloured small and large circles and squares are displayed and oral commands are issued for increasingly complex manipulations of tokens</P>
</TD>
<TD>
<P>Boller 1966</P>
</TD>
</TR>
<TR>
<TD>
<P>Wechsler Memory Test</P>
</TD>
<TD>
<P>WMS</P>
</TD>
<TD>
<P>consists of seven subtests, information, orientation, mental control, logical memory, digit span, visual reproduction, and associate</P>
</TD>
<TD>
<P>Wechsler 1945</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-06-02 14:09:21 +0100" MODIFIED_BY="Helen Collins">
<COMPARISON ID="CMP-001" NO="1">
<NAME>physostigmine (oral) vs placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="4.822415677719198" CI_START="-7.822415677719198" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.4999999999999998" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.01" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.641928888449" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="10" TOTAL_2="6" UNITS="" WEIGHT="100.0" Z="0.4650035882915345">
<NAME>BDS (change from baseline) at 10 weeks ITT</NAME>
<GROUP_LABEL_1>Physostigmine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favoursphysostigmine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.822415677719198" CI_START="-7.822415677719198" EFFECT_SIZE="-1.4999999999999998" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="2.3" ORDER="2195" SD_1="5.8" SD_2="6.5" SE="3.2257815590437406" STUDY_ID="STD-Thal-1989" TOTAL_1="10" TOTAL_2="6" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.5759783907240325" CI_START="-1.7759783907240325" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.6" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.31731052126128756" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="10" TOTAL_2="6" UNITS="" WEIGHT="100.0" Z="1.0">
<NAME>ADL (change from baseline) at 10 weeks ITT</NAME>
<GROUP_LABEL_1>Physostigmine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favoursphysostigmine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.5759783907240325" CI_START="-1.7759783907240325" EFFECT_SIZE="-0.6" ESTIMABLE="YES" MEAN_1="-0.7" MEAN_2="-0.1" ORDER="2196" SD_1="1.5" SD_2="0.9" SE="0.6" STUDY_ID="STD-Thal-1989" TOTAL_1="10" TOTAL_2="6" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.2691891186889077E-32" CI_END="3.2780722226926735" CI_START="-8.278072222692673" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.4999999999999996" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-001.03" NO="3" P_CHI2="0.0" P_Q="1.0" P_Z="0.3964278862968392" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="10" TOTAL_2="6" UNITS="" WEIGHT="100.0" Z="0.8480181230872014">
<NAME>PADL (change from baseline) at 10 weeks ITT</NAME>
<GROUP_LABEL_1>Physostigmine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favoursphysostigmine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.278072222692673" CI_START="-8.278072222692673" EFFECT_SIZE="-2.5" ESTIMABLE="YES" MEAN_1="-0.3" MEAN_2="2.2" ORDER="2197" SD_1="6.6" SD_2="5.1" SE="2.9480502031003475" STUDY_ID="STD-Thal-1989" TOTAL_1="10" TOTAL_2="6" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="19.064914930754934" CI_START="-2.0649149307549344" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="8.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.04" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.11482116108560496" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="10" TOTAL_2="6" UNITS="" WEIGHT="100.0" Z="1.5768885956756127">
<NAME>MDRS (change from baseline) at 10 weeks ITT</NAME>
<GROUP_LABEL_1>Physostigmine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favoursphysostigmine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="19.064914930754934" CI_START="-2.0649149307549344" EFFECT_SIZE="8.5" ESTIMABLE="YES" MEAN_1="5.3" MEAN_2="-3.2" ORDER="2198" SD_1="12.1" SD_2="9.3" SE="5.390361768935366" STUDY_ID="STD-Thal-1989" TOTAL_1="10" TOTAL_2="6" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2008-06-02 14:09:21 +0100" MODIFIED_BY="Helen Collins" NO="2">
<NAME>physostigmine (CR) vs placebo</NAME>
<DICH_OUTCOME CHI2="4.856226526535468" CI_END="5.0731850410140815" CI_START="2.6208077820285105" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="3.6463465050870214" ESTIMABLE="YES" EVENTS_1="275" EVENTS_2="51" I2="58.815759745317294" I2_Q="58.815759745317294" ID="CMP-002.01" LOG_CI_END="0.7052807032055854" LOG_CI_START="0.4184351696434435" LOG_EFFECT_SIZE="0.5618579364245144" METHOD="PETO" NO="1" P_CHI2="0.0882031394239754" P_Q="0.0882031394239754" P_Z="1.6140416802040514E-14" Q="4.856226526535468" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="624" TOTAL_2="393" WEIGHT="300.0" Z="7.678148626856528">
<NAME>Number of withdrawals before end of treatment</NAME>
<GROUP_LABEL_1>Physostigmine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favoursphysostigmine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.533704893554988" CI_START="1.3258376376087617" DF="0.0" EFFECT_SIZE="2.708651735327927" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="9" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="0.743015994971543" LOG_CI_START="0.12249034351978597" LOG_EFFECT_SIZE="0.43275316924566454" NO="1" P_CHI2="1.0" P_Z="0.006261779680429486" STUDIES="1" TAU2="0.0" TOTAL_1="183" TOTAL_2="183" WEIGHT="100.0" Z="2.7337487948570685">
<NAME>Responders at 6 weeks (mean dose 24mg /day)</NAME>
<DICH_DATA CI_END="5.533704893554988" CI_START="1.3258376376087617" EFFECT_SIZE="2.708651735327927" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="9" LOG_CI_END="0.743015994971543" LOG_CI_START="0.12249034351978597" LOG_EFFECT_SIZE="0.43275316924566454" ORDER="2199" O_E="7.5" SE="0.36449983931427576" STUDY_ID="STD-Thal-1996a" TOTAL_1="183" TOTAL_2="183" VAR="7.526712328767124" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.263302880668247" CI_START="0.8490449658503423" DF="0.0" EFFECT_SIZE="1.9025603403641729" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="11" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="0.6297461876155261" LOG_CI_START="-0.07106930869179397" LOG_EFFECT_SIZE="0.2793384394618661" NO="2" P_CHI2="1.0" P_Z="0.11818289292924751" STUDIES="1" TAU2="0.0" TOTAL_1="83" TOTAL_2="93" WEIGHT="100.0" Z="1.5624462750258428">
<NAME>Responders at 12 weeks (mean dose 27mg/day)</NAME>
<DICH_DATA CI_END="4.263302880668247" CI_START="0.8490449658503423" EFFECT_SIZE="1.9025603403641729" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="11" LOG_CI_END="0.6297461876155261" LOG_CI_START="-0.07106930869179397" LOG_EFFECT_SIZE="0.2793384394618661" ORDER="2200" O_E="3.795454545454545" SE="0.4116624916235754" STUDY_ID="STD-van-Dyck-2000" TOTAL_1="83" TOTAL_2="93" VAR="5.900888429752067" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.332574157054127" CI_START="3.166684830546574" DF="0.0" EFFECT_SIZE="4.818708473439863" ESTIMABLE="YES" EVENTS_1="234" EVENTS_2="31" I2="0.0" ID="CMP-002.01.03" LOG_CI_END="0.8652564638566873" LOG_CI_START="0.5006048416587189" LOG_EFFECT_SIZE="0.6829306527577031" NO="3" P_CHI2="1.0" P_Z="2.1143366703608877E-13" STUDIES="1" TAU2="0.0" TOTAL_1="358" TOTAL_2="117" WEIGHT="100.0" Z="7.3413603662338796">
<NAME>All patients at 24 weeks (mean dose 33 mg/day)</NAME>
<DICH_DATA CI_END="7.332574157054127" CI_START="3.166684830546574" EFFECT_SIZE="4.818708473439863" ESTIMABLE="YES" EVENTS_1="234" EVENTS_2="31" LOG_CI_END="0.8652564638566873" LOG_CI_START="0.5006048416587189" LOG_EFFECT_SIZE="0.6829306527577031" ORDER="2201" O_E="34.27368421052631" SE="0.2141981679337281" STUDY_ID="STD-Thal-1999" TOTAL_1="358" TOTAL_2="117" VAR="21.795583295346958" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.9901125445873458" CI_END="8.256119708702931" CI_START="4.100598002368153" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="5.818507367428486" ESTIMABLE="YES" EVENTS_1="231" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.9167759813340342" LOG_CI_START="0.6128471957906275" LOG_EFFECT_SIZE="0.7648115885623308" METHOD="PETO" NO="2" P_CHI2="0.3697027464548106" P_Q="0.3697027464548106" P_Z="5.952249207945479E-23" Q="1.9901125445873458" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="624" TOTAL_2="393" WEIGHT="300.0" Z="9.864173713331603">
<NAME>Number of withdrawals due to adverse events before end of treatment</NAME>
<GROUP_LABEL_1>Physostigmine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favoursphysostigmine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="13.53626412270707" CI_START="2.591229718991813" DF="0.0" EFFECT_SIZE="5.9224631597740816" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="2" I2="0.0" ID="CMP-002.02.01" LOG_CI_END="1.131498819831704" LOG_CI_START="0.41350591598395803" LOG_EFFECT_SIZE="0.7725023679078309" NO="1" P_CHI2="1.0" P_Z="2.4699750250068134E-5" STUDIES="1" TAU2="0.0" TOTAL_1="183" TOTAL_2="183" WEIGHT="100.0" Z="4.217525858423602">
<NAME>Responders at 6 weeks (mean dose 24mg /day)</NAME>
<DICH_DATA CI_END="13.53626412270707" CI_START="2.591229718991813" EFFECT_SIZE="5.9224631597740816" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="2" LOG_CI_END="1.131498819831704" LOG_CI_START="0.41350591598395803" LOG_EFFECT_SIZE="0.7725023679078309" ORDER="2202" O_E="10.0" SE="0.4217525858423601" STUDY_ID="STD-Thal-1996a" TOTAL_1="183" TOTAL_2="183" VAR="5.6219178082191785" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.068223042865009" CI_START="1.1503233895890361" DF="0.0" EFFECT_SIZE="3.04648415039843" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="5" I2="0.0" ID="CMP-002.02.02" LOG_CI_END="0.9067778956074821" LOG_CI_START="0.06081995041481807" LOG_EFFECT_SIZE="0.48379892301115013" NO="2" P_CHI2="1.0" P_Z="0.024975187257487076" STUDIES="1" TAU2="0.0" TOTAL_1="83" TOTAL_2="93" WEIGHT="100.0" Z="2.241786297414974">
<NAME>Responders at 12 weeks (mean dose 27mg/day)</NAME>
<DICH_DATA CI_END="8.068223042865009" CI_START="1.150323389589036" EFFECT_SIZE="3.04648415039843" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="5" LOG_CI_END="0.9067778956074821" LOG_CI_START="0.06081995041481799" LOG_EFFECT_SIZE="0.48379892301115013" ORDER="2203" O_E="4.511363636363637" SE="0.49691988456553565" STUDY_ID="STD-van-Dyck-2000" TOTAL_1="83" TOTAL_2="93" VAR="4.049740997638725" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.953346713647665" CI_START="4.2908352198608535" DF="0.0" EFFECT_SIZE="6.535148860921662" ESTIMABLE="YES" EVENTS_1="196" EVENTS_2="10" I2="0.0" ID="CMP-002.02.03" LOG_CI_END="0.9979691324931326" LOG_CI_START="0.6325418367234774" LOG_EFFECT_SIZE="0.8152554846083051" NO="3" P_CHI2="1.0" P_Z="2.2257786038533335E-18" STUDIES="1" TAU2="0.0" TOTAL_1="358" TOTAL_2="117" WEIGHT="100.0" Z="8.745221862344046">
<NAME>All patients at 24 weeks (mean dose 33 mg/day)</NAME>
<DICH_DATA CI_END="9.95334671364767" CI_START="4.2908352198608535" EFFECT_SIZE="6.535148860921662" ESTIMABLE="YES" EVENTS_1="196" EVENTS_2="10" LOG_CI_END="0.9979691324931328" LOG_CI_START="0.6325418367234774" LOG_EFFECT_SIZE="0.8152554846083051" ORDER="2204" O_E="40.74105263157895" SE="0.21465380242938306" STUDY_ID="STD-Thal-1999" TOTAL_1="358" TOTAL_2="117" VAR="21.703152789368488" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.3516487488033686" CI_END="13.752269796187926" CI_START="7.71649739020691" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="10.301424852500038" ESTIMABLE="YES" EVENTS_1="388" EVENTS_2="30" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="1.1383743838830607" LOG_CI_START="0.8874202136400884" LOG_EFFECT_SIZE="1.0128972987615745" METHOD="PETO" NO="3" P_CHI2="0.5087369022499977" P_Q="0.5087369022499977" P_Z="2.2097765524366393E-56" Q="1.3516487488033686" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="624" TOTAL_2="393" WEIGHT="300.0" Z="15.821551988464622">
<NAME>At least one adverse event of nausea before end of treatment</NAME>
<GROUP_LABEL_1>Physostigmine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favoursphysostigmine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="13.50257735255598" CI_START="5.238632425210265" DF="0.0" EFFECT_SIZE="8.410412566753758" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="9" I2="0.0" ID="CMP-002.03.01" LOG_CI_END="1.130416673914127" LOG_CI_START="0.7192179267351669" LOG_EFFECT_SIZE="0.924817300324647" NO="1" P_CHI2="1.0" P_Z="1.183923947583382E-18" STUDIES="1" TAU2="0.0" TOTAL_1="183" TOTAL_2="183" WEIGHT="100.0" Z="8.816216553923477">
<NAME>Responders at 6 weeks (mean dose 24mg /day)</NAME>
<DICH_DATA CI_END="13.50257735255598" CI_START="5.238632425210265" EFFECT_SIZE="8.410412566753758" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="9" LOG_CI_END="1.130416673914127" LOG_CI_START="0.7192179267351669" LOG_EFFECT_SIZE="0.924817300324647" ORDER="2205" O_E="36.5" SE="0.2415401795595473" STUDY_ID="STD-Thal-1996a" TOTAL_1="183" TOTAL_2="183" VAR="17.14041095890411" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="27.212440224605334" CI_START="6.654291149255128" DF="0.0" EFFECT_SIZE="13.456578322003908" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="1" I2="0.0" ID="CMP-002.03.02" LOG_CI_END="1.4347674880701864" LOG_CI_START="0.8231017988996011" LOG_EFFECT_SIZE="1.1289346434848937" NO="2" P_CHI2="1.0" P_Z="4.658588712717348E-13" STUDIES="1" TAU2="0.0" TOTAL_1="83" TOTAL_2="93" WEIGHT="100.0" Z="7.234903906839458">
<NAME>Responders at 12 weeks (mean dose 27mg/day)</NAME>
<DICH_DATA CI_END="27.212440224605334" CI_START="6.654291149255128" EFFECT_SIZE="13.456578322003908" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="1" LOG_CI_END="1.4347674880701864" LOG_CI_START="0.8231017988996011" LOG_EFFECT_SIZE="1.1289346434848937" ORDER="2206" O_E="20.136363636363637" SE="0.35929545361279475" STUDY_ID="STD-van-Dyck-2000" TOTAL_1="83" TOTAL_2="93" VAR="7.746340023612752" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="16.86436404830957" CI_START="7.188500249651127" DF="0.0" EFFECT_SIZE="11.010426202989638" ESTIMABLE="YES" EVENTS_1="267" EVENTS_2="20" I2="0.0" ID="CMP-002.03.03" LOG_CI_END="1.2269699686786513" LOG_CI_START="0.8566382921575043" LOG_EFFECT_SIZE="1.0418041304180778" NO="3" P_CHI2="1.0" P_Z="2.818833955809565E-28" STUDIES="1" TAU2="0.0" TOTAL_1="358" TOTAL_2="117" WEIGHT="100.0" Z="11.02740437299807">
<NAME>All patients at 24 weeks (mean dose 33 mg/day)</NAME>
<DICH_DATA CI_END="16.86436404830957" CI_START="7.188500249651127" EFFECT_SIZE="11.010426202989638" ESTIMABLE="YES" EVENTS_1="267" EVENTS_2="20" LOG_CI_END="1.2269699686786513" LOG_CI_START="0.8566382921575043" LOG_EFFECT_SIZE="1.0418041304180778" ORDER="2207" O_E="50.692631578947356" SE="0.21753465995988558" STUDY_ID="STD-Thal-1999" TOTAL_1="358" TOTAL_2="117" VAR="21.132120256670987" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6330367209432308" CI_END="11.539742804775845" CI_START="6.454974033295843" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="8.630685960903723" ESTIMABLE="YES" EVENTS_1="324" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="1.0621961294686408" LOG_CI_START="0.8098944995506946" LOG_EFFECT_SIZE="0.9360453145096677" METHOD="PETO" NO="4" P_CHI2="0.7286816804002428" P_Q="0.7286816804002428" P_Z="6.466563985985946E-48" Q="0.6330367209432308" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="624" TOTAL_2="393" WEIGHT="300.0" Z="14.54303014160528">
<NAME>At least one adverse event of vomiting before end of treatment</NAME>
<GROUP_LABEL_1>Physostigmine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favoursphysostigmine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="14.218592271420501" CI_START="5.258429052422196" DF="0.0" EFFECT_SIZE="8.64681783574647" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="6" I2="0.0" ID="CMP-002.04.01" LOG_CI_END="1.1528566006822327" LOG_CI_START="0.720856018723055" LOG_EFFECT_SIZE="0.9368563097026439" NO="1" P_CHI2="1.0" P_Z="1.8806822173741887E-17" STUDIES="1" TAU2="0.0" TOTAL_1="183" TOTAL_2="183" WEIGHT="100.0" Z="8.500935889386364">
<NAME>Responders at 6 weeks (mean dose 24mg /day)</NAME>
<DICH_DATA CI_END="14.218592271420501" CI_START="5.258429052422196" EFFECT_SIZE="8.64681783574647" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="6" LOG_CI_END="1.1528566006822327" LOG_CI_START="0.720856018723055" LOG_EFFECT_SIZE="0.9368563097026439" ORDER="2208" O_E="33.5" SE="0.25375928028019" STUDY_ID="STD-Thal-1996a" TOTAL_1="183" TOTAL_2="183" VAR="15.52945205479452" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="21.917551040815475" CI_START="5.488191713812117" DF="0.0" EFFECT_SIZE="10.967575940437232" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="3" I2="0.0" ID="CMP-002.04.02" LOG_CI_END="1.3407920265971383" LOG_CI_START="0.7394292737621909" LOG_EFFECT_SIZE="1.0401106501796646" NO="2" P_CHI2="1.0" P_Z="1.202874704975919E-11" STUDIES="1" TAU2="0.0" TOTAL_1="83" TOTAL_2="93" WEIGHT="100.0" Z="6.77986591180914">
<NAME>Responders at 12 weeks (mean dose 27mg/day)</NAME>
<DICH_DATA CI_END="21.917551040815475" CI_START="5.488191713812117" EFFECT_SIZE="10.967575940437232" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="3" LOG_CI_END="1.3407920265971383" LOG_CI_START="0.7394292737621909" LOG_EFFECT_SIZE="1.0401106501796646" ORDER="2209" O_E="19.193181818181817" SE="0.3532434578088836" STUDY_ID="STD-van-Dyck-2000" TOTAL_1="83" TOTAL_2="93" VAR="8.014044421487604" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="11.997107546329758" CI_START="5.199964604048477" DF="0.0" EFFECT_SIZE="7.89838810086448" ESTIMABLE="YES" EVENTS_1="212" EVENTS_2="9" I2="0.0" ID="CMP-002.04.03" LOG_CI_END="1.0790765520404988" LOG_CI_START="0.7160003874196554" LOG_EFFECT_SIZE="0.897538469730077" NO="3" P_CHI2="1.0" P_Z="3.3182891029280155E-22" STUDIES="1" TAU2="0.0" TOTAL_1="358" TOTAL_2="117" WEIGHT="100.0" Z="9.690215149469807">
<NAME>All patients at 24 weeks (mean dose 33 mg/day)</NAME>
<DICH_DATA CI_END="11.997107546329758" CI_START="5.199964604048477" EFFECT_SIZE="7.89838810086448" ESTIMABLE="YES" EVENTS_1="212" EVENTS_2="9" LOG_CI_END="1.0790765520404988" LOG_CI_START="0.7160003874196554" LOG_EFFECT_SIZE="0.897538469730077" ORDER="2210" O_E="45.435789473684224" SE="0.213272736354284" STUDY_ID="STD-Thal-1999" TOTAL_1="358" TOTAL_2="117" VAR="21.985144163540095" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.4229795121707003" CI_END="5.75960389318251" CI_START="2.646586289271043" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="3.9042654488813837" ESTIMABLE="YES" EVENTS_1="137" EVENTS_2="14" I2="41.57137099743581" I2_Q="41.57137099743581" ID="CMP-002.05" LOG_CI_END="0.7603926165967582" LOG_CI_START="0.4226860582907623" LOG_EFFECT_SIZE="0.5915393374437602" METHOD="PETO" NO="5" P_CHI2="0.18059682114058606" P_Q="0.18059682114058606" P_Z="6.5892469379307804E-12" Q="3.4229795121707003" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="624" TOTAL_2="393" WEIGHT="300.0" Z="6.86629127159519">
<NAME>At least one adverse event of diarrhoea before end of treatment</NAME>
<GROUP_LABEL_1>Physostigmine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favoursphysostigmine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="13.59015902302495" CI_START="2.683535143919266" DF="0.0" EFFECT_SIZE="6.03901228262859" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="2" I2="0.0" ID="CMP-002.05.01" LOG_CI_END="1.1332245385881357" LOG_CI_START="0.42870728723634555" LOG_EFFECT_SIZE="0.7809659129122407" NO="1" P_CHI2="1.0" P_Z="1.3909325947272962E-5" STUDIES="1" TAU2="0.0" TOTAL_1="183" TOTAL_2="183" WEIGHT="100.0" Z="4.345287669037139">
<NAME>Responders at 6 weeks (mean dose 24mg /day)</NAME>
<DICH_DATA CI_END="13.59015902302495" CI_START="2.6835351439192663" EFFECT_SIZE="6.03901228262859" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="2" LOG_CI_END="1.1332245385881357" LOG_CI_START="0.42870728723634566" LOG_EFFECT_SIZE="0.7809659129122407" ORDER="2211" O_E="10.5" SE="0.41383692086067997" STUDY_ID="STD-Thal-1996a" TOTAL_1="183" TOTAL_2="183" VAR="5.83904109589041" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="16.923807867223303" CI_START="2.412904542567643" DF="0.0" EFFECT_SIZE="6.390268607841546" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="2" I2="0.0" ID="CMP-002.05.02" LOG_CI_END="1.2284980862244685" LOG_CI_START="0.3825401410318045" LOG_EFFECT_SIZE="0.8055191136281366" NO="2" P_CHI2="1.0" P_Z="1.8955410295852046E-4" STUDIES="1" TAU2="0.0" TOTAL_1="83" TOTAL_2="93" WEIGHT="100.0" Z="3.7325459511115806">
<NAME>Responders at 12 weeks (mean dose 27mg/day)</NAME>
<DICH_DATA CI_END="16.92380786722331" CI_START="2.412904542567643" EFFECT_SIZE="6.390268607841546" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="2" LOG_CI_END="1.2284980862244685" LOG_CI_START="0.3825401410318045" LOG_EFFECT_SIZE="0.8055191136281366" ORDER="2212" O_E="7.511363636363637" SE="0.49691988456553565" STUDY_ID="STD-van-Dyck-2000" TOTAL_1="83" TOTAL_2="93" VAR="4.049740997638725" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.791894552171817" CI_START="1.7718444843683403" DF="0.0" EFFECT_SIZE="2.9138448709463467" ESTIMABLE="YES" EVENTS_1="98" EVENTS_2="10" I2="0.0" ID="CMP-002.05.03" LOG_CI_END="0.6805072526379788" LOG_CI_START="0.24842560099088332" LOG_EFFECT_SIZE="0.46446642681443107" NO="3" P_CHI2="1.0" P_Z="2.5118878061654987E-5" STUDIES="1" TAU2="0.0" TOTAL_1="358" TOTAL_2="117" WEIGHT="100.0" Z="4.213728887186424">
<NAME>All patients at 24 weeks (mean dose 33 mg/day)</NAME>
<DICH_DATA CI_END="4.791894552171817" CI_START="1.7718444843683403" EFFECT_SIZE="2.9138448709463467" ESTIMABLE="YES" EVENTS_1="98" EVENTS_2="10" LOG_CI_END="0.6805072526379788" LOG_CI_START="0.24842560099088332" LOG_EFFECT_SIZE="0.46446642681443107" ORDER="2213" O_E="16.602105263157895" SE="0.2538069010161743" STUDY_ID="STD-Thal-1999" TOTAL_1="358" TOTAL_2="117" VAR="15.523625148146847" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.3692890405970393" CI_END="4.750283004832669" CI_START="1.905880354934623" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="3.008898645566247" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="0.6767194841040066" LOG_CI_START="0.28009563354122435" LOG_EFFECT_SIZE="0.47840755882261554" METHOD="PETO" NO="6" P_CHI2="0.5042695045536907" P_Q="0.5042695045536907" P_Z="2.265013429038902E-6" Q="1.3692890405970393" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="624" TOTAL_2="393" WEIGHT="300.0" Z="4.728215834189375">
<NAME>At least one adverse event of anorexia before end of treatment</NAME>
<GROUP_LABEL_1>Physostigmine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favoursphysostigmine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.484148518253148" CI_START="1.8155384142219986" DF="0.0" EFFECT_SIZE="4.1495585260453" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="4" I2="0.0" ID="CMP-002.06.01" LOG_CI_END="0.9769983462501376" LOG_CI_START="0.25900544240239176" LOG_EFFECT_SIZE="0.6180018943262647" NO="1" P_CHI2="1.0" P_Z="7.407880048807576E-4" STUDIES="1" TAU2="0.0" TOTAL_1="183" TOTAL_2="183" WEIGHT="100.0" Z="3.374020686738881">
<NAME>Responders at 6 weeks (mean dose 24mg /day)</NAME>
<DICH_DATA CI_END="9.484148518253148" CI_START="1.8155384142219986" EFFECT_SIZE="4.1495585260453" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="4" LOG_CI_END="0.9769983462501376" LOG_CI_START="0.25900544240239176" LOG_EFFECT_SIZE="0.6180018943262647" ORDER="2214" O_E="8.0" SE="0.4217525858423601" STUDY_ID="STD-Thal-1996a" TOTAL_1="183" TOTAL_2="183" VAR="5.6219178082191785" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="14.355772453613508" CI_START="1.1213502602394632" DF="0.0" EFFECT_SIZE="4.012212503943183" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" I2="0.0" ID="CMP-002.06.02" LOG_CI_END="1.1570265659245613" LOG_CI_START="0.04974128817890256" LOG_EFFECT_SIZE="0.6033839270517319" NO="2" P_CHI2="1.0" P_Z="0.03267498423386591" STUDIES="1" TAU2="0.0" TOTAL_1="83" TOTAL_2="93" WEIGHT="100.0" Z="2.1360543477638134">
<NAME>Responders at 12 weeks (mean dose 27mg/day)</NAME>
<DICH_DATA CI_END="14.355772453613508" CI_START="1.1213502602394632" EFFECT_SIZE="4.012212503943183" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="1.1570265659245613" LOG_CI_START="0.04974128817890256" LOG_EFFECT_SIZE="0.6033839270517319" ORDER="2215" O_E="3.284090909090909" SE="0.6504248532983237" STUDY_ID="STD-van-Dyck-2000" TOTAL_1="83" TOTAL_2="93" VAR="2.3637728748524207" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.348971321763031" CI_START="1.2925441263734245" DF="0.0" EFFECT_SIZE="2.3709148735691197" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="7" I2="0.0" ID="CMP-002.06.03" LOG_CI_END="0.6383865438251126" LOG_CI_START="0.11144537846877485" LOG_EFFECT_SIZE="0.37491596114694375" NO="3" P_CHI2="1.0" P_Z="0.005286962382172607" STUDIES="1" TAU2="0.0" TOTAL_1="358" TOTAL_2="117" WEIGHT="100.0" Z="2.7890088282638286">
<NAME>All patients at 24 weeks (mean dose 33 mg/day)</NAME>
<DICH_DATA CI_END="4.348971321763031" CI_START="1.2925441263734245" EFFECT_SIZE="2.3709148735691197" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="7" LOG_CI_END="0.6383865438251126" LOG_CI_START="0.11144537846877485" LOG_EFFECT_SIZE="0.37491596114694375" ORDER="2216" O_E="9.010526315789477" SE="0.3095278489311491" STUDY_ID="STD-Thal-1999" TOTAL_1="358" TOTAL_2="117" VAR="10.437597391212874" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.060302722914588" CI_END="4.044742990293654" CI_START="1.9140084362313186" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.782386063401257" ESTIMABLE="YES" EVENTS_1="136" EVENTS_2="26" I2="50.74258900172966" I2_Q="50.74258900172966" ID="CMP-002.07" LOG_CI_END="0.6068909310302737" LOG_CI_START="0.281943847652233" LOG_EFFECT_SIZE="0.44441738934125335" METHOD="PETO" NO="7" P_CHI2="0.13131588850705667" P_Q="0.13131588850705667" P_Z="8.270213038581247E-8" Q="4.060302722914588" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="624" TOTAL_2="393" WEIGHT="300.0" Z="5.361131838187995">
<NAME>At least one adverse event of dizziness before end of treatment</NAME>
<GROUP_LABEL_1>Physostigmine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favoursphysostigmine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.169415230306891" CI_START="1.2892143498946997" DF="0.0" EFFECT_SIZE="2.8202302468717972" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="7" I2="0.0" ID="CMP-002.07.01" LOG_CI_END="0.790244001263961" LOG_CI_START="0.11032513088109742" LOG_EFFECT_SIZE="0.45028456607252926" NO="1" P_CHI2="1.0" P_Z="0.009431054367052483" STUDIES="1" TAU2="0.0" TOTAL_1="183" TOTAL_2="183" WEIGHT="100.0" Z="2.5960201157512897">
<NAME>Responders at 6 weeks (mean dose 24mg /day)</NAME>
<DICH_DATA CI_END="6.169415230306891" CI_START="1.2892143498946997" EFFECT_SIZE="2.8202302468717972" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="7" LOG_CI_END="0.790244001263961" LOG_CI_START="0.11032513088109742" LOG_EFFECT_SIZE="0.45028456607252926" ORDER="2217" O_E="6.5" SE="0.399387710115583" STUDY_ID="STD-Thal-1996a" TOTAL_1="183" TOTAL_2="183" VAR="6.269178082191781" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="13.267561794017347" CI_START="2.5141156366190804" DF="0.0" EFFECT_SIZE="5.775481327659964" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="4" I2="0.0" ID="CMP-002.07.02" LOG_CI_END="1.122791119044084" LOG_CI_START="0.4003852491616389" LOG_EFFECT_SIZE="0.7615881841028613" NO="2" P_CHI2="1.0" P_Z="3.58777017065602E-5" STUDIES="1" TAU2="0.0" TOTAL_1="83" TOTAL_2="93" WEIGHT="100.0" Z="4.132539543555395">
<NAME>Responders at 12 weeks (mean dose 27mg/day)</NAME>
<DICH_DATA CI_END="13.267561794017347" CI_START="2.5141156366190804" EFFECT_SIZE="5.775481327659964" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="4" LOG_CI_END="1.122791119044084" LOG_CI_START="0.4003852491616389" LOG_EFFECT_SIZE="0.7615881841028613" ORDER="2218" O_E="9.738636363636363" SE="0.42434478393567654" STUDY_ID="STD-van-Dyck-2000" TOTAL_1="83" TOTAL_2="93" VAR="5.553442296340023" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.5048793318065745" CI_START="1.3001421879391655" DF="0.0" EFFECT_SIZE="2.1346759667260415" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="15" I2="0.0" ID="CMP-002.07.03" LOG_CI_END="0.5446730703960695" LOG_CI_START="0.11399085081497277" LOG_EFFECT_SIZE="0.32933196060552117" NO="3" P_CHI2="1.0" P_Z="0.002722295504767747" STUDIES="1" TAU2="0.0" TOTAL_1="358" TOTAL_2="117" WEIGHT="100.0" Z="2.997471232374583">
<NAME>All patients at 24 weeks (mean dose 33 mg/day)</NAME>
<DICH_DATA CI_END="3.5048793318065745" CI_START="1.3001421879391655" EFFECT_SIZE="2.1346759667260415" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="15" LOG_CI_END="0.5446730703960695" LOG_CI_START="0.11399085081497277" LOG_EFFECT_SIZE="0.32933196060552117" ORDER="2219" O_E="11.84842105263158" SE="0.2529848676933062" STUDY_ID="STD-Thal-1999" TOTAL_1="358" TOTAL_2="117" VAR="15.624672057225007" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.3681538011778258" CI_END="4.374502392131452" CI_START="1.091072052819359" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.1846961585186304" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-002.08" LOG_CI_END="0.6409286583543637" LOG_CI_START="0.03785343171445235" LOG_EFFECT_SIZE="0.3393910450344081" METHOD="PETO" NO="8" P_CHI2="0.5440125980627064" P_Q="0.5440125980627064" P_Z="0.027383477268226035" Q="0.3681538011778258" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="266" TOTAL_2="276" WEIGHT="200.0" Z="2.2060074616198104">
<NAME>At least one adverse event of headache before end of treatment</NAME>
<GROUP_LABEL_1>Physostigmine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favoursphysostigmine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.2937333725731595" CI_START="0.8729389680489992" DF="0.0" EFFECT_SIZE="1.9360183830045525" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="9" I2="0.0" ID="CMP-002.08.01" LOG_CI_END="0.6328350726071291" LOG_CI_START="-0.05901611914219908" LOG_EFFECT_SIZE="0.286909476732465" NO="1" P_CHI2="1.0" P_Z="0.10403748740568411" STUDIES="1" TAU2="0.0" TOTAL_1="183" TOTAL_2="183" WEIGHT="99.99999999999999" Z="1.625587259008751">
<NAME>Responders at 6 weeks (mean dose 24mg /day)</NAME>
<DICH_DATA CI_END="4.2937333725731595" CI_START="0.8729389680489992" EFFECT_SIZE="1.9360183830045525" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="9" LOG_CI_END="0.6328350726071291" LOG_CI_START="-0.05901611914219908" LOG_EFFECT_SIZE="0.286909476732465" ORDER="2220" O_E="4.0" SE="0.4063968147521877" STUDY_ID="STD-Thal-1996a" TOTAL_1="183" TOTAL_2="183" VAR="6.054794520547945" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="13.204608083738336" CI_START="0.7764865667278134" DF="0.0" EFFECT_SIZE="3.2020619600389235" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" I2="0.0" ID="CMP-002.08.02" LOG_CI_END="1.1207255157590974" LOG_CI_START="-0.10986605319549807" LOG_EFFECT_SIZE="0.5054297312817997" NO="2" P_CHI2="1.0" P_Z="0.10739861663287945" STUDIES="1" TAU2="0.0" TOTAL_1="83" TOTAL_2="93" WEIGHT="100.0" Z="1.6099965171541584">
<NAME>Responders at 12 weeks (mean dose 27mg/day)</NAME>
<DICH_DATA CI_END="13.204608083738336" CI_START="0.7764865667278134" EFFECT_SIZE="3.2020619600389235" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.1207255157590974" LOG_CI_START="-0.10986605319549807" LOG_EFFECT_SIZE="0.5054297312817997" ORDER="2221" O_E="2.227272727272727" SE="0.7228555791304385" STUDY_ID="STD-van-Dyck-2000" TOTAL_1="83" TOTAL_2="93" VAR="1.913801652892562" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.847994284358086" CI_END="5.0050448087710455" CI_START="1.9625213517657583" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="3.13408795405578" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="11" I2="58.745825950064706" I2_Q="58.745825950064706" ID="CMP-002.09" LOG_CI_END="0.6994079699501816" LOG_CI_START="0.29281439046371244" LOG_EFFECT_SIZE="0.496111180206947" METHOD="PETO" NO="9" P_CHI2="0.08856694122329611" P_Q="0.08856694122329611" P_Z="1.7273406459685349E-6" Q="4.847994284358086" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="624" TOTAL_2="393" WEIGHT="300.0" Z="4.7829581901483795">
<NAME>At least one adverse event of stomach pain before end of treatment</NAME>
<GROUP_LABEL_1>Physostigmine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favoursphysostigmine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="16.741326980321176" CI_START="2.3948923351311473" DF="0.0" EFFECT_SIZE="6.331956701138714" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="1" I2="0.0" ID="CMP-002.09.01" LOG_CI_END="1.2237898788299186" LOG_CI_START="0.3792859940305591" LOG_EFFECT_SIZE="0.8015379364302389" NO="1" P_CHI2="1.0" P_Z="1.98834082451294E-4" STUDIES="1" TAU2="0.0" TOTAL_1="183" TOTAL_2="183" WEIGHT="100.0" Z="3.720493217195951">
<NAME>Responders at 6 weeks (mean dose 24mg /day)</NAME>
<DICH_DATA CI_END="16.741326980321176" CI_START="2.3948923351311473" EFFECT_SIZE="6.331956701138714" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="1" LOG_CI_END="1.2237898788299186" LOG_CI_START="0.3792859940305591" LOG_EFFECT_SIZE="0.8015379364302389" ORDER="2222" O_E="7.5" SE="0.4960657622927935" STUDY_ID="STD-Thal-1996a" TOTAL_1="183" TOTAL_2="183" VAR="4.063698630136987" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="21.915729317330147" CI_START="1.7118694833547554" DF="0.0" EFFECT_SIZE="6.125101486816411" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="1" I2="0.0" ID="CMP-002.09.02" LOG_CI_END="1.340755927794985" LOG_CI_START="0.23347065004932613" LOG_EFFECT_SIZE="0.7871132889221555" NO="2" P_CHI2="1.0" P_Z="0.005328403738480813" STUDIES="1" TAU2="0.0" TOTAL_1="83" TOTAL_2="93" WEIGHT="100.0" Z="2.786479201062137">
<NAME>Responders at 12 weeks (mean dose 27mg/day)</NAME>
<DICH_DATA CI_END="21.915729317330147" CI_START="1.7118694833547554" EFFECT_SIZE="6.125101486816411" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="1" LOG_CI_END="1.340755927794985" LOG_CI_START="0.23347065004932613" LOG_EFFECT_SIZE="0.7871132889221555" ORDER="2223" O_E="4.284090909090909" SE="0.6504248532983237" STUDY_ID="STD-van-Dyck-2000" TOTAL_1="83" TOTAL_2="93" VAR="2.3637728748524207" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.782923033744855" CI_START="1.1666202357516027" DF="0.0" EFFECT_SIZE="2.100769992516456" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="9" I2="0.0" ID="CMP-002.09.03" LOG_CI_END="0.5778275053530302" LOG_CI_START="0.06692950526649684" LOG_EFFECT_SIZE="0.3223785053097634" NO="3" P_CHI2="1.0" P_Z="0.013380096979305462" STUDIES="1" TAU2="0.0" TOTAL_1="358" TOTAL_2="117" WEIGHT="100.0" Z="2.4734888752352577">
<NAME>All patients at 24 weeks (mean dose 33 mg/day)</NAME>
<DICH_DATA CI_END="3.782923033744855" CI_START="1.1666202357516027" EFFECT_SIZE="2.100769992516456" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="9" LOG_CI_END="0.5778275053530302" LOG_CI_START="0.06692950526649684" LOG_EFFECT_SIZE="0.3223785053097634" ORDER="2224" O_E="8.242105263157896" SE="0.30010401423671706" STUDY_ID="STD-Thal-1999" TOTAL_1="358" TOTAL_2="117" VAR="11.103410358006942" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0801410353855343" CI_END="5.038470946641125" CI_START="1.411701459426298" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.6669864620298087" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-002.10" LOG_CI_END="0.7022987586302385" LOG_CI_START="0.14974286369014175" LOG_EFFECT_SIZE="0.4260208111601901" METHOD="PETO" NO="10" P_CHI2="0.7771063845185847" P_Q="0.7771063845185847" P_Z="0.002508899765986603" Q="0.0801410353855343" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="441" TOTAL_2="210" WEIGHT="200.0" Z="3.0222659976472936">
<NAME>At least one adverse event of dyspepsia before end of treatment</NAME>
<GROUP_LABEL_1>Physostigmine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favoursphysostigmine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="13.204608083738336" CI_START="0.7764865667278134" DF="0.0" EFFECT_SIZE="3.2020619600389235" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" I2="0.0" ID="CMP-002.10.01" LOG_CI_END="1.1207255157590974" LOG_CI_START="-0.10986605319549807" LOG_EFFECT_SIZE="0.5054297312817997" NO="1" P_CHI2="1.0" P_Z="0.10739861663287945" STUDIES="1" TAU2="0.0" TOTAL_1="83" TOTAL_2="93" WEIGHT="100.0" Z="1.6099965171541584">
<NAME>Responders at 12 weeks (mean dose 27mg/day)</NAME>
<DICH_DATA CI_END="13.204608083738336" CI_START="0.7764865667278134" EFFECT_SIZE="3.2020619600389235" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.1207255157590974" LOG_CI_START="-0.10986605319549807" LOG_EFFECT_SIZE="0.5054297312817997" ORDER="2225" O_E="2.227272727272727" SE="0.7228555791304385" STUDY_ID="STD-van-Dyck-2000" TOTAL_1="83" TOTAL_2="93" VAR="1.913801652892562" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.190010541980179" CI_START="1.2495888618143758" DF="0.0" EFFECT_SIZE="2.546640800340249" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="4" I2="0.0" ID="CMP-002.10.02" LOG_CI_END="0.7151682399908799" LOG_CI_START="0.09676714547519588" LOG_EFFECT_SIZE="0.4059676927330379" NO="2" P_CHI2="1.0" P_Z="0.010071851574413267" STUDIES="1" TAU2="0.0" TOTAL_1="358" TOTAL_2="117" WEIGHT="100.0" Z="2.5733526790302186">
<NAME>All patients at 24 weeks (mean dose 33 mg/day)</NAME>
<DICH_DATA CI_END="5.190010541980179" CI_START="1.2495888618143758" EFFECT_SIZE="2.546640800340249" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="4" LOG_CI_END="0.7151682399908799" LOG_CI_START="0.09676714547519588" LOG_EFFECT_SIZE="0.4059676927330379" ORDER="2226" O_E="7.084210526315786" SE="0.36325186405329996" STUDY_ID="STD-Thal-1999" TOTAL_1="358" TOTAL_2="117" VAR="7.578518180861881" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="27.268250466374628" CI_START="2.2153281836281176" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="7.772266321761644" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.11" LOG_CI_END="1.4356572744589122" LOG_CI_START="0.34543807267240173" LOG_EFFECT_SIZE="0.8905476735656569" METHOD="PETO" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="0.0013647662899760999" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="183" TOTAL_2="183" WEIGHT="100.0" Z="3.2020007790074083">
<NAME>At least one adverse event of flatulence before end of treatment</NAME>
<GROUP_LABEL_1>Physostigmine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favoursphysostigmine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="27.268250466374628" CI_START="2.2153281836281176" DF="0.0" EFFECT_SIZE="7.772266321761644" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="0" I2="0.0" ID="CMP-002.11.01" LOG_CI_END="1.4356572744589122" LOG_CI_START="0.34543807267240173" LOG_EFFECT_SIZE="0.8905476735656569" NO="1" P_CHI2="1.0" P_Z="0.0013647662899760999" STUDIES="1" TAU2="0.0" TOTAL_1="183" TOTAL_2="183" WEIGHT="100.0" Z="3.2020007790074083">
<NAME>Responders at 6 weeks (mean dose 24mg /day)</NAME>
<DICH_DATA CI_END="27.268250466374628" CI_START="2.2153281836281176" EFFECT_SIZE="7.772266321761644" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="0" LOG_CI_END="1.4356572744589122" LOG_CI_START="0.34543807267240173" LOG_EFFECT_SIZE="0.8905476735656569" ORDER="2227" O_E="5.0" SE="0.6404001558014815" STUDY_ID="STD-Thal-1996a" TOTAL_1="183" TOTAL_2="183" VAR="2.4383561643835616" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.098024972535403" CI_END="6.815950919383731" CI_START="2.6907581835417616" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="4.282531461057906" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-002.12" LOG_CI_END="0.8335264544820066" LOG_CI_START="0.42987466979187794" LOG_EFFECT_SIZE="0.6317005621369423" METHOD="PETO" NO="12" P_CHI2="0.5775199635016783" P_Q="0.5775199635016783" P_Z="8.540238412723956E-10" Q="1.098024972535403" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="624" TOTAL_2="393" WEIGHT="300.0" Z="6.134546645210914">
<NAME>At least one adverse event of sweating before end of treatment</NAME>
<GROUP_LABEL_1>Physostigmine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favoursphysostigmine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="16.741326980321176" CI_START="2.3948923351311473" DF="0.0" EFFECT_SIZE="6.331956701138714" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="1" I2="0.0" ID="CMP-002.12.01" LOG_CI_END="1.2237898788299186" LOG_CI_START="0.3792859940305591" LOG_EFFECT_SIZE="0.8015379364302389" NO="1" P_CHI2="1.0" P_Z="1.98834082451294E-4" STUDIES="1" TAU2="0.0" TOTAL_1="183" TOTAL_2="183" WEIGHT="100.0" Z="3.720493217195951">
<NAME>Responders at 6 weeks (mean dose 24mg /day)</NAME>
<DICH_DATA CI_END="16.741326980321176" CI_START="2.3948923351311473" EFFECT_SIZE="6.331956701138714" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="1" LOG_CI_END="1.2237898788299186" LOG_CI_START="0.3792859940305591" LOG_EFFECT_SIZE="0.8015379364302389" ORDER="2228" O_E="7.5" SE="0.4960657622927935" STUDY_ID="STD-Thal-1996a" TOTAL_1="183" TOTAL_2="183" VAR="4.063698630136987" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="15.519326223973408" CI_START="1.6248870671783828" DF="0.0" EFFECT_SIZE="5.02166829576155" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" I2="0.0" ID="CMP-002.12.02" LOG_CI_END="1.190872862311195" LOG_CI_START="0.21082318204989964" LOG_EFFECT_SIZE="0.7008480221805473" NO="2" P_CHI2="1.0" P_Z="0.005059852137333318" STUDIES="1" TAU2="0.0" TOTAL_1="83" TOTAL_2="93" WEIGHT="100.0" Z="2.803198469987298">
<NAME>Responders at 12 weeks (mean dose 27mg/day)</NAME>
<DICH_DATA CI_END="15.519326223973408" CI_START="1.6248870671783824" EFFECT_SIZE="5.02166829576155" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" LOG_CI_END="1.190872862311195" LOG_CI_START="0.21082318204989955" LOG_EFFECT_SIZE="0.7008480221805473" ORDER="2229" O_E="4.869318181818182" SE="0.5756860335096434" STUDY_ID="STD-van-Dyck-2000" TOTAL_1="83" TOTAL_2="93" VAR="3.017370314344746" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.425284711143624" CI_START="1.9391216043318953" DF="0.0" EFFECT_SIZE="3.5297887185158867" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="3" I2="0.0" ID="CMP-002.12.03" LOG_CI_END="0.8078923764763399" LOG_CI_START="0.2876050449912028" LOG_EFFECT_SIZE="0.5477487107337714" NO="3" P_CHI2="1.0" P_Z="3.6780384362770714E-5" STUDIES="1" TAU2="0.0" TOTAL_1="358" TOTAL_2="117" WEIGHT="100.00000000000001" Z="4.126826392455063">
<NAME>All patients at 24 weeks (mean dose 33 mg/day)</NAME>
<DICH_DATA CI_END="6.425284711143624" CI_START="1.9391216043318955" EFFECT_SIZE="3.5297887185158867" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="3" LOG_CI_END="0.8078923764763399" LOG_CI_START="0.2876050449912029" LOG_EFFECT_SIZE="0.5477487107337714" ORDER="2230" O_E="13.503157894736844" SE="0.3056193539781969" STUDY_ID="STD-Thal-1999" TOTAL_1="358" TOTAL_2="117" VAR="10.706272506048597" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.2830018272515338" CI_END="0.7563063495490518" CI_START="0.21716650758234377" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.4052707842836921" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-002.13" LOG_CI_END="-0.1213022534812681" LOG_CI_START="-0.6632071528113609" LOG_EFFECT_SIZE="-0.3922547031463145" METHOD="PETO" NO="13" P_CHI2="0.5947404947530351" P_Q="0.5947404947530351" P_Z="0.004548016769086049" Q="0.2830018272515338" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="441" TOTAL_2="210" WEIGHT="200.0" Z="2.8374170149914857">
<NAME>At least one adverse event of agitation before end of treatment</NAME>
<GROUP_LABEL_1>Physostigmine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favoursphysostigmine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.134725298303856" CI_START="0.1464403076514953" DF="0.0" EFFECT_SIZE="0.5591152201783159" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" I2="0.0" ID="CMP-002.13.01" LOG_CI_END="0.3293419968755737" LOG_CI_START="-0.8343393673949424" LOG_EFFECT_SIZE="-0.2524986852596844" NO="1" P_CHI2="1.0" P_Z="0.395015813703554" STUDIES="1" TAU2="0.0" TOTAL_1="83" TOTAL_2="93" WEIGHT="100.00000000000001" Z="0.8505564228278754">
<NAME>Responders at 12 weeks (mean dose 27mg/day)</NAME>
<DICH_DATA CI_END="2.134725298303856" CI_START="0.1464403076514953" EFFECT_SIZE="0.5591152201783159" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.3293419968755737" LOG_CI_START="-0.8343393673949424" LOG_EFFECT_SIZE="-0.2524986852596844" ORDER="2231" O_E="-1.2443181818181817" SE="0.6835521936881556" STUDY_ID="STD-van-Dyck-2000" TOTAL_1="83" TOTAL_2="93" VAR="2.140211223435655" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.7502792415424873" CI_START="0.18317578696248077" DF="0.0" EFFECT_SIZE="0.3707195577672674" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="19" I2="0.0" ID="CMP-002.13.02" LOG_CI_END="-0.1247770692878935" LOG_CI_START="-0.7371319339626776" LOG_EFFECT_SIZE="-0.4309545016252856" NO="2" P_CHI2="1.0" P_Z="0.005802968329552563" STUDIES="1" TAU2="0.0" TOTAL_1="358" TOTAL_2="117" WEIGHT="100.0" Z="2.758711821811219">
<NAME>All patients at 24 weeks (mean dose 33 mg/day)</NAME>
<DICH_DATA CI_END="0.7502792415424873" CI_START="0.18317578696248077" EFFECT_SIZE="0.3707195577672674" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="19" LOG_CI_END="-0.1247770692878935" LOG_CI_START="-0.7371319339626776" LOG_EFFECT_SIZE="-0.4309545016252856" ORDER="2232" O_E="-7.669473684210523" SE="0.359700278715435" STUDY_ID="STD-Thal-1999" TOTAL_1="358" TOTAL_2="117" VAR="7.72891358042007" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.5861391925721224" CI_END="4.292762411250421" CI_START="0.8851150845855696" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.9492533864892143" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="9" I2="61.33232105711139" I2_Q="61.33232105711139" ID="CMP-002.14" LOG_CI_END="0.6327368525282936" LOG_CI_START="-0.0530002577190886" LOG_EFFECT_SIZE="0.28986829740460246" METHOD="PETO" NO="14" P_CHI2="0.10780320862037718" P_Q="0.10780320862037718" P_Z="0.0975205203675876" Q="2.5861391925721224" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="266" TOTAL_2="276" WEIGHT="200.0" Z="1.65699482989337">
<NAME>At least one adverse event of tremor before end of treatment</NAME>
<GROUP_LABEL_1>Physostigmine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favoursphysostigmine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.478836597069348" CI_START="0.6218678078328115" DF="0.0" EFFECT_SIZE="1.4708421018002147" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="9" I2="0.0" ID="CMP-002.14.01" LOG_CI_END="0.5414340301681938" LOG_CI_START="-0.2063019246825977" LOG_EFFECT_SIZE="0.167566052742798" NO="1" P_CHI2="1.0" P_Z="0.37970087041343503" STUDIES="1" TAU2="0.0" TOTAL_1="183" TOTAL_2="183" WEIGHT="99.99999999999999" Z="0.8784476024640522">
<NAME>Responders at 6 weeks (mean dose 24mg /day)</NAME>
<DICH_DATA CI_END="3.478836597069348" CI_START="0.6218678078328115" EFFECT_SIZE="1.4708421018002147" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="9" LOG_CI_END="0.5414340301681938" LOG_CI_START="-0.2063019246825977" LOG_EFFECT_SIZE="0.167566052742798" ORDER="2233" O_E="2.0" SE="0.4392238012320261" STUDY_ID="STD-Thal-1996a" TOTAL_1="183" TOTAL_2="183" VAR="5.183561643835617" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="62.65533178418413" CI_START="1.1939717720693697" DF="0.0" EFFECT_SIZE="8.649202131986316" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" ID="CMP-002.14.02" LOG_CI_END="1.7969580340839313" LOG_CI_START="0.07699405930639565" LOG_EFFECT_SIZE="0.9369760466951634" NO="2" P_CHI2="1.0" P_Z="0.03272514599274878" STUDIES="1" TAU2="0.0" TOTAL_1="83" TOTAL_2="93" WEIGHT="100.0" Z="2.135439268298361">
<NAME>Responders at 12 weeks (mean dose 27mg/day)</NAME>
<DICH_DATA CI_END="62.65533178418413" CI_START="1.1939717720693697" EFFECT_SIZE="8.649202131986316" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.7969580340839313" LOG_CI_START="0.07699405930639565" LOG_EFFECT_SIZE="0.9369760466951634" ORDER="2234" O_E="2.1136363636363633" SE="1.0103153527433109" STUDY_ID="STD-van-Dyck-2000" TOTAL_1="83" TOTAL_2="93" VAR="0.9796841794569068" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.9648745433945554" CI_END="5.519679442076292" CI_START="2.1799018809756507" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="3.4687691762590287" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-002.15" LOG_CI_END="0.7419138566096607" LOG_CI_START="0.33843694612302605" LOG_EFFECT_SIZE="0.5401754013663433" METHOD="PETO" NO="15" P_CHI2="0.37439757237890425" P_Q="0.37439757237890425" P_Z="1.5375549723535628E-7" Q="1.9648745433945554" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="624" TOTAL_2="393" WEIGHT="300.0" Z="5.2480045548855365">
<NAME>At least one adverse event of asthenia before end of treatment</NAME>
<GROUP_LABEL_1>Physostigmine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favoursphysostigmine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.0682564603094855" CI_START="0.8369286676924433" DF="0.0" EFFECT_SIZE="2.43220608958931" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" I2="0.0" ID="CMP-002.15.01" LOG_CI_END="0.8493122987968944" LOG_CI_START="-0.07731155580328934" LOG_EFFECT_SIZE="0.38600037149680255" NO="1" P_CHI2="1.0" P_Z="0.10248785993803297" STUDIES="1" TAU2="0.0" TOTAL_1="183" TOTAL_2="183" WEIGHT="100.0" Z="1.6329103171626127">
<NAME>Responders at 6 weeks (mean dose 24mg /day)</NAME>
<DICH_DATA CI_END="7.0682564603094855" CI_START="0.8369286676924432" EFFECT_SIZE="2.43220608958931" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" LOG_CI_END="0.8493122987968944" LOG_CI_START="-0.0773115558032894" LOG_EFFECT_SIZE="0.38600037149680255" ORDER="2235" O_E="3.0" SE="0.5443034390542042" STUDY_ID="STD-Thal-1996a" TOTAL_1="183" TOTAL_2="183" VAR="3.375342465753425" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="40.68540475622771" CI_START="1.9850839330217092" DF="0.0" EFFECT_SIZE="8.986876169730651" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" I2="0.0" ID="CMP-002.15.02" LOG_CI_END="1.6094386409048616" LOG_CI_START="0.29777887426162525" LOG_EFFECT_SIZE="0.9536087575832434" NO="2" P_CHI2="1.0" P_Z="0.004373523336857039" STUDIES="1" TAU2="0.0" TOTAL_1="83" TOTAL_2="93" WEIGHT="100.0" Z="2.8498835867907077">
<NAME>Responders at 12 weeks (mean dose 27mg/day)</NAME>
<DICH_DATA CI_END="40.68540475622771" CI_START="1.9850839330217092" EFFECT_SIZE="8.986876169730651" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="1.6094386409048616" LOG_CI_START="0.29777887426162525" LOG_EFFECT_SIZE="0.9536087575832434" ORDER="2236" O_E="3.6988636363636362" SE="0.7704754397467967" STUDY_ID="STD-van-Dyck-2000" TOTAL_1="83" TOTAL_2="93" VAR="1.6845441632231406" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.818490350126719" CI_START="1.9404785909145659" DF="0.0" EFFECT_SIZE="3.3601571326150648" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="5" I2="0.0" ID="CMP-002.15.03" LOG_CI_END="0.7648103183858757" LOG_CI_START="0.2879088555795341" LOG_EFFECT_SIZE="0.5263595869827049" NO="3" P_CHI2="1.0" P_Z="1.5152977457682897E-5" STUDIES="1" TAU2="0.0" TOTAL_1="358" TOTAL_2="117" WEIGHT="100.0" Z="4.3264527952282945">
<NAME>All patients at 24 weeks (mean dose 33 mg/day)</NAME>
<DICH_DATA CI_END="5.818490350126719" CI_START="1.9404785909145659" EFFECT_SIZE="3.3601571326150648" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="5" LOG_CI_END="0.7648103183858757" LOG_CI_START="0.2879088555795341" LOG_EFFECT_SIZE="0.5263595869827049" ORDER="2237" O_E="15.444210526315793" SE="0.28013427995275886" STUDY_ID="STD-Thal-1999" TOTAL_1="358" TOTAL_2="117" VAR="12.742876875065743" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.20100247305193297" CI_END="9.647928076048824" CI_START="1.2876280509230766" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="3.5246195289717126" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.16" LOG_CI_END="0.984434057203669" LOG_CI_START="0.10979042920370281" LOG_EFFECT_SIZE="0.547112243203686" METHOD="PETO" NO="16" P_CHI2="0.653912902932011" P_Q="0.653912902932011" P_Z="0.014205815819136812" Q="0.20100247305193297" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="441" TOTAL_2="210" WEIGHT="200.0" Z="2.452016473571531">
<NAME>At least one adverse event of dyspnea before end of treatment</NAME>
<GROUP_LABEL_1>Physostigmine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favoursphysostigmine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="21.58026368651449" CI_START="0.22581965927576364" DF="0.0" EFFECT_SIZE="2.2075433841195142" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-002.16.01" LOG_CI_END="1.334056746968697" LOG_CI_START="-0.6462382522103106" LOG_EFFECT_SIZE="0.3439092473791932" NO="1" P_CHI2="1.0" P_Z="0.4960253327455112" STUDIES="1" TAU2="0.0" TOTAL_1="83" TOTAL_2="93" WEIGHT="100.0" Z="0.6807568964148705">
<NAME>Responders at 12 weeks (mean dose 27mg/day)</NAME>
<DICH_DATA CI_END="21.58026368651449" CI_START="0.22581965927576372" EFFECT_SIZE="2.2075433841195142" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.334056746968697" LOG_CI_START="-0.6462382522103104" LOG_EFFECT_SIZE="0.3439092473791932" ORDER="2238" O_E="0.5852272727272727" SE="1.1632350851360893" STUDY_ID="STD-van-Dyck-2000" TOTAL_1="83" TOTAL_2="93" VAR="0.7390350132821724" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="12.128347643963671" CI_START="1.2850390001284246" DF="0.0" EFFECT_SIZE="3.9478348153904577" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="0" I2="0.0" ID="CMP-002.16.02" LOG_CI_END="1.0838016369762404" LOG_CI_START="0.10891630843271713" LOG_EFFECT_SIZE="0.5963589727044788" NO="2" P_CHI2="1.0" P_Z="0.01648905744117647" STUDIES="1" TAU2="0.0" TOTAL_1="358" TOTAL_2="117" WEIGHT="100.0" Z="2.3979068596802695">
<NAME>All patients at 24 weeks (mean dose 33 mg/day)</NAME>
<DICH_DATA CI_END="12.128347643963671" CI_START="1.2850390001284246" EFFECT_SIZE="3.9478348153904577" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="0" LOG_CI_END="1.0838016369762404" LOG_CI_START="0.10891630843271713" LOG_EFFECT_SIZE="0.5963589727044788" ORDER="2239" O_E="4.187368421052632" SE="0.5726524677466707" STUDY_ID="STD-Thal-1999" TOTAL_1="358" TOTAL_2="117" VAR="3.049423387916827" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="8.42953181763843" CI_START="1.1086871875892765" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="3.0570760415128495" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.17" LOG_CI_END="0.9258034542614481" LOG_CI_START="0.04480902868546248" LOG_EFFECT_SIZE="0.48530624147345525" METHOD="PETO" MODIFIED="2008-06-02 14:09:21 +0100" MODIFIED_BY="Helen Collins" NO="17" P_CHI2="1.0" P_Q="1.0" P_Z="0.03082388646686538" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="358" TOTAL_2="117" WEIGHT="100.0" Z="2.1593388724079543">
<NAME>At least one adverse event of abnormal dreaming before end of treatment</NAME>
<GROUP_LABEL_1>Physostigmine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favoursphysostigmine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.42953181763843" CI_START="1.1086871875892765" DF="0.0" EFFECT_SIZE="3.0570760415128495" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="1" I2="0.0" ID="CMP-002.17.01" LOG_CI_END="0.9258034542614481" LOG_CI_START="0.04480902868546248" LOG_EFFECT_SIZE="0.48530624147345525" MODIFIED="2008-06-02 14:09:21 +0100" MODIFIED_BY="Helen Collins" NO="1" P_CHI2="1.0" P_Z="0.03082388646686538" STUDIES="1" TAU2="0.0" TOTAL_1="358" TOTAL_2="117" WEIGHT="100.0" Z="2.1593388724079543">
<NAME>All patients at 24 weeks (mean dose 33 mg/day)</NAME>
<DICH_DATA CI_END="8.42953181763843" CI_START="1.1086871875892765" EFFECT_SIZE="3.0570760415128495" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="1" LOG_CI_END="0.9258034542614481" LOG_CI_START="0.04480902868546248" LOG_EFFECT_SIZE="0.48530624147345525" ORDER="2240" O_E="4.172631578947369" SE="0.5175004865760737" STUDY_ID="STD-Thal-1999" TOTAL_1="358" TOTAL_2="117" VAR="3.7340357796556676" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.07436309249022623" CI_END="-0.9190317275040947" CI_START="-2.7697581191256155" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.844394923314855" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.18" NO="18" P_CHI2="0.7850869390302828" P_Q="0.7850869390302828" P_Z="9.363582101485188E-5" Q="0.07436309249022623" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="263" TOTAL_2="273" UNITS="" WEIGHT="200.0" Z="3.9065176131177135">
<NAME>ADAS-Cog (change from baseline) ITT</NAME>
<GROUP_LABEL_1>Physostigmine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favoursphysostigmine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.6025716631686395" CI_START="-2.8974283368313607" DF="0.0" EFFECT_SIZE="-1.75" ESTIMABLE="YES" I2="0.0" ID="CMP-002.18.01" NO="1" P_CHI2="1.0" P_Z="0.002796737210878461" STUDIES="1" TAU2="0.0" TOTAL_1="183" TOTAL_2="183" WEIGHT="100.00000000000001" Z="2.98923851089203">
<NAME>Responders at 6 weeks (mean dose 24mg /day)</NAME>
<CONT_DATA CI_END="-0.6025716631686395" CI_START="-2.8974283368313607" EFFECT_SIZE="-1.75" ESTIMABLE="YES" MEAN_1="-1.12" MEAN_2="0.63" ORDER="2241" SD_1="5.6" SD_2="5.6" SE="0.5854333783080347" STUDY_ID="STD-Thal-1996a" TOTAL_1="183" TOTAL_2="183" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.4549803834439283" CI_START="-3.585019616556072" DF="0.0" EFFECT_SIZE="-2.02" ESTIMABLE="YES" I2="0.0" ID="CMP-002.18.02" NO="2" P_CHI2="1.0" P_Z="0.011413990169209803" STUDIES="1" TAU2="0.0" TOTAL_1="80" TOTAL_2="90" WEIGHT="100.0" Z="2.5297620597773904">
<NAME>Responders at 12 weeks (mean dose 27mg /day)</NAME>
<CONT_DATA CI_END="-0.4549803834439283" CI_START="-3.585019616556072" EFFECT_SIZE="-2.02" ESTIMABLE="YES" MEAN_1="-0.96" MEAN_2="1.06" ORDER="2242" SD_1="5.22" SD_2="5.17" SE="0.7984940687179697" STUDY_ID="STD-van-Dyck-2000" TOTAL_1="80" TOTAL_2="90" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.228575922100485" CI_END="0.38876117465830756" CI_START="0.06878638760931954" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.22877378113381355" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.19" NO="19" P_CHI2="0.632581797837431" P_Q="0.632581797837431" P_Z="0.005068493228094526" Q="0.228575922100485" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="265" TOTAL_2="273" UNITS="" WEIGHT="200.0" Z="2.8026481446531935">
<NAME>CGIC (change from baseline) ITT</NAME>
<GROUP_LABEL_1>Physostigmine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favoursphysostigmine</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.4648979172913144" CI_START="0.05510208270868561" DF="0.0" EFFECT_SIZE="0.26" ESTIMABLE="YES" I2="0.0" ID="CMP-002.19.01" NO="1" P_CHI2="1.0" P_Z="0.012880858294339664" STUDIES="1" TAU2="0.0" TOTAL_1="183" TOTAL_2="183" WEIGHT="100.00000000000001" Z="2.487046441062169">
<NAME>Responders at 6 weeks (mean dose 24mg /day)</NAME>
<CONT_DATA CI_END="0.4648979172913144" CI_START="0.05510208270868561" EFFECT_SIZE="0.26" ESTIMABLE="YES" MEAN_1="0.22" MEAN_2="-0.04" ORDER="2243" SD_1="1.0" SD_2="1.0" SE="0.10454167469786334" STUDY_ID="STD-Thal-1996a" TOTAL_1="183" TOTAL_2="183" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.43607728511447535" CI_START="-0.07607728511447537" DF="0.0" EFFECT_SIZE="0.18" ESTIMABLE="YES" I2="0.0" ID="CMP-002.19.02" NO="2" P_CHI2="1.0" P_Z="0.16830094729789233" STUDIES="1" TAU2="0.0" TOTAL_1="82" TOTAL_2="90" WEIGHT="100.0" Z="1.3776837608204842">
<NAME>Responders at 12 weeks (mean dose 27mg /day)</NAME>
<CONT_DATA CI_END="0.43607728511447535" CI_START="-0.07607728511447537" EFFECT_SIZE="0.18" ESTIMABLE="YES" MEAN_1="-0.12" MEAN_2="-0.3" ORDER="2244" SD_1="0.87" SD_2="0.84" SE="0.13065407687813668" STUDY_ID="STD-van-Dyck-2000" TOTAL_1="82" TOTAL_2="90" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.002122511644597066" CI_END="1.2694301854010344" CI_START="0.004573879629438116" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.6370020325152362" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.20" NO="20" P_CHI2="0.9632538908174875" P_Q="0.9632538908174875" P_Z="0.048365946926807964" Q="0.002122511644597066" RANDOM="NO" SCALE="4.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="258" TOTAL_2="267" UNITS="" WEIGHT="200.0" Z="1.9741389375405083">
<NAME>MMSE (change from baseline) ITT</NAME>
<GROUP_LABEL_1>Physostigmine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favoursphysostigmine</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.490081460894389" CI_START="-0.19008146089438904" DF="0.0" EFFECT_SIZE="0.65" ESTIMABLE="YES" I2="0.0" ID="CMP-002.20.01" NO="1" P_CHI2="1.0" P_Z="0.12939505930384412" STUDIES="1" TAU2="0.0" TOTAL_1="183" TOTAL_2="183" WEIGHT="100.0" Z="1.5164917323549811">
<NAME>Responders at 6 weeks (mean dose 24mg /day)</NAME>
<CONT_DATA CI_END="1.490081460894389" CI_START="-0.19008146089438904" EFFECT_SIZE="0.65" ESTIMABLE="YES" MEAN_1="0.05" MEAN_2="-0.6" ORDER="2245" SD_1="4.1" SD_2="4.1" SE="0.4286208662612397" STUDY_ID="STD-Thal-1996a" TOTAL_1="183" TOTAL_2="183" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.580802443301549" CI_START="-0.3408024433015491" DF="0.0" EFFECT_SIZE="0.62" ESTIMABLE="YES" I2="0.0" ID="CMP-002.20.02" NO="2" P_CHI2="1.0" P_Z="0.20595994751126456" STUDIES="1" TAU2="0.0" TOTAL_1="75" TOTAL_2="84" WEIGHT="100.0" Z="1.264752893674156">
<NAME>Responders at 12 weeks (mean dose 27mg /day)</NAME>
<CONT_DATA CI_END="1.580802443301549" CI_START="-0.3408024433015491" EFFECT_SIZE="0.62" ESTIMABLE="YES" MEAN_1="-0.25" MEAN_2="-0.87" ORDER="3" SD_1="2.98" SD_2="3.2" SE="0.49021433601853714" STUDY_ID="STD-van-Dyck-2000" TOTAL_1="75" TOTAL_2="84" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.6202856263117602" CI_START="-0.24028562631176026" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.19" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.21" NO="21" P_CHI2="1.0" P_Q="1.0" P_Z="0.3867887179139534" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="183" TOTAL_2="183" UNITS="" WEIGHT="100.0" Z="0.86545572124874">
<NAME>PSMS (change from baseline) ITT</NAME>
<GROUP_LABEL_1>Physostigmine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favoursphysostigmine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.6202856263117602" CI_START="-0.24028562631176026" DF="0.0" EFFECT_SIZE="0.19" ESTIMABLE="YES" I2="0.0" ID="CMP-002.21.01" NO="1" P_CHI2="1.0" P_Z="0.3867887179139534" STUDIES="1" TAU2="0.0" TOTAL_1="183" TOTAL_2="183" WEIGHT="100.0" Z="0.86545572124874">
<NAME>Responders at 6 weeks (mean dose 24mg /day)</NAME>
<CONT_DATA CI_END="0.6202856263117602" CI_START="-0.24028562631176026" EFFECT_SIZE="0.19" ESTIMABLE="YES" MEAN_1="0.33" MEAN_2="0.14" ORDER="2247" SD_1="2.1" SD_2="2.1" SE="0.219537516865513" STUDY_ID="STD-Thal-1996a" TOTAL_1="183" TOTAL_2="183" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.007958324410377617" CI_END="-0.04885157095677384" CI_START="-4.70945963036681" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.379155600661792" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.22" NO="22" P_CHI2="0.9289154625945756" P_Q="0.9289154625945756" P_Z="0.04538679782889741" Q="0.007958324410377617" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="261" TOTAL_2="268" UNITS="" WEIGHT="200.0" Z="2.001051893432183">
<NAME>IADL (change from baseline) ITT</NAME>
<GROUP_LABEL_1>Physostigmine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favoursphysostigmine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="8.824486873162816E-32" CI_END="0.4700402172657965" CI_START="-5.3900402172657955" DF="0.0" EFFECT_SIZE="-2.4599999999999995" ESTIMABLE="YES" I2="100.0" ID="CMP-002.22.01" NO="1" P_CHI2="0.0" P_Z="0.0998575850957074" STUDIES="1" TAU2="0.0" TOTAL_1="183" TOTAL_2="183" WEIGHT="100.0" Z="1.6455444445973464">
<NAME>Responders at 6 weeks (mean dose 24mg /day)</NAME>
<CONT_DATA CI_END="0.47004021726579603" CI_START="-5.3900402172657955" EFFECT_SIZE="-2.46" ESTIMABLE="YES" MEAN_1="1.67" MEAN_2="4.13" ORDER="2248" SD_1="14.3" SD_2="14.3" SE="1.4949459481794458" STUDY_ID="STD-Thal-1996a" TOTAL_1="183" TOTAL_2="183" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.604137887909233" CI_START="-6.084137887909233" DF="0.0" EFFECT_SIZE="-2.24" ESTIMABLE="YES" I2="0.0" ID="CMP-002.22.02" NO="2" P_CHI2="1.0" P_Z="0.2534201030787445" STUDIES="1" TAU2="0.0" TOTAL_1="78" TOTAL_2="85" WEIGHT="100.0" Z="1.1420816457126486">
<NAME>Responders at 12 weeks (mean dose 27mg /day)</NAME>
<CONT_DATA CI_END="1.604137887909233" CI_START="-6.084137887909233" EFFECT_SIZE="-2.24" ESTIMABLE="YES" MEAN_1="1.28" MEAN_2="3.52" ORDER="2249" SD_1="12.48" SD_2="12.54" SE="1.9613308806852074" STUDY_ID="STD-van-Dyck-2000" TOTAL_1="78" TOTAL_2="85" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2008-06-02 14:09:03 +0100" MODIFIED_BY="Helen Collins" NO="3">
<NAME>physostigmine (verum patch) vs placebo</NAME>
<DICH_OUTCOME CHI2="0.0025005840263057633" CI_END="1.276175210014758" CI_START="0.4068250061531271" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.7205414545095391" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="36" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.10591030410210384" LOG_CI_START="-0.39059236032022426" LOG_EFFECT_SIZE="-0.14234102810906024" METHOD="PETO" NO="1" P_CHI2="0.9601177511786249" P_Q="0.9601177511786249" P_Z="0.2611005637741103" Q="0.0025005840263057633" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="119" TOTAL_2="124" WEIGHT="199.99999999999997" Z="1.1237937219964513">
<NAME>Number of withdrawals before end of treatment</NAME>
<GROUP_LABEL_1>Physostigmine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favoursphysostigmine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.630664274284975" CI_START="0.3276661962487045" DF="0.0" EFFECT_SIZE="0.7309675506570807" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="18" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="0.2123645564825273" LOG_CI_START="-0.4845683603872373" LOG_EFFECT_SIZE="-0.13610190195235503" NO="1" P_CHI2="1.0" P_Z="0.4439674635523012" STUDIES="1" TAU2="0.0" TOTAL_1="61" TOTAL_2="62" WEIGHT="99.99999999999999" Z="0.7655107675273309">
<NAME>At 24 weeks (dose 5.7 mg/day)</NAME>
<DICH_DATA CI_END="1.630664274284975" CI_START="0.32766619624870447" EFFECT_SIZE="0.7309675506570807" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="18" LOG_CI_END="0.2123645564825273" LOG_CI_START="-0.4845683603872374" LOG_EFFECT_SIZE="-0.13610190195235503" ORDER="2250" O_E="-1.8699186991869912" SE="0.40938184524287713" STUDY_ID="STD-M_x00f6_ller-1999" TOTAL_1="61" TOTAL_2="62" VAR="5.966818692577169" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6031831094568734" CI_START="0.3143945445945402" DF="0.0" EFFECT_SIZE="0.709952127681404" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="18" I2="0.0" ID="CMP-003.01.02" LOG_CI_END="0.20498312864553617" LOG_CI_START="-0.5025249984883656" LOG_EFFECT_SIZE="-0.14877093492141472" NO="2" P_CHI2="1.0" P_Z="0.4097912872905528" STUDIES="1" TAU2="0.0" TOTAL_1="58" TOTAL_2="62" WEIGHT="99.99999999999999" Z="0.8242609892653293">
<NAME>At 24 weeks (dose 11.4 mg/day)</NAME>
<DICH_DATA CI_END="1.6031831094568734" CI_START="0.3143945445945402" EFFECT_SIZE="0.709952127681404" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="18" LOG_CI_END="0.20498312864553617" LOG_CI_START="-0.5025249984883656" LOG_EFFECT_SIZE="-0.14877093492141472" ORDER="2251" O_E="-1.9833333333333325" SE="0.4155937761001663" STUDY_ID="STD-M_x00f6_ller-1999" TOTAL_1="58" TOTAL_2="62" VAR="5.7897782446311865" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0830529744928411" CI_END="0.957289854967332" CI_START="0.14809599345385377" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.37652462349052634" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="-0.018956543567818097" LOG_CI_START="-0.8294566905970873" LOG_EFFECT_SIZE="-0.42420661708245266" METHOD="PETO" MODIFIED="2008-06-02 14:09:02 +0100" MODIFIED_BY="Helen Collins" NO="2" P_CHI2="0.7732019803939779" P_Q="0.7732019803939779" P_Z="0.04020407845278821" Q="0.0830529744928411" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="119" TOTAL_2="124" WEIGHT="200.0" Z="2.0516459979251698">
<NAME>A serious adverse event before end of treatment</NAME>
<GROUP_LABEL_1>Physostigmine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favoursphysostigmine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5555570198946285" CI_START="0.11833108843743917" DF="0.0" EFFECT_SIZE="0.4290346784242861" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" I2="0.0" ID="CMP-003.02.01" LOG_CI_END="0.1918859350665358" LOG_CI_START="-0.9269011407221506" LOG_EFFECT_SIZE="-0.36750760282780737" NO="1" P_CHI2="1.0" P_Z="0.19786871211006515" STUDIES="1" TAU2="0.0" TOTAL_1="61" TOTAL_2="62" WEIGHT="100.0" Z="1.2876474553111512">
<NAME>At 24 weeks (dose 5.7 mg/day)</NAME>
<DICH_DATA CI_END="1.5555570198946285" CI_START="0.11833108843743917" EFFECT_SIZE="0.4290346784242861" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.1918859350665358" LOG_CI_START="-0.9269011407221506" LOG_EFFECT_SIZE="-0.36750760282780737" ORDER="2252" O_E="-1.9593495934959346" SE="0.6571810664036166" STUDY_ID="STD-M_x00f6_ller-1999" TOTAL_1="61" TOTAL_2="62" VAR="2.3154207151827615" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2619987155972747" CI_START="0.0841943704135686" DF="0.0" EFFECT_SIZE="0.32596500935291317" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" I2="0.0" ID="CMP-003.02.02" LOG_CI_END="0.10105891290391583" LOG_CI_START="-1.0747169462682695" LOG_EFFECT_SIZE="-0.4868290166821768" NO="2" P_CHI2="1.0" P_Z="0.10458023111097886" STUDIES="1" TAU2="0.0" TOTAL_1="58" TOTAL_2="62" WEIGHT="100.0" Z="1.623042915675961">
<NAME>At 24 weeks (dose 11.4 mg/day)</NAME>
<DICH_DATA CI_END="1.2619987155972745" CI_START="0.08419437041356864" EFFECT_SIZE="0.32596500935291317" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.10105891290391576" LOG_CI_START="-1.0747169462682693" LOG_EFFECT_SIZE="-0.4868290166821768" ORDER="2253" O_E="-2.3499999999999996" SE="0.6906565598621112" STUDY_ID="STD-M_x00f6_ller-1999" TOTAL_1="58" TOTAL_2="62" VAR="2.09640756302521" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="123.51809593971309" CI_START="0.47223810130020005" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="7.637404736085816" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="2.091730588292427" LOG_CI_START="-0.3258389759254853" LOG_EFFECT_SIZE="0.8829458061834707" METHOD="PETO" MODIFIED="2008-06-02 14:09:02 +0100" MODIFIED_BY="Helen Collins" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.15224750715880087" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="119" TOTAL_2="124" WEIGHT="100.0" Z="1.431637795274875">
<NAME>At least one adverse event of eczema before end of treatment</NAME>
<GROUP_LABEL_1>Physostigmine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favoursphysostigmine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="123.51809593971309" CI_START="0.47223810130020005" DF="0.0" EFFECT_SIZE="7.637404736085816" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-003.03.01" LOG_CI_END="2.091730588292427" LOG_CI_START="-0.3258389759254853" LOG_EFFECT_SIZE="0.8829458061834707" NO="1" P_CHI2="1.0" P_Z="0.15224750715880087" STUDIES="1" TAU2="0.0" TOTAL_1="61" TOTAL_2="62" WEIGHT="100.0" Z="1.431637795274875">
<NAME>At 24 weeks (dose 5.7 mg/day)</NAME>
<DICH_DATA CI_END="123.51809593971309" CI_START="0.47223810130020005" EFFECT_SIZE="7.637404736085816" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.091730588292427" LOG_CI_START="-0.3258389759254853" LOG_EFFECT_SIZE="0.8829458061834707" ORDER="2254" O_E="1.0081300813008132" SE="1.4200923291839485" STUDY_ID="STD-M_x00f6_ller-1999" TOTAL_1="61" TOTAL_2="62" VAR="0.4958688611276356" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.03.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="58" TOTAL_2="62" WEIGHT="0.0" Z="0.0">
<NAME>At 24 weeks (dose 11.4 mg/day)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2255" O_E="0.0" SE="0.0" STUDY_ID="STD-M_x00f6_ller-1999" TOTAL_1="58" TOTAL_2="62" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.2772605056351477" CI_END="2.6107316471654887" CI_START="0.42130627370180446" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.0487695752178674" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="0.4167622336978132" LOG_CI_START="-0.37540207371486045" LOG_EFFECT_SIZE="0.020680079991476346" METHOD="PETO" MODIFIED="2008-06-02 14:09:02 +0100" MODIFIED_BY="Helen Collins" NO="4" P_CHI2="0.5985024847697296" P_Q="0.5985024847697296" P_Z="0.9184924889452585" Q="0.2772605056351477" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="119" TOTAL_2="124" WEIGHT="200.0" Z="0.10233284080441668">
<NAME>At least one adverse event of nausea before end of treatment</NAME>
<GROUP_LABEL_1>Physostigmine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favoursphysostigmine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.0997672922556117" CI_START="0.20759063142633352" DF="0.0" EFFECT_SIZE="0.8021737028063427" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" I2="0.0" ID="CMP-003.04.01" LOG_CI_END="0.49132909142048287" LOG_CI_START="-0.6827922501090133" LOG_EFFECT_SIZE="-0.09573157934426524" NO="1" P_CHI2="1.0" P_Z="0.74926401046073" STUDIES="1" TAU2="0.0" TOTAL_1="61" TOTAL_2="62" WEIGHT="99.99999999999999" Z="0.3196099773699325">
<NAME>At 24 weeks (dose 5.7 mg/day)</NAME>
<DICH_DATA CI_END="3.0997672922556117" CI_START="0.20759063142633352" EFFECT_SIZE="0.8021737028063427" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.49132909142048287" LOG_CI_START="-0.6827922501090133" LOG_EFFECT_SIZE="-0.09573157934426524" ORDER="2256" O_E="-0.4634146341463419" SE="0.6896846880088012" STUDY_ID="STD-M_x00f6_ller-1999" TOTAL_1="61" TOTAL_2="62" VAR="2.1023200475907196" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.514069109777454" CI_START="0.3813520851420324" DF="0.0" EFFECT_SIZE="1.3120402690042976" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" I2="0.0" ID="CMP-003.04.02" LOG_CI_END="0.6545682037814503" LOG_CI_START="-0.41867387465037426" LOG_EFFECT_SIZE="0.11794716456553794" NO="2" P_CHI2="1.0" P_Z="0.666619423204716" STUDIES="1" TAU2="0.0" TOTAL_1="58" TOTAL_2="62" WEIGHT="100.0" Z="0.43079226816162913">
<NAME>At 24 weeks (dose 11.4 mg/day)</NAME>
<DICH_DATA CI_END="4.514069109777454" CI_START="0.3813520851420324" EFFECT_SIZE="1.3120402690042976" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.6545682037814503" LOG_CI_START="-0.41867387465037426" LOG_EFFECT_SIZE="0.11794716456553794" ORDER="2257" O_E="0.6833333333333336" SE="0.630427709504823" STUDY_ID="STD-M_x00f6_ller-1999" TOTAL_1="58" TOTAL_2="62" VAR="2.516108776844071" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="60.86897435096148" CI_START="1.1459372942490698" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="8.351767942864361" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="1.7843959839039765" LOG_CI_START="0.05916085366392954" LOG_EFFECT_SIZE="0.921778418783953" METHOD="PETO" MODIFIED="2008-06-02 14:09:02 +0100" MODIFIED_BY="Helen Collins" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.036225779056180844" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="119" TOTAL_2="124" WEIGHT="100.0" Z="2.0943840881462368">
<NAME>At least one adverse event of vomiting before end of treatment</NAME>
<GROUP_LABEL_1>Physostigmine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favoursphysostigmine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.05.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="61" TOTAL_2="62" WEIGHT="0.0" Z="0.0">
<NAME>At 24 weeks (dose 5.7 mg/day)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2258" O_E="0.0" SE="0.0" STUDY_ID="STD-M_x00f6_ller-1999" TOTAL_1="61" TOTAL_2="62" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="60.86897435096148" CI_START="1.1459372942490698" DF="0.0" EFFECT_SIZE="8.351767942864361" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" ID="CMP-003.05.02" LOG_CI_END="1.7843959839039765" LOG_CI_START="0.05916085366392954" LOG_EFFECT_SIZE="0.921778418783953" NO="2" P_CHI2="1.0" P_Z="0.036225779056180844" STUDIES="1" TAU2="0.0" TOTAL_1="58" TOTAL_2="62" WEIGHT="100.0" Z="2.0943840881462368">
<NAME>At 24 weeks (dose 11.4 mg/day)</NAME>
<DICH_DATA CI_END="60.86897435096148" CI_START="1.145937294249069" EFFECT_SIZE="8.351767942864361" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.7843959839039765" LOG_CI_START="0.059160853663929286" LOG_EFFECT_SIZE="0.921778418783953" ORDER="2259" O_E="2.0666666666666664" SE="1.0134116555546306" STUDY_ID="STD-M_x00f6_ller-1999" TOTAL_1="58" TOTAL_2="62" VAR="0.9737068160597573" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0026268041243776713" CI_END="40.816517226134074" CI_START="1.6088473799824456" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="8.10355149297357" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.06" LOG_CI_END="1.6108359446720426" LOG_CI_START="0.20651484759486102" LOG_EFFECT_SIZE="0.9086753961334519" METHOD="PETO" MODIFIED="2008-06-02 14:09:02 +0100" MODIFIED_BY="Helen Collins" NO="6" P_CHI2="0.9591244503685566" P_Q="0.9591244503685566" P_Z="0.0111993698123085" Q="0.0026268041243776713" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="119" TOTAL_2="124" WEIGHT="200.0" Z="2.5364157154171845">
<NAME>At least one adverse event of headache before end of treatment</NAME>
<GROUP_LABEL_1>Physostigmine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favoursphysostigmine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="123.51809593971309" CI_START="0.47223810130020005" DF="0.0" EFFECT_SIZE="7.637404736085816" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-003.06.01" LOG_CI_END="2.091730588292427" LOG_CI_START="-0.3258389759254853" LOG_EFFECT_SIZE="0.8829458061834707" NO="1" P_CHI2="1.0" P_Z="0.15224750715880087" STUDIES="1" TAU2="0.0" TOTAL_1="61" TOTAL_2="62" WEIGHT="100.0" Z="1.431637795274875">
<NAME>At 24 weeks (dose 5.7 mg/day)</NAME>
<DICH_DATA CI_END="123.51809593971309" CI_START="0.47223810130020005" EFFECT_SIZE="7.637404736085816" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.091730588292427" LOG_CI_START="-0.3258389759254853" LOG_EFFECT_SIZE="0.8829458061834707" ORDER="2260" O_E="1.0081300813008132" SE="1.4200923291839485" STUDY_ID="STD-M_x00f6_ller-1999" TOTAL_1="61" TOTAL_2="62" VAR="0.4958688611276356" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="60.86897435096148" CI_START="1.1459372942490698" DF="0.0" EFFECT_SIZE="8.351767942864361" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" ID="CMP-003.06.02" LOG_CI_END="1.7843959839039765" LOG_CI_START="0.05916085366392954" LOG_EFFECT_SIZE="0.921778418783953" NO="2" P_CHI2="1.0" P_Z="0.036225779056180844" STUDIES="1" TAU2="0.0" TOTAL_1="58" TOTAL_2="62" WEIGHT="100.0" Z="2.0943840881462368">
<NAME>At 24 weeks (dose 11.4 mg/day)</NAME>
<DICH_DATA CI_END="60.86897435096148" CI_START="1.145937294249069" EFFECT_SIZE="8.351767942864361" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.7843959839039765" LOG_CI_START="0.059160853663929286" LOG_EFFECT_SIZE="0.921778418783953" ORDER="2261" O_E="2.0666666666666664" SE="1.0134116555546306" STUDY_ID="STD-M_x00f6_ller-1999" TOTAL_1="58" TOTAL_2="62" VAR="0.9737068160597573" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.621709900330787E-4" CI_END="0.6848600447474947" CI_START="0.027133145339787303" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.13631730312600457" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-003.07" LOG_CI_END="-0.1643981701192755" LOG_CI_START="-1.566499858854141" LOG_EFFECT_SIZE="-0.8654490144867082" METHOD="PETO" MODIFIED="2008-06-02 14:09:03 +0100" MODIFIED_BY="Helen Collins" NO="7" P_CHI2="0.9765752836650324" P_Q="0.9765752836650324" P_Z="0.015538424323495762" Q="8.621709900330787E-4" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="119" TOTAL_2="124" WEIGHT="200.0" Z="2.41958042341448">
<NAME>At least one adverse event of sweating before end of treatment</NAME>
<GROUP_LABEL_1>Physostigmine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favoursphysostigmine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3035525036371036" CI_START="0.013582620602902929" DF="0.0" EFFECT_SIZE="0.13306261343017056" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-003.07.01" LOG_CI_END="0.11512852808636916" LOG_CI_START="-1.867016430086422" LOG_EFFECT_SIZE="-0.8759439510000265" NO="1" P_CHI2="1.0" P_Z="0.08322308147723466" STUDIES="1" TAU2="0.0" TOTAL_1="61" TOTAL_2="62" WEIGHT="100.0" Z="1.732283594453548">
<NAME>At 24 weeks (dose 5.7 mg/day)</NAME>
<DICH_DATA CI_END="1.3035525036371043" CI_START="0.013582620602902915" EFFECT_SIZE="0.13306261343017056" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.11512852808636938" LOG_CI_START="-1.8670164300864225" LOG_EFFECT_SIZE="-0.8759439510000265" ORDER="2262" O_E="-1.4878048780487805" SE="1.164321760206483" STUDY_ID="STD-M_x00f6_ller-1999" TOTAL_1="61" TOTAL_2="62" VAR="0.7376561570493753" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3704413754290616" CI_START="0.014231876724831742" DF="0.0" EFFECT_SIZE="0.13965655270596963" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-003.07.02" LOG_CI_END="0.13686046207746969" LOG_CI_START="-1.8467378267255083" LOG_EFFECT_SIZE="-0.8549386823240193" NO="2" P_CHI2="1.0" P_Z="0.09112280783464304" STUDIES="1" TAU2="0.0" TOTAL_1="58" TOTAL_2="62" WEIGHT="99.99999999999999" Z="1.689504408028498">
<NAME>At 24 weeks (dose 11.4 mg/day)</NAME>
<DICH_DATA CI_END="1.3704413754290616" CI_START="0.014231876724831742" EFFECT_SIZE="0.13965655270596963" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.13686046207746969" LOG_CI_START="-1.8467378267255083" LOG_EFFECT_SIZE="-0.8549386823240193" ORDER="2263" O_E="-1.45" SE="1.1651754538127572" STUDY_ID="STD-M_x00f6_ller-1999" TOTAL_1="58" TOTAL_2="62" VAR="0.7365756302521008" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="76.09851237775014" CI_START="0.7929233530589279" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="7.767901106306774" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.08" LOG_CI_END="1.8813761669880618" LOG_CI_START="-0.10076879118472934" LOG_EFFECT_SIZE="0.8903036879016664" METHOD="PETO" MODIFIED="2008-06-02 14:09:03 +0100" MODIFIED_BY="Helen Collins" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.07829229414678182" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="119" TOTAL_2="124" WEIGHT="100.0" Z="1.7606816861659011">
<NAME>At least one adverse event of stomach pain before end of treatment</NAME>
<GROUP_LABEL_1>Physostigmine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favoursphysostigmine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="76.09851237775014" CI_START="0.7929233530589279" DF="0.0" EFFECT_SIZE="7.767901106306774" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-003.08.01" LOG_CI_END="1.8813761669880618" LOG_CI_START="-0.10076879118472934" LOG_EFFECT_SIZE="0.8903036879016664" NO="1" P_CHI2="1.0" P_Z="0.07829229414678182" STUDIES="1" TAU2="0.0" TOTAL_1="61" TOTAL_2="62" WEIGHT="100.0" Z="1.7606816861659011">
<NAME>At 24 weeks (dose 5.7 mg/day)</NAME>
<DICH_DATA CI_END="76.09851237775021" CI_START="0.7929233530589276" EFFECT_SIZE="7.767901106306774" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.8813761669880622" LOG_CI_START="-0.10076879118472953" LOG_EFFECT_SIZE="0.8903036879016664" ORDER="2264" O_E="1.5121951219512195" SE="1.164321760206483" STUDY_ID="STD-M_x00f6_ller-1999" TOTAL_1="61" TOTAL_2="62" VAR="0.7376561570493753" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.08.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="58" TOTAL_2="62" WEIGHT="0.0" Z="0.0">
<NAME>At 24 weeks (dose 11.4 mg/day)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2265" O_E="0.0" SE="0.0" STUDY_ID="STD-M_x00f6_ller-1999" TOTAL_1="58" TOTAL_2="62" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.621709900330787E-4" CI_END="0.6848600447474947" CI_START="0.027133145339787303" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.13631730312600457" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-003.09" LOG_CI_END="-0.1643981701192755" LOG_CI_START="-1.566499858854141" LOG_EFFECT_SIZE="-0.8654490144867082" METHOD="PETO" MODIFIED="2008-06-02 14:09:03 +0100" MODIFIED_BY="Helen Collins" NO="9" P_CHI2="0.9765752836650324" P_Q="0.9765752836650324" P_Z="0.015538424323495762" Q="8.621709900330787E-4" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="119" TOTAL_2="124" WEIGHT="200.0" Z="2.41958042341448">
<NAME>At least one adverse event of tremor before end of treatment</NAME>
<GROUP_LABEL_1>Physostigmine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favoursphysostigmine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3035525036371036" CI_START="0.013582620602902929" DF="0.0" EFFECT_SIZE="0.13306261343017056" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-003.09.01" LOG_CI_END="0.11512852808636916" LOG_CI_START="-1.867016430086422" LOG_EFFECT_SIZE="-0.8759439510000265" NO="1" P_CHI2="1.0" P_Z="0.08322308147723466" STUDIES="1" TAU2="0.0" TOTAL_1="61" TOTAL_2="62" WEIGHT="100.0" Z="1.732283594453548">
<NAME>At 24 weeks (dose 5.7 mg/day)</NAME>
<DICH_DATA CI_END="1.3035525036371043" CI_START="0.013582620602902915" EFFECT_SIZE="0.13306261343017056" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.11512852808636938" LOG_CI_START="-1.8670164300864225" LOG_EFFECT_SIZE="-0.8759439510000265" ORDER="2266" O_E="-1.4878048780487805" SE="1.164321760206483" STUDY_ID="STD-M_x00f6_ller-1999" TOTAL_1="61" TOTAL_2="62" VAR="0.7376561570493753" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3704413754290616" CI_START="0.014231876724831742" DF="0.0" EFFECT_SIZE="0.13965655270596963" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-003.09.02" LOG_CI_END="0.13686046207746969" LOG_CI_START="-1.8467378267255083" LOG_EFFECT_SIZE="-0.8549386823240193" NO="2" P_CHI2="1.0" P_Z="0.09112280783464304" STUDIES="1" TAU2="0.0" TOTAL_1="58" TOTAL_2="62" WEIGHT="99.99999999999999" Z="1.689504408028498">
<NAME>At 24 weeks (dose 11.4 mg/day)</NAME>
<DICH_DATA CI_END="1.3704413754290616" CI_START="0.014231876724831742" EFFECT_SIZE="0.13965655270596963" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.13686046207746969" LOG_CI_START="-1.8467378267255083" LOG_EFFECT_SIZE="-0.8549386823240193" ORDER="2267" O_E="-1.45" SE="1.1651754538127572" STUDY_ID="STD-M_x00f6_ller-1999" TOTAL_1="58" TOTAL_2="62" VAR="0.7365756302521008" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.009777555076701527" CI_END="5.868846749857964" CI_START="0.9079305346637108" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.3083555114968584" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-003.10" LOG_CI_END="0.7685527691557618" LOG_CI_START="-0.04194737787350742" LOG_EFFECT_SIZE="0.36330269564112716" METHOD="PETO" MODIFIED="2008-06-02 14:09:03 +0100" MODIFIED_BY="Helen Collins" NO="10" P_CHI2="0.9212323422736538" P_Q="0.9212323422736538" P_Z="0.0789027444504914" Q="0.009777555076701527" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="119" TOTAL_2="124" WEIGHT="200.0" Z="1.7570883893182365">
<NAME>At least one adverse event of erythema before end of treatment</NAME>
<GROUP_LABEL_1>Physostigmine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favoursphysostigmine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.752868802675087" CI_START="0.6658299754520134" DF="0.0" EFFECT_SIZE="2.414109032338814" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" I2="0.0" ID="CMP-003.10.01" LOG_CI_END="0.9421504188477859" LOG_CI_START="-0.17663665694090058" LOG_EFFECT_SIZE="0.3827568809534426" NO="1" P_CHI2="1.0" P_Z="0.17989551553636787" STUDIES="1" TAU2="0.0" TOTAL_1="61" TOTAL_2="62" WEIGHT="100.0" Z="1.3410768103033155">
<NAME>At 24 weeks (dose 5.7 mg/day)</NAME>
<DICH_DATA CI_END="8.752868802675087" CI_START="0.6658299754520134" EFFECT_SIZE="2.414109032338814" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.9421504188477859" LOG_CI_START="-0.17663665694090058" LOG_EFFECT_SIZE="0.3827568809534426" ORDER="2268" O_E="2.0406504065040654" SE="0.6571810664036166" STUDY_ID="STD-M_x00f6_ller-1999" TOTAL_1="61" TOTAL_2="62" VAR="2.3154207151827615" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.505582231754408" CI_START="0.5674507684934323" DF="0.0" EFFECT_SIZE="2.1969294876925662" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" I2="0.0" ID="CMP-003.10.02" LOG_CI_END="0.9297040476820893" LOG_CI_START="-0.24607181149009605" LOG_EFFECT_SIZE="0.34181611809599655" NO="2" P_CHI2="1.0" P_Z="0.25445995521088816" STUDIES="1" TAU2="0.0" TOTAL_1="58" TOTAL_2="62" WEIGHT="100.0" Z="1.1395833237724835">
<NAME>At 24 weeks (dose 11.4 mg/day)</NAME>
<DICH_DATA CI_END="8.505582231754408" CI_START="0.5674507684934325" EFFECT_SIZE="2.1969294876925662" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.9297040476820893" LOG_CI_START="-0.24607181149009597" LOG_EFFECT_SIZE="0.34181611809599655" ORDER="2269" O_E="1.6500000000000004" SE="0.6906565598621112" STUDY_ID="STD-M_x00f6_ller-1999" TOTAL_1="58" TOTAL_2="62" VAR="2.09640756302521" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.621709900330787E-4" CI_END="0.6848600447474947" CI_START="0.027133145339787303" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.13631730312600457" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-003.11" LOG_CI_END="-0.1643981701192755" LOG_CI_START="-1.566499858854141" LOG_EFFECT_SIZE="-0.8654490144867082" METHOD="PETO" MODIFIED="2008-06-02 14:09:03 +0100" MODIFIED_BY="Helen Collins" NO="11" P_CHI2="0.9765752836650324" P_Q="0.9765752836650324" P_Z="0.015538424323495762" Q="8.621709900330787E-4" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="119" TOTAL_2="124" WEIGHT="200.0" Z="2.41958042341448">
<NAME>At least one adverse event of hypersalivation before end of treatment</NAME>
<GROUP_LABEL_1>Physostigmine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favoursphysostigmine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3035525036371036" CI_START="0.013582620602902929" DF="0.0" EFFECT_SIZE="0.13306261343017056" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-003.11.01" LOG_CI_END="0.11512852808636916" LOG_CI_START="-1.867016430086422" LOG_EFFECT_SIZE="-0.8759439510000265" NO="1" P_CHI2="1.0" P_Z="0.08322308147723466" STUDIES="1" TAU2="0.0" TOTAL_1="61" TOTAL_2="62" WEIGHT="100.0" Z="1.732283594453548">
<NAME>At 24 weeks (dose 5.7 mg/day)</NAME>
<DICH_DATA CI_END="1.3035525036371043" CI_START="0.013582620602902915" EFFECT_SIZE="0.13306261343017056" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.11512852808636938" LOG_CI_START="-1.8670164300864225" LOG_EFFECT_SIZE="-0.8759439510000265" ORDER="2270" O_E="-1.4878048780487805" SE="1.164321760206483" STUDY_ID="STD-M_x00f6_ller-1999" TOTAL_1="61" TOTAL_2="62" VAR="0.7376561570493753" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3704413754290616" CI_START="0.014231876724831742" DF="0.0" EFFECT_SIZE="0.13965655270596963" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-003.11.02" LOG_CI_END="0.13686046207746969" LOG_CI_START="-1.8467378267255083" LOG_EFFECT_SIZE="-0.8549386823240193" NO="2" P_CHI2="1.0" P_Z="0.09112280783464304" STUDIES="1" TAU2="0.0" TOTAL_1="58" TOTAL_2="62" WEIGHT="99.99999999999999" Z="1.689504408028498">
<NAME>At 24 weeks (dose 11.4 mg/day)</NAME>
<DICH_DATA CI_END="1.3704413754290616" CI_START="0.014231876724831742" EFFECT_SIZE="0.13965655270596963" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.13686046207746969" LOG_CI_START="-1.8467378267255083" LOG_EFFECT_SIZE="-0.8549386823240193" ORDER="2271" O_E="-1.45" SE="1.1651754538127572" STUDY_ID="STD-M_x00f6_ller-1999" TOTAL_1="58" TOTAL_2="62" VAR="0.7365756302521008" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6859475429748535" CI_END="1.9775321369984273" CI_START="0.39029796431897673" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.8785367194635872" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-003.12" LOG_CI_END="0.2961235499738476" LOG_CI_START="-0.40860371386694727" LOG_EFFECT_SIZE="-0.05624008194654988" METHOD="PETO" MODIFIED="2008-06-02 14:09:03 +0100" MODIFIED_BY="Helen Collins" NO="12" P_CHI2="0.4075465801513046" P_Q="0.4075465801513046" P_Z="0.7544127976038388" Q="0.6859475429748535" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="119" TOTAL_2="124" WEIGHT="200.0" Z="0.3128260839578382">
<NAME>At least one adverse event of itching before end of treatment</NAME>
<GROUP_LABEL_1>Physostigmine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favoursphysostigmine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.4720842750327643" CI_START="0.40382961391157773" DF="0.0" EFFECT_SIZE="1.1841158947733712" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" I2="0.0" ID="CMP-003.12.01" LOG_CI_END="0.5405902579035053" LOG_CI_START="-0.3938018362422988" LOG_EFFECT_SIZE="0.07339421083060325" NO="1" P_CHI2="1.0" P_Z="0.7581578610476103" STUDIES="1" TAU2="0.0" TOTAL_1="61" TOTAL_2="62" WEIGHT="100.0" Z="0.30790074274595775">
<NAME>At 24 weeks (dose 5.7 mg/day)</NAME>
<DICH_DATA CI_END="3.472084275032765" CI_START="0.4038296139115776" EFFECT_SIZE="1.1841158947733712" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.5405902579035053" LOG_CI_START="-0.3938018362422989" LOG_EFFECT_SIZE="0.07339421083060325" ORDER="2272" O_E="0.5609756097560972" SE="0.5488665414167077" STUDY_ID="STD-M_x00f6_ller-1999" TOTAL_1="61" TOTAL_2="62" VAR="3.319452706722189" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.0387172163459972" CI_START="0.17223242324414384" DF="0.0" EFFECT_SIZE="0.5925649386192425" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" I2="0.0" ID="CMP-003.12.02" LOG_CI_END="0.3093569904189001" LOG_CI_START="-0.7638850880129244" LOG_EFFECT_SIZE="-0.2272640487970121" NO="2" P_CHI2="1.0" P_Z="0.40650308780356115" STUDIES="1" TAU2="0.0" TOTAL_1="58" TOTAL_2="62" WEIGHT="100.0" Z="0.8300631508480167">
<NAME>At 24 weeks (dose 11.4 mg/day)</NAME>
<DICH_DATA CI_END="2.0387172163459972" CI_START="0.17223242324414384" EFFECT_SIZE="0.5925649386192425" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.3093569904189001" LOG_CI_START="-0.7638850880129244" LOG_EFFECT_SIZE="-0.2272640487970121" ORDER="2273" O_E="-1.3166666666666664" SE="0.630427709504823" STUDY_ID="STD-M_x00f6_ller-1999" TOTAL_1="58" TOTAL_2="62" VAR="2.516108776844071" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="60.86897435096148" CI_START="1.1459372942490698" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="8.351767942864361" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.13" LOG_CI_END="1.7843959839039765" LOG_CI_START="0.05916085366392954" LOG_EFFECT_SIZE="0.921778418783953" METHOD="PETO" MODIFIED="2008-06-02 14:09:03 +0100" MODIFIED_BY="Helen Collins" NO="13" P_CHI2="1.0" P_Q="1.0" P_Z="0.036225779056180844" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="119" TOTAL_2="124" WEIGHT="100.0" Z="2.0943840881462368">
<NAME>At least one adverse event of abdominal cramps before end of treatment</NAME>
<GROUP_LABEL_1>Physostigmine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favoursphysostigmine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.13.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="61" TOTAL_2="62" WEIGHT="0.0" Z="0.0">
<NAME>At 24 weeks (dose 5.7 mg/day)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2274" O_E="0.0" SE="0.0" STUDY_ID="STD-M_x00f6_ller-1999" TOTAL_1="61" TOTAL_2="62" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="60.86897435096148" CI_START="1.1459372942490698" DF="0.0" EFFECT_SIZE="8.351767942864361" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" ID="CMP-003.13.02" LOG_CI_END="1.7843959839039765" LOG_CI_START="0.05916085366392954" LOG_EFFECT_SIZE="0.921778418783953" NO="2" P_CHI2="1.0" P_Z="0.036225779056180844" STUDIES="1" TAU2="0.0" TOTAL_1="58" TOTAL_2="62" WEIGHT="100.0" Z="2.0943840881462368">
<NAME>At 24 weeks (dose 11.4 mg/day)</NAME>
<DICH_DATA CI_END="60.86897435096148" CI_START="1.145937294249069" EFFECT_SIZE="8.351767942864361" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.7843959839039765" LOG_CI_START="0.059160853663929286" LOG_EFFECT_SIZE="0.921778418783953" ORDER="2275" O_E="2.0666666666666664" SE="1.0134116555546306" STUDY_ID="STD-M_x00f6_ller-1999" TOTAL_1="58" TOTAL_2="62" VAR="0.9737068160597573" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="57.501332371800856" CI_START="1.0861568740190513" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="7.902877160938648" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.14" LOG_CI_END="1.7596779079073177" LOG_CI_START="0.03589255508764006" LOG_EFFECT_SIZE="0.8977852314974788" METHOD="PETO" MODIFIED="2008-06-02 14:09:03 +0100" MODIFIED_BY="Helen Collins" NO="14" P_CHI2="1.0" P_Q="1.0" P_Z="0.04119276517192487" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="119" TOTAL_2="124" WEIGHT="100.0" Z="2.0415844892854076">
<NAME>At least one adverse event of gastrointestinal complaints before end of treatment</NAME>
<GROUP_LABEL_1>Physostigmine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favoursphysostigmine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="57.501332371800856" CI_START="1.0861568740190513" DF="0.0" EFFECT_SIZE="7.902877160938648" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" ID="CMP-003.14.01" LOG_CI_END="1.7596779079073177" LOG_CI_START="0.03589255508764006" LOG_EFFECT_SIZE="0.8977852314974788" NO="1" P_CHI2="1.0" P_Z="0.04119276517192487" STUDIES="1" TAU2="0.0" TOTAL_1="61" TOTAL_2="62" WEIGHT="100.0" Z="2.0415844892854076">
<NAME>At 24 weeks (dose 5.7 mg/day)</NAME>
<DICH_DATA CI_END="57.501332371800856" CI_START="1.0861568740190513" EFFECT_SIZE="7.902877160938648" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.7596779079073177" LOG_CI_START="0.03589255508764006" LOG_EFFECT_SIZE="0.8977852314974788" ORDER="2276" O_E="2.0162601626016263" SE="1.0125600491213915" STUDY_ID="STD-M_x00f6_ller-1999" TOTAL_1="61" TOTAL_2="62" VAR="0.9753453632097295" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.14.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="58" TOTAL_2="62" WEIGHT="0.0" Z="0.0">
<NAME>At 24 weeks (dose 11.4 mg/day)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2277" O_E="0.0" SE="0.0" STUDY_ID="STD-M_x00f6_ller-1999" TOTAL_1="58" TOTAL_2="62" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.7786082810450717" CI_END="1.2917069346403969" CI_START="0.4285819770587033" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.7440445630663653" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="40" I2="0.0" I2_Q="0.0" ID="CMP-003.15" LOG_CI_END="0.11116399113133424" LOG_CI_START="-0.3679660960765711" LOG_EFFECT_SIZE="-0.12840105247261846" METHOD="PETO" MODIFIED="2008-06-02 14:09:03 +0100" MODIFIED_BY="Helen Collins" NO="15" P_CHI2="0.377567157887691" P_Q="0.377567157887691" P_Z="0.29349145182804925" Q="0.7786082810450717" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="119" TOTAL_2="124" WEIGHT="200.0" Z="1.0504931547501348">
<NAME>CGIC (improved compared with baseline at 12 weeks) ITT</NAME>
<GROUP_LABEL_1>Physostigmine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favoursphysostigmine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2730571858388733" CI_START="0.25986848614896685" DF="0.0" EFFECT_SIZE="0.575176011030547" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="20" I2="0.0" ID="CMP-003.15.01" LOG_CI_END="0.10484791263751325" LOG_CI_START="-0.5852463835287351" LOG_EFFECT_SIZE="-0.2401992354456109" NO="1" P_CHI2="1.0" P_Z="0.17244214391450546" STUDIES="1" TAU2="0.0" TOTAL_1="61" TOTAL_2="62" WEIGHT="100.00000000000001" Z="1.364398613936782">
<NAME>At 24 weeks (dose 5.7 mg/day)</NAME>
<DICH_DATA CI_END="1.2730571858388735" CI_START="0.2598684861489668" EFFECT_SIZE="0.575176011030547" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="20" LOG_CI_END="0.10484791263751334" LOG_CI_START="-0.5852463835287351" LOG_EFFECT_SIZE="-0.2401992354456109" ORDER="2278" O_E="-3.3658536585365866" SE="0.4053648055899133" STUDY_ID="STD-M_x00f6_ller-1999" TOTAL_1="61" TOTAL_2="62" VAR="6.085663295657347" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.03479303146422" CI_START="0.43931319977911143" DF="0.0" EFFECT_SIZE="0.9454688982408594" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="20" I2="0.0" ID="CMP-003.15.02" LOG_CI_END="0.3085202416378023" LOG_CI_START="-0.35722574755391995" LOG_EFFECT_SIZE="-0.02435275295805885" NO="2" P_CHI2="1.0" P_Z="0.8859825123255983" STUDIES="1" TAU2="0.0" TOTAL_1="58" TOTAL_2="62" WEIGHT="100.0" Z="0.14338957950057166">
<NAME>At 24 weeks (dose 11.4 mg/day)</NAME>
<DICH_DATA CI_END="2.03479303146422" CI_START="0.43931319977911143" EFFECT_SIZE="0.9454688982408594" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="20" LOG_CI_END="0.3085202416378023" LOG_CI_START="-0.35722574755391995" LOG_EFFECT_SIZE="-0.02435275295805885" ORDER="2279" O_E="-0.36666666666666714" SE="0.39106248954701317" STUDY_ID="STD-M_x00f6_ller-1999" TOTAL_1="58" TOTAL_2="62" VAR="6.538944911297853" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.7911828965853593" CI_END="1.1161383025403266" CI_START="0.3389015519198059" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.6150292699441666" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="40" I2="0.0" I2_Q="0.0" ID="CMP-003.16" LOG_CI_END="0.0477180120824083" LOG_CI_START="-0.46992644240881565" LOG_EFFECT_SIZE="-0.21110421516320368" METHOD="PETO" MODIFIED="2008-06-02 14:09:03 +0100" MODIFIED_BY="Helen Collins" NO="16" P_CHI2="0.3737427310482888" P_Q="0.3737427310482888" P_Z="0.10990654931657964" Q="0.7911828965853593" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="92" TOTAL_2="88" WEIGHT="200.0" Z="1.5986133150451376">
<NAME>CGIC (improved compared with baseline at 12 weeks) OC</NAME>
<GROUP_LABEL_1>Physostigmine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favoursphysostigmine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0931184017783995" CI_START="0.1995027951421704" DF="0.0" EFFECT_SIZE="0.46699055298381864" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="20" I2="0.0" ID="CMP-003.16.01" LOG_CI_END="0.03866720536602907" LOG_CI_START="-0.7000510152337899" LOG_EFFECT_SIZE="-0.3306919049338804" NO="1" P_CHI2="1.0" P_Z="0.07929683277972313" STUDIES="1" TAU2="0.0" TOTAL_1="47" TOTAL_2="44" WEIGHT="100.0" Z="1.7547806608129246">
<NAME>At 24 weeks (dose 5.7 mg/day)</NAME>
<DICH_DATA CI_END="1.0931184017783995" CI_START="0.1995027951421704" EFFECT_SIZE="0.46699055298381864" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="20" LOG_CI_END="0.03866720536602907" LOG_CI_START="-0.7000510152337899" LOG_EFFECT_SIZE="-0.3306919049338804" ORDER="2280" O_E="-4.043956043956044" SE="0.4339267394945004" STUDY_ID="STD-M_x00f6_ller-1999" TOTAL_1="47" TOTAL_2="44" VAR="5.3108883790202475" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8495075254119435" CI_START="0.3479187601738782" DF="0.0" EFFECT_SIZE="0.8021710323700183" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="20" I2="0.0" ID="CMP-003.16.02" LOG_CI_END="0.2670561027442661" LOG_CI_START="-0.4585221529703435" LOG_EFFECT_SIZE="-0.09573302511303868" NO="2" P_CHI2="1.0" P_Z="0.6050189697935358" STUDIES="1" TAU2="0.0" TOTAL_1="45" TOTAL_2="44" WEIGHT="100.0" Z="0.5171965391047381">
<NAME>At 24 weeks (dose 11.4 mg/day)</NAME>
<DICH_DATA CI_END="1.8495075254119435" CI_START="0.3479187601738782" EFFECT_SIZE="0.8021710323700183" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="20" LOG_CI_END="0.2670561027442661" LOG_CI_START="-0.4585221529703435" LOG_EFFECT_SIZE="-0.09573302511303868" ORDER="2281" O_E="-1.2134831460674143" SE="0.4262082590770532" STUDY_ID="STD-M_x00f6_ller-1999" TOTAL_1="45" TOTAL_2="44" VAR="5.504986744097968" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>